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ABSTRACT   
 
Background: South Africa is considered to be a country in epidemiologic transition with 
increasing rates of cardiovascular disease. In addition, it faces an HIV pandemic, with an 
estimated 5.5 million people infected and five hundred thousand HIV-related deaths 
annually. Current evidence suggests that patients infected with HIV are at a heightened 
risk for acute coronary syndromes (ACS) related to traditional cardiovascular risk factors, 
as well as factors related to the virus and its treatment (highly active anti-retroviral 
therapy (HAART)). HIV infection itself may independently predispose to coronary artery 
disease (CAD) by promoting endothelial dysfunction, a heightened pro-inflammatory 
state, dyslipidaemia and thrombosis, the aetiology of which is thought to be multifactoral 
in nature.  
 
Protease inhibitor (PI) therapy, as part of HAART, has the potential to induce an adverse 
metabolic phenotype, including: dyslipidaemia, insulin resistance, endothelial dysfunction 
and a prothrombotic state. The attributable risk of these factors in HIV-associated CAD 
and ACS is currently unknown, but it seems that the risk of ACS is increased by 
prolonged exposure to PI’s. No data currently exists on CAD in HIV patients not 
receiving HAART, which is problematic considering that this makes up the majority of 
patients in sub-Saharan Africa and that the combination of epidemiologic transition and 
HIV infection has the potential for greater cardiovascular morbidity, particularly with 
respect to atherothrombotic events. 
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Aims: The aims of this thesis are twofold. Firstly, to confirm reports of epidemiologic 
transition in South Africa from a broad epidemiological perspective. Secondly, by focusing on 
treatment-naïve HIV positive black South Africans with ACS, it aims to determine differences 
compared to HIV negative patients with respect to demographics and risk factors, 
angiographic and treatment related factors as well as markers of thrombosis and inflammation 
with a view to providing more focused primary and secondary prevention.  
 
Methods: All the studies contained in this thesis were conducted in the Department of 
Cardiology, Chris Hani Baragwanath Hospital and adhere to the declaration of Helsinki. The 
first of the epidemiological studies, The Heart of Soweto (HOS) study (Chapter 3), was a 
prospectively designed registry that recorded epidemiologic data relating to the presentation, 
investigations and treatment of 1593 patients from Soweto with newly diagnosed 
cardiovascular disease during the year 2006. The second study (Chapter 4) was a cross 
sectional study of patients with ACS admitted to the Baragwanath coronary care unit over the 
year 2004 compared to the years 1975-1980.  
 
The HIV sub-study (chapters 5-8) was a prospective single centre study conducted from 
March 2004 to February 2008. During this time, 30 consecutive black HIV patients 
presenting with ACS (ACS+: HIV+ group) were enrolled. For each HIV patient with 
ACS, the first presenting non-HIV black patient with ACS was selected as a case control 
comparator (ACS+ : HIV- group). In addition, a second control group of 30 asymptomatic 
HIV patients, who were matched for age, sex and ethnicity (ACS- : HIV+ group), were 
recruited from the HIV clinic. The methodology used to compare the groups involved: 
clinical and demographic data collection, routine blood test evaluation, angiographic 
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analysis and specific laboratory testing of various research blood parameters (including 
thrombotic screening and markers of inflammation and endothelial activation).  
 
Results: Chapter 3 presents the results of the large HOS study, which showed good 
evidence to support the theory of epidemiologic transition in Soweto. Adding to this data 
are the results of Chapter 4, which clearly demonstrate a substantial increase in the 
number of patients diagnosed with ACS at Baragwanath in recent years. Consistent with a 
population in epidemiologic transition, there was more than a ten-fold increase in the rate 
of coronary events over two decades, paralleled by increased rates of modifiable risk 
factors. Chapter 5 presents the clinical and angiographic data from the HIV sub-study.  
 
HIV patients with ACS were younger and had fewer traditional risk factors for CAD 
except for higher rates of smoking and lower HDL cholesterol levels. HIV patients had 
less atherosclerotic burden angiographically, but a higher thrombus burden in the infarct 
related arteries, suggesting a possible prothrombotic state. In addition, HIV patients had 
higher rates of in-stent restenosis of bare metal coronary stents at follow up. Chapters 6 
and 7 present data on the thrombotic parameters between the groups, with Chapter 6 
focusing mainly on coagulation pathways and Chapter 7 focusing on antiphospholipid 
antibodies (aPL). Chapter 8 presents data on levels of pro-inflammatory cytokines and 
endothelial activation markers.  Greater evidence of thrombophilia was found in HIV 
patients with ACS as evidenced by lower Protein C (PC) levels, higher levels of Factor 
VIII and a higher inflammatory burden with greater degrees of endothelial cell activation 
- all of which increase thrombotic risk. Antiphospholipid antibodies were more prevalent 
in HIV patients but did not seem to be causal in the pathogenesis of thrombosis.  
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Conclusion: Soweto, a large, predominantly black urban area in South Africa, is in a state of 
epidemiologic transition, with an increasing prevalence of modifiable cardiovascular risk 
factors and ischaemic heart disease. Treatment-naïve HIV positive black patients presenting 
with ACS have different clinical and angiographic features compared to the HIV negative 
population. The patients are younger, more commonly male, with high rates of smoking, lower 
HDL levels and less atherosclerotic burden. However, there is a higher thrombotic burden, 
suggesting a prothrombotic state, which was evident by lower PC levels, higher factor VIII 
levels with a higher inflammatory burden and a greater degree of endothelial cell activation – 
all factors associated with a pro-atherogenic and prothrombotic state. The exact pathogenic 
role of HIV, independent of associated modifiable and non-modifiable risk factors, is difficult 
to determine, but may be important as a contributory factor in an already “vulnerable” patient. 
Importantly, we identified modifiable risk factors in the HIV group. Smoking may play a 
crucial role in the pathogenesis of ACS in these otherwise seemingly low risk patients and 
remains an important target for cardiovascular risk reduction.  
 
The role of HDL in the pathogenesis and prevention of HIV-associated CAD needs to be 
further defined, as does the role of drug eluting coronary stents in the prevention of in-stent 
restenosis. Cardiovascular risk assessment and appropriate primary prevention should be an 
important component in the management of HIV patients, regardless of treatment status. With 
the anticipated increase in CVD in South Africa, further research projects appropriate to the 
South African context will be vital in order to explore cost effective ways to provide primary 
and secondary prevention in order to effectively deal with the burden of epidemiological 
transition as well as the cardiovascular burden likely to be imposed by the HIV pandemic. 
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CHAPTER ONE: INTRODUCTION AND BACKGROUND TO THE THESIS 
 
1.1     INTRODUCTION TO THE THESIS 
 
South Africa is thought to be a country in epidemiologic transition facing an epidemic of 
cardiovascular disease (1). The spectrum of heart disease facing the country ranges from 
the so-called traditional forms of infectious diseases to newer non-communicable 
diseases, with a high prevalence of modifiable risk factors that are often reported in high 
income countries (2, 3). Rates of cardiovascular disease in the predominantly black 
population of Soweto ,which have  traditionally been low, are on the increase (4); this 
“double burden” of disease is particularly concerning, considering the current human 
immunodeficiency virus (HIV) pandemic, with an estimated: 5.5 million South Africans 
infected, one million having AIDS and five hundred thousand HIV-related deaths 
annually (5).  
 
While cardiac complications of HIV infection are well described (6), controversy still 
exists as to whether HIV seropositive subjects have a higher incidence of coronary artery 
disease (CAD) and acute coronary syndromes (ACS). Autopsy studies in HIV positive 
patients from the developed world have shown unexpectedly high rates of atherosclerotic 
CAD compared to aged-matched HIV negative patients (7). 
 
The phenomenon of premature CAD and related events in HIV positive patients can be 
directly attributed to the virus and/or treatment related factors. HIV infection itself may 
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independently predispose to premature atherosclerosis through endothelial dysfunction 
(8), a heightened proinflammatory state (9, 10) and dyslipidaemia characterized by 
reductions in high density lipoprotein (HDL) cholesterol and elevations in triglycerides 
(11, 12). HIV patients are also at higher risk for thrombosis, owing to various 
abnormalities of the coagulation and fibrinolytic systems, resulting in a prothrombotic  
state (13-15). Alternatively, protease inhibitors (key drugs in certain anti-retroviral 
(ARV) regimens) have the potential to induce an adverse metabolic phenotype including 
dyslipidemia and insulin resistance, endothelial dysfunction and a prothrombotic state (6, 
14, 16).  
 
Following an earlier report suggesting a strong link between highly active anti-retroviral 
therapy (HAART) and premature CAD (17),  the subsequent evidence regarding the 
relationship between HIV, coronary artery disease and acute coronary syndromes has 
been conflicting (6).  It seems, however, that the risk of ACS is increased by prolonged 
exposure to protease inhibitors (18) independent of their effect on traditional risk factors. 
With HAART being the standard of care for all eligible patients in affluent societies, very 
little data regarding CAD in treatment-naïve patients exists. This historical lack of data 
for treatment-naïve patients presenting with concurrent HIV and CAD has, therefore, 
hindered attempts to understand the fundamental role of HIV status (and by its very 
absence, HAART)  in the development of premature CAD. 
 
With the great majority of HIV infected patients living in Sub-Saharan Africa (19) having 
limited access to HAART,  the lack of data is problematic, particularly in view of the 
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anticipated cardiovascular pandemic facing developing countries (20). The research 
contained in this thesis will represent a sub-study of the larger “Heart of Soweto Study” 
(Figure 1.1). It will systematically examine the epidemiologic transition in risk 
behaviours and clinical presentations of heart disease in the predominantly black African 
population of approximately one million people living in the townships that comprise the 
internationally renowned and celebrated area of Soweto.  
 
Figure 1.1:  Study schema for the “Heart of Soweto Study” 
 
 
Key: RCT, Randomised Controlled Trial; CHF, Congestive heart failure; MP, Management Programme 
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The aim of the research contained in this thesis is to address a number of important issues 
regarding:  
1)   Epidemiologic transition (“Heart of Soweto” study, Chapter 3 and Emerging 
epidemic of cardiovascular disease among urban Africans: Acute coronary syndrome at 
Baragwanath Hospital Soweto study, chapter 4).  
2)   Acute coronary syndromes in the setting of HIV infection (“Heart of Soweto” 
sub-study, chapters 5 to 8).  
 
The objective is to provide a better understanding and hopefully better prevention and 
treatment for our patients, particularly those suffering from HIV and AIDS. It is to this 
end that the specific research questions to be addressed by the research contained in this 
thesis are: 
 
Research Question 1: (Addressed in chapters 3 and 4) 
1a)   What is the current spectrum of cardiovascular disease seen in a large urban 
population of black South Africans, including the prevalence, incidence and associated 
risk factors? 
1b)   Is this pattern consistent with epidemiologic transition? 
 
Research Question 2: (Addressed in chapter 5) 
2)   Are there differences in the demographic, clinical and angiographic features as well 
as treatment outcomes in black South Africans presenting with ACS according to HIV 
status? 
5 
 
Research Question 3: (Addressed in chapters 6 and 7) 
3)   Do thrombotic profiles in black South Africans with ACS differ according to HIV 
status? 
 
Research Question 4: (Addressed in chapter 8) 
4)   Do markers of inflammation and endothelial cell activation differ in black 
South Africans with ACS according to HIV status and what is their role in the 
pathogenesis of ACS? 
 
1.1.1  OVERVIEW OF THE THESIS 
 
This thesis is divided into nine chapters. The first includes this introduction to the 
research and a detailed literature review. The review begins with a broad epidemiological 
account of the current cardiovascular and HIV pandemic facing South Africa. This is 
followed by a more focused look at the current available literature on the cardiovascular 
manifestations of HIV/AIDS and the effects of anti-retroviral therapy.  
 
The remainder of the review details the current understanding of the elements influencing 
coronary artery disease and acute coronary syndromes in HIV positive patients as well as 
the gaps in our knowledge. Chapter two discusses the methodology used to answer the 
research questions. Chapters three to eight present peer reviewed manuscripts, each 
addressing a specific research question. Chapter three presents the findings of the large 
epidemiological “Heart of Soweto” study (Figure 1.1), which discusses epidemiologic 
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transition in Soweto, South Africa. Chapter four presents the findings of an 
epidemiologic study done at Chris Hani Baragwanath Hospital, which looked specifically 
at the incidence of acute coronary syndromes as part of an emerging epidemic of 
cardiovascular disease in the population of Soweto. Chapter five presents the findings of 
a prospective case-control observational study that looked at the clinical, angiographic 
and outcomes data of black South African patients with HIV and ACS. Chapters six to 
eight report the findings of three prospective case-control observational studies and 
compare various parameters concerned with the possible pathogenesis of ACS in HIV 
positive and negative patients. Chapter six discusses thrombotic profiles; chapter seven 
describes the incidence and clinical correlates of antiphospholipid antibodies and the 
antiphospholipid syndrome; chapter eight presents data on markers of inflammation and 
endothelial activation. The final chapter of this thesis (chapter nine) includes an in-depth 
discussion, a conclusion and suggestions on the way forward for future research.  
 
In keeping with the guidelines of the University of the Witwatersrand, each chapter in 
this thesis is based on published peer reviewed papers or those accepted for publication. 
Preceding each chapter is a signed statement of originality, required by the University, 
which details the contribution of each author listed on each paper. Each chapter is 
introduced within the context of the thesis. Permission has been granted from each 
journal to include a copy of the published paper in this thesis. A condition of this 
permission is to include the publication as it appears in the journal. 
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1.2  EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE IN DEVELOPING 
COUNTRIES 
 
Despite marked improvement in its prevention and treatment, cardiovascular disease 
(CVD) remains one of the largest contributors to morbidity and premature mortality in 
the world today. Moreover, the global burden of CVD is predicted to rise by around 50% 
and 150%, in the developed and developing worlds respectively, in the first quarter of the 
21st Century (21) . By 2020, this burden will have increased by 130% in Africa alone, 
directly affecting 1.3 million people (20). Figure 1.2, specifically shows the impact of 
coronary artery disease (CAD), the greatest contributor to the burden of CVD overall, in 
terms of “healthy life-years lost” globally. Even in low to middle income countries, such 
as South Africa, it is responsible for close to 10% of healthy life-years lost, and is second 
only to HIV/AIDS in this regard.  
 
These data support the hypothesis that the overall health status of human societies is 
linked to economic development. With industrialization, the major causes of death have 
shifted from infectious diseases and nutritional deficiencies to more chronic disorders, a 
phenomenon with distinct stages known as “epidemiologic transition” (21, 22).  There are 
strong indications that in South Africa this phenomenon is occurring, even within specific 
disease categories, with increasing rates of CAD (23, 24) and acute coronary syndromes, 
(ACS) including acute myocardial infarction (AMI)  (25, 26) - all common precursors of 
chronic heart failure. Similar to other countries in transition, South Africa is suffering a 
double or even triple burden from: a) the historical and lingering burden of infectious 
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disease; b) an emerging epidemic of chronic disease (particularly CAD); c) the re-
emergence of infections such as HIV/AIDS and tuberculosis. Furthermore, as will be 
discussed later, HIV may in fact be adding to the burden of CAD and acute coronary 
events. 
Figure 1.2:   Impact of the most common causes of death and disability in the world 
population: Disability adjusted life-years lost (DALY’s) (20) 
 
 
 
 
 
 
Key: CAD - Coronary artery disease; TB - Tuberculosis; CAL, Congenital anomalies; OA - 
Osteoarthritis 
 
This epidemiologic transition is already quite evident when considering the increasing 
demands for acute and outpatient cardiac clinical services from the one million people 
living in Soweto. For example, in a study recently published in ‘The Lancet’, 250 black 
African patients with acute myocardial infarction (AMI) were recruited as part of the 
INTERHEART Study (27). This large, international, standardized case control study of 
similar cohorts in 52 countries, examined the importance of risk factors for CAD on a 
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world-wide basis. During the study, 262 centers recruited men and women with a first-
ever AMI and presenting to their local coronary care unit (CCU). At least one age and 
sex-matched control was recruited for each case of AMI. Overall 12 461 cases and 14 
637 controls were analysed. On an adjusted basis, the following five “modifiable” risk 
factors were found to be most predictive of this event: 
1. Current smoking: OR 2.87 (99% CI 2.58 to 3.19) 
2. Raised Apoprotein B/Apoprotein A1 ratio *: OR 3.25 (99% CI 2.81 to 3.76) 
3. Diabetes: OR 2.37 (99% CI 2.07 to 2.71) 
4. Hypertension: OR 1.91 (99% CI 1.74 to 2.10) 
5. Psychosocial Stress: OR 2.67 (99% CI 2.21 to 3.22)  
* Top versus lowest quintile.  Combined index comparing exposure versus non-exposure 
to depression, high perceived stress, poor locus of control and major life events. 
 
Overall, the INTERHEART Study suggests that nine risk factors amenable to 
modification accounted for around 90% of the risk of an incident AMI (28).  Moreover, 
this study also demonstrated that the effect of these risk factors is consistent across a 
wide-range of ethnic, cultural and geographic regions across the globe: providing strong 
evidence that negative changes in the risk behaviour profile of the Soweto population 
(e.g. higher rates of obesity and hypertension) is likely to lead to a dramatic increase in 
the incidence of CAD. It is within this context that Figure 1.3 highlights regional 
differences in the population’s attributable risk of AMI (reflective of the relative 
prevalence and risk associated with each risk factor) associated with smoking (25% to 
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45%), dyslipidemia (55% to 75%) and hypertension (5% to 40%), with a specific focus 
on the black African cohort (28). 
 
Figure 1.3:   Global comparison of the population’s attributable risk of CAD for 
smoking, dyslipidaemia and hypertension (28) 
 
 
 
 
 
 
 
 
Key: Apo B - Apoprotein B; Apo A1 - Apoprotein A1; MEC - Middle East Crescent; China/HK - 
China/Hong Kong; SE Asia - South East Asia; Aust & NZ -, Australia & New Zealand 
 
Despite obvious trends in health care utilisation rates and some research reports from the 
African continent  (26, 29), there is a paucity of data collected on a systematic basis to 
describe this “epidemiologic transition” in the developing world, particularly in a large 
vulnerable population subject to generally improved economic conditions. What is clear 
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is that both CVD and HIV/AIDS are significant contributors to global disability and 
premature mortality.  
 
1.3 EPIDEMIOLOGY OF HUMAN IMMUNODEFICIENCY VIRUS 
INFECTION IN SOUTHERN AFRICA 
 
Southern Africa has the largest prevalence of HIV/AIDS in the world. In 2007, this sub-
region accounted for almost a third (32%) of all new HIV infections and AIDS-related 
deaths globally, with the national adult HIV prevalence exceeding 15% in eight countries 
in 2005 (Botswana, Lesotho, Mozambique, Namibia, South Africa, Swaziland, Zambia 
and Zimbabwe) (5). Nowhere else has the national adult HIV prevalence reached such 
high levels. While there is some evidence of slight declines in the epidemic in some 
countries, notably Zimbabwe, the epidemic in most countries in the Southern African 
region seems to have reached or is approaching a plateau.  
 
With an estimated 5.5 million [4.9 million-6.1 million] people living with HIV (19), 
South Africa is the country with the largest number of infections in the world. South 
Africa’s Department of Health estimates that 18.3% of adults (15 - 49 years) were living 
with HIV in 2006 (30). More than half (55%) of all South Africans infected with HIV 
reside in the KwaZulu-Natal and Gauteng provinces (31). The latest data collected at 
antenatal clinics in South Africa suggest that infection levels may be levelling off, with 
HIV prevalence in pregnant women at 30% in 2005 and 29% in 2006 (30). The decrease 
in percentage of young pregnant women (15 - 24 years) found to be HIV positive also 
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suggests a possible decline in the annual number of new infections. Young women in 
South Africa face greater risks of becoming infected than men. Among 15-24 year-olds, 
women account for around 90% of new HIV infections (32). HIV incidence among 20-29 
year-old women in 2005 was around 5.6%, more than six times higher than for men of 
the same age (0.9%) (32).  
 
An estimated 1.8 million South Africans have died form AIDS-related disease since the 
epidemic began (31). The total of all cause mortality increased by 87% from 1997 to 
2005 (from 316505 to 591213) (33, 34), with at least 40% of those deaths estimated to 
have been AIDS-related. (35). Rising death rates lowered life expectancy at birth to 49 
years for males and 52.5 years for females in 2006, and has probably contributed to the 
decline in the country’s population growth rate from 1.25% in 2001-2002 to slightly more 
than 1% in 2005-2006 (36). 
 
1.3.1  SOUTH AFRICAN ANTI-RETROVIRAL ROLLOUT PROGRAMME 
 
On 8 August 2003, the South African government made a commitment to provide anti-
retroviral (ARV) treatment in the public health sector. On 19 November 2003, it 
published the Operational Plan on Comprehensive HIV and AIDS Care, Management and 
Treatment for South Africa (the Operational Plan) (37). The estimated requirement set 
out in the Operational Plan was for 500 000 patients to access ARV’s per year. By 
January 2006 the total number of adult patients on ARV treatment in both the public and 
private sector was estimated to be around 200 000 to 220 000 - well below expectation. 
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About 110 000 to 120 000 people were puportedly accessing ARV’s in the public sector, 
with an additional 90 000 to 100 000 receiving it in the private and not-for-profit sectors 
(38).  
 
The lack of monitoring and evaluation of the programme has made efforts to obtain 
accurate statistics difficult. As in most other countries, human resources have been a 
major barrier to the speedy implementation of prevention and treatment programmes. In 
November 2005 the International Treatment Preparedness Coalition (ITPC) issued 
“Missing the Target: A Report on HIV/AIDS Treatment Access from the frontlines”. The 
report detailed specific barriers and potential solutions to AIDS treatment delivery in six 
countries heavily affected by the pandemic, including South Africa, and made 
recommendations for national governments and mutilateral institutions (38). With regard 
to SA, the ITPC identified a lack of proper leadership, coupled with AIDS denialism as 
the main obstacles to increasing the number of patients on treatment. Other barriers 
include an acute shortage of health workers (mainly nurses and pharmacists), a lack of 
proper infrastructure and insufficient access to and promotion of voluntary testing (38). 
 
The upshot of all these barriers to treatment has been that the great majority of South 
Africans infected with HIV have not had access to appropriate treatment, including the  
patients who participated in this study, who were all treatment-naïve. In June 2007, the 
South African Government released a guiding document with a view to comprehensively 
dealing with HIV from 2007-2011: the National Strategic Plan (NSP) (39). The structure 
of the document broadly follows four key areas, namely: 1) Prevention 2) Treatment, care 
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and support 3) Research, monitoring and surveillance 4) Human rights and access to 
justice. The primary aims of the plan are to reduce the rate of new HIV infections by 50% 
by 2011 and to reduce the impact of HIV and AIDS on individuals, families, 
communities and society by expanding access to appropriate treatment, care and support 
to 80% of all HIV positive people and their families by 2011 (39).  The selected targets of 
the NSP are shown in Table 1.1. 
 
Table 1.1:  Selected targets of the National Strategic Plan 
Target 2007 2011 
PEP for sexual assault survivors 30% coverage 90% coverage 
% of pregnant women tested for HIV 70% 95% 
% of HIV-positive women given PMTCT 60% 95% 
Adult population tested annually 7% 25% 
New adult initiates on ART 120 000 420 000 
% adult initiates started on ART outside hospital setting 30% 70% 
% adult initiates started by nurses on ART 10% 80% 
% HIV exposed children screened by PCR 45% 90% 
New child initiates on ART 17 000 40 000 
% of TB patients screened for HIV 40% 90% 
     
PEP=Post-exposure prophylaxis, PCR=polymerase chain reaction 
 
Considering the above mentioned ambitious aims and targets of the NSP, it is considered 
unlikely that these will be achieved without a radical restructuring of the current 
healthcare delivery system (40). 
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1.4  CARDIOVASCULAR MANIFESTATIONS OF HIV 
 
1.4.1 INTRODUCTION 
 
Although advances in highly active anti-retroviral therapy (HAART) have increased the 
overall survival of patients infected with HIV, the long term effects of immunodeficiency 
and opportunistic infections remain increasingly important (41). Heart involvement due 
to HIV infection was first described in 1983 by Autran et al. (42) who described a 
myocardial case of Kaposi’s sarcoma in a patient with AIDS. Since then,  the reported 
prevalence of cardiac involvement has ranged from 28% to 73% (43). Unfortunately most 
data has emanated from developed countries and little data has been reported from the 
developing world, where the main burden of disease lies.  
 
The clinical expression of cardiac involvement is variable and affected by the stage of 
HIV disease, the degree of immunodeficiency and the use of drugs to treat HIV and/or 
opportunistic infections and neoplasms (44). The epidemiology of cardiovascular 
manifestations, like other organ systems, has changed since the introduction of HAART. 
On the one hand, HAART has significantly modified the course of HIV disease, 
lengthened survival and improved quality of life for infected patients; but on the other 
hand, the early data have raised concerns that HAART is associated with an increase in 
both peripheral and coronary artery diseases (45). The HAART-associated changes are 
relevant only to a minority of HIV infected individuals worldwide who have had access 
to the drugs and therefore, the results of studies conducted pre-HAART remain globally 
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applicable. Where possible, a distinction between pre and post HAART manifestations 
will be made. The direct effects of HAART on the cardiovascular system will be 
discussed in more detail in chapter 3.1 and coronary artery disease in chapter 4. 
  
1.4.2 BIOLOGY OF HIV AND PATHOPHYSIOLOGY OF CARDIAC 
DISEASE 
 
HIV was first isolated in 1983. It is a ribonucleic acid (RNA) retrovirus that uses reverse 
transcriptase to produce deoxyribonucelic acid (DNA) from RNA. Once in DNA form, 
the genetic information of HIV is incorporated as a provirus with the host cell DNA. The 
proviral genome can subsequently be transcribed into viral RNA that functions as 
messenger RNA for translation into HIV proteins and as genomes for the subsequent 
generation of the virus. Furthermore, HIV-1 has genes that encode the structural proteins 
of the virus. These are gag (the core of the virion, including p24 antigen), pol (enzymes 
for reverse transcription and integration), and env (envelope glycoprotein). Although the 
CD4+ T Lymphocytes and CD4+ cells of monocyte lineage are the principal targets of 
HIV, any cell expressing CD4 can potentially be infected with HIV. Hence cells from a 
variety of organs may also be affected (46).  
 
The potential pathophysiological mechanisms of cardiac involvement by HIV are shown  
in Table 1.2.  
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 Table 1.2:   Potential mechanisms of cardiac disease in HIV/AIDS 
MECHANISM: EFFECT: 
    
Direct effects of HIV:   
Infection of cardiac myocytes Myocarditis and cardiomyopathy 
    
 
Indirect effects of HIV: 
 
  
Pro-inflammatory cytokines Impaired myocyte contractility 
Anti-α-myosin autoantibodies  Endothelial dysfunction 
Immune processes involving MHC-1  Cardiomyopathy 
Apoptosis   
    
Nutritional deficiencies (carnitine,selenium,thiamine) Cardiomyopathy 
    
Drug toxicity: 1) Anti-retroviral treatment   
                          - NRTI's Cardiomyopathy 
                          - PI's Dyslipidaemia, atherosclerosis,  
  increased coronary events 
                      2) Agents used in opportunistic infections   
                          - Trimethoprim/sulfamethoxazole Prolonged QT interval,arrhythmias 
                          -  Pentamidine Prolonged QT interval,arrhythmias 
                          -  Fluoroquinolones Prolonged QT interval,arrhythmias 
                          -  Amphotericin B Prolonged QT interval,arrhythmias, 
  bradycardia, hypokalaemia 
                          -  Gancyclovir Arrhythmias 
                          -  Foscarnet Cardiomyopathy 
                          -  Anti-fungal agents Prolonged QT interval,arrhythmias 
                    
                      3) Agents used in HIV-associated malignancies   
                          -  Chemotherapeutic agents Cardiomyopathy, ventricular  
  
arrhythmias, heart blocks, 
hypertension, CAD 
                          -  Corticosteroids Atherosclerosis and CAD 
                          -  Interferon-α CAD 
                          -  Interleukin-2 CAD, Cardiomyopathy 
                                
MHC= Major histocompatibility complex, NRTI= Non-nucleoside reverse transcriptase inhibitor, 
PI= Protease inhibitor, CAD= coronary artery disease 
   
 
[Source: adapted from (47)] 
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1.4.3 CLINICAL SPECTRUM OF DISEASE 
 
The clinical spectrum of cardiovascular disease in HIV/AIDS is wide and includes 
involvement of all three embryological layers of the heart: endocardium, myocardium 
and pericardium. The principle HIV-associated cardiovascular abnormalities and their 
reported incidence are listed in Table 1.3. 
 
Table 1.3:  The main cardiovascular complications of HIV/AIDS 
CONDITION: INCIDENCE: 
    
Pericardial effusion 11% per year in asymptomatic AIDS patients 
  before the introduction of HAART (pre-HAART) 
    
Myocardial disease:   
                         Dilated cardiomyopathy 15.9 patients in 1000 asymptomatic HIV-infected 
  persons pre-HAART 
                         Myocarditis 1/3 of AIDS patients identified post mortem 
    
Coronary artery disease Incidence pre-HAART unknown 
  Data limited to case reports post-HAART 
    
Endocarditis 10-17% of AIDS patients identified post mortem 
    
HIV-associated pulmonary hypertension 1/200 of HIV-infected persons pre-HAART  
    
Systemic arterial hypertension 20-25% of HIV infected persons pre-HAART 
  Up to 74% in HIV-infected persons with HAART- 
  related metabolic syndrome 
    
AIDS related tumours:   
                       Kaposi's sarcoma        12-28% of AIDS patients pre-HAART 
                       Non-Hodgkins lymphoma  limited to case reports pre-HAART 
    
Thrombosis and embolism  limited to case reports pre and post HAART 
HIV vasculopathy  limited to case reports pre and post HAART 
Conduction abnormalities  limited to case reports pre and post HAART 
 
[Source: adapted from  (48)] 
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Pericardial effusion 
 
Pericardial effusion is the commonest manifestation of HIV infection with a reported 
incidence of 11% per year before the advent of HAART (49). In Africa, an estimated 
70% of patients hospitalised with pericardial effusion have concomitant HIV infection 
with more than 90% of cases caused by tuberculosis (50).and the incidence of 
tuberculous pericarditis is said to be rising as a direct result of the HIV epidemic (51). 
The IMPI Africa (Investigation of the Management of Pericarditis in Africa) registry 
showed that clinically evident HIV infection had a major impact on the death rate, raising 
it from 17% in patients without clinical features of HIV infection to 40% in those with 
overt HIV disease (52). Furthermore, HIV positive patients were found to have greater 
evidence of myopericarditis, dyspnoea, and haemodynamic instability. These findings, if 
confirmed in other studies, may suggest that more intensive management is warranted in 
patients with HIV-associated pericardial disease (53).   HIV itself can cause effusion as 
part of a generalised serous effusive process involving pleural and peritoneal surfaces 
(i.e. capillary leak syndrome related to enhanced cytokine expression in later stages) (54). 
The presence of effusion is an ominous sign that suggests an advanced stage of infection 
and is an independent predictor of mortality regardless of symptomatology (55). 
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Myocardial Disease 
 
The prevalence of myocardial abnormalities among AIDS patients is 25%-75% (43). The 
spectrum of myocardial abnormalities includes myocarditis, dilated cardiomyopathy, 
ischaemic heart disease and myocardial involvement in Kaposi’s sarcoma or lymphoma.  
Histopathologic evidence of myocarditis has been found in approximately one third of 
AIDS patients at autopsy, but no specific cause was identified in more than 80% of the 
cases (56).  
 
Multiple pathogens have been implicated in the pathogenesis of myocarditis, including 
Toxoplasma gondii, Mycobacterium tuberculosis, Cryptococcus neoformans, 
Cytomegalovirus, Herpesvirus types 1 and 2 as well as HIV itself (57). HIV-1 virions 
appear to infect myocardial cells in patchy distributions (58) without a clear direct 
association between HIV-1 and cadiac myocyte dysfunction. It is unclear how HIV-1 
may enter CD4-receptor-negative cells such as myocytes. Reservoir cells (i.e. dendritic 
cells) may play a pathogenic role in the interaction between HIV-1 and the myocyte and 
in the activation of multi-functional cytokines (tumour necrosis factor-α [TNF-α], 
interleukin -1 [IL-1}, interleukin -6 [IL-6], interleukin -10 [IL-10]) that contribute to 
progressive and late tissue damage (59).   
 
Cardiomyopathy (CMO) is now recognised as an important complication of HIV/AIDS, 
with an estimated annual incidence of 15.9 in 1000 before the introduction of HAART 
(60). The present day prevalence has been reduced by 30% in developed countries, 
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attributable to the introduction of HAART and the reduction of opportunistic infections 
(61).  
 
The cause of CMO is complex and multifactoral including viral infections, nutritional 
deficiencies (selenium, carnitine, and vitamins B1 and B12), autonomic insufficiency and 
autoimmune factors (cytokine imbalances) (62). Increased levels of anti-α-myosin 
antibodies in patients with HIV and heart muscle disease have also been described (63). 
Compelling evidence from animal models indicates that thymidine analogues (zidovudine 
and stavudine) and didanosine have marked adverse effects on myocardial structure and 
function that are mediated by mitochondrial toxicity (64). Abnormal myocardial 
mitochondrial function and depletion of mitochondrial DNA have been documented in 
these animal models (64).  
 
Combination ART that includes an HIV-1 protease inhibitor, by altering myocardial 
glucose uptake via glut-4 blockade (65), may also predispose susceptible patients to 
myocardial dysfunction. However, clinical data linking specific ART classes or agents 
with myocardial dysfunction in adult patients are lacking. CMO is usually a late 
manifestation of HIV disease with a poor prognosis. Various studies have shown a 
correlation between CMO and a poor prognosis. In patients with CMO, the median 
survival period is reduced to 101 days, compared with 472 days for patients who are at a 
similar stage of AIDS but whose hearts are normal (66). 
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There are presently no controlled clinical studies in the adult population to suggest the 
efficacy of specific therapeutic regimens for CMO in HIV and the treatment remains 
standard. 
 
Endocarditis 
 
Patients with AIDS may develop either infective endocarditis or non-bacterial thrombotic 
(marantic) endocarditis. Marantic endocarditis has been reported with increasing 
frequency in HIV-positive patients who are in the terminal stage of disease (57). The 
prevalence of endocarditis in autopsy studies of patients with AIDS has been reported as 
10%-17%, with multi-valvular involvement being common (67). The condition is not 
limited to the valves and may arise or involve the endocardial lining or vascular 
endothelium (43). Autopsy has also revealed pulmonary and/or systemic 
thromboembolism in at least 40% of HIV-positive patients with thrombotic endocarditis.   
 
The overall incidence of infective endocarditis is the same in patients with and without 
HIV (46) and does not seem to be affected by HAART (48). The use of intravenous drug 
use increases the risk for developing right-sided endocarditis. Marantic endocarditis is, 
however, less frequent in the post-HAART era (62). The diagnosis and management is 
standard. 
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Primary pulmonary hypertension 
 
The incidence of primary pulmonary hypertension is estimated to occur in 0.5% of 
hospitalised patients with HIV (68). The pathogenesis is multifactoral and poorly 
understood. HIV may cause endothelial damage and mediator-related vasoconstriction 
through stimulation by the envelope gp120, with direct release of endothelins, 
interleukins and tumour necrosis factor-α (69). The development and progression of 
pulmonary hypertension bear no relation to the stage of underlying HIV disease (47). The 
prognosis for patients with this complication is poor, with reported 1-year survival rates 
of 51% (70). Effects of HAART regimens on the clinical course are unknown and current 
guidelines suggest similar treatment as for patients without HIV. 
 
Systemic hypertension 
 
The prevalence of systemic hypertension in HAART-naïve HIV positive black South 
Africans is lower than the general population (71). In a large population-based survey of 
body mass index (BMI) and blood pressure (BP) in rural KwaZulu-Natal, South Africa, 
an area of high HIV prevalence, it was shown that HAART-naïve HIV positive patients 
had significantly lower BMI’s and systolic blood pressure (SBP) compared to age and 
sex matched HIV negative individuals. Furthermore, after adjusting for BMI and other 
determinants of BP,  HIV remained a significant predictor for SBP possibly due to HIV-
related hypoadrenalism or side effects of traditional medicines against HIV (71).  
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In this community in rural Africa, the epidemiologic transition from diseases of poverty 
to those of affluence (22), while already far advanced, has been partially halted by the 
advent of HIV. Obesity and hypertension- both conditions of affluence- are very 
common, but would be even more prevalent in the absence of untreated HIV infection 
(71).  This data contrasts with that of the developed world where the prevalence of 
hypertension in HIV positive patients on treatment is significantly higher than the HIV 
negative population with a prevalence of  up to 74% in patients with HAART-related 
metabolic syndrome (14). Predisposing factors include: leukocytoclastic vasculitis in 
small, medium and large vessels and aneurysms of the large vessels, such as carotid, 
femoral and abdominal aorta, with impairment to flow to renal arteries; HAART-induced 
insulin resistance with increased sympathetic activity; and sodium retention. Acute and 
chronic renal failure also contributes to hypertension in this population (72).. 
 
Cardiac tumours 
 
The two main types of tumours found in patients with HIV/AIDS are Kaposi’s sarcoma 
(KS) and non-Hodgkins lymphoma (NHL). Since the introduction of HAART, the 
incidence of KS has decreased markedly and NHL involving the heart is infrequent (48). 
Cardiac KS is usually occult and rarely diagnosed during life. Pericardial involvement 
may rarely manifest as tamponade or constriction.The frequency of NHL in patients with 
AIDS is estimated to be 25 to 60 times greater than in the general population. Most 
NHL’s affecting the heart are high grade tumours and the overall survival rate is poor 
(41).  
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Thrombosis and embolism 
 
HIV positive patients, especially those with fat redistribution, may develop coagulation 
abnormalities, such as: increased levels of fibrinogen, D-dimer, plasminogen activator 
inhibitor-1(PAI-1) and Tissue-type Plasminogen activator antigen, or a deficiency of 
protein S (PS) (73, 74). These abnormalities have been associated with documented 
thromboses involving both veins and arteries and seem to be related to protease inhibitor-
containing HAART (74). In a series of HIV positive patients with venous or arterial 
thrombosis, deep vein involvement most commonly in the lower extremity and secondary 
pulmonary emboli accounted for 66% of all thrombotic events. In this cohort, persistent 
antiphospholipid antibodies were the most common finding (75). An association between 
cigarette smoking and spontaneous thrombosis in HIV patients has been reported (76) 
and was reported to affect 77% of the patients in one series (75). 
 
HIV vasculopathy 
 
A wide range of inflammatory vascular diseases, both infective and non-infective may 
develop in HIV individuals. These include polyarteritis nodosa, Henoch Schönlein 
purpura and drug induced hypersensitivity vasculitis (45). Kawasaki-like syndrome (77) 
and Takayasu’s arteritis (78) have also been described. Large-vessel disease may be 
aneurysmal or occlusive. Aneurysms may be single or multiple and may affect vessels 
such as the aorta or common carotid, common iliac, femoral or popliteal arteries (79). 
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Occlusive disease has been reported in Africa in young HIV positive patients and is less 
common than aneurysmal dilatation (79, 80). In both processes, the main histopathologic 
features are found in the adventitia, with leukocytoclastic vasculitis of the vasa vasorum 
and periadventitial vessels, chronic inflammation and fibrosis (80).  
 
Conduction abnormalities 
 
Prolonged QTc intervals and consequential torsades de pointes have been described in 
patients with HIV infection. In one study, up to 29% of hospitalised HIV patients were 
shown to have a prolonged QTc interval, without an obvious cause being apparent (81). 
In addition, certain drugs used commonly in patients with HIV infection may prolong the 
QTc interval: trimethoprim/sulfamethoxazole, fluoroquinolones, amphotericin B and 
pentamidine. Protease inhibitors have also been shown to block the human ether-a-go-go 
related gene channel and prolong QT intervals (82). 
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1.5   HIV AND CORONARY ARTERY DISEASE 
 
1.5.1   INTRODUCTION 
 
The first case report of severe premature CAD in 2 young men with HIV infection 
receiving protease inhibitor (PI) containing HAART was reported in 1998 (83). This was 
the first sign of the potentially deleterious effects of PI’s on the vasculature, which has 
resulted in widespread research on the topic. Necropsy studies, however, had 
demonstrated premature CAD in HIV-infected patients even before the advent of PI’s 
(84).  
 
Subsequent to this, in 2000 Tabib et al. (85) described pathological findings in 15 HIV 
positive patients who had died aged 23-32 years, after having been seropositive for 2-5 
years with minimal cardiovascular risk factors. The coronary arteries showed accelerated 
atherosclerosis and arteriosclerosis, with particular features intermediate between the 
lesions observed in common coronary atherosclerosis and atherosclerosis associated with 
chronic rejection of cardiac transplants, which evolves more rapidly (85).  
 
The striking histopathological feature in this study was the presence of hyperplastic 
endothelial cells lining a thickened intima, characterised by the proliferation of smooth 
muscle cells and monocytic macrophages associated with the expression of the pro-
inflammatory cytokines, TNF-α and interleukin-1α and rare lymphocytes on a framework 
rich in elastic fibres, resulting in endoluminal protrusions (85). The findings in this study 
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argued for the role of an inflammatory response to the HIV virus as a contributing 
aetiological factor to the development of atherosclerosis and it seems plausible that 
atherosclerotic lesions in HIV positive patients are of multifactoral origin. 
 Other forms of CAD in HIV, besides atherosclerotic disease, have been described, but 
are limited to case reports only.  Barbaro et al.(86) described a case of HIV-associated 
coronary arteritis in a HAART-naïve patient, with no known cardiovascular risk factors, 
who suffered a fatal MI. Histologic analysis of  both the anterior descending and 
circumflex arteries showed a dense infiltration of lymphocytes with necrosis of the 
intima. In-situ hybridization performed on serial sections of these arteries showed the 
presence of HIV-1 sequences within the arterial wall. Potential mechanisms through 
which HIV-1 may cause coronary arteritis are activation of pro-inflammatory cytokines 
and cell adhesion molecules and alteration of major-histocompatibility-complex (MHC) 
class 1 molecules on the surface of smooth muscle cells (87). Infected cells may also 
generate reactive oxygen species with the activation of factors that induce apoptosis (87). 
There have also been case reports on the presence of thrombophilic states associated with 
HIV infection causing MI. Santos et al. (88) described a case of recurrent coronary 
thrombosis associated with HIV infection, factor V Leiden, antithrombin deficiency and 
the primary antiphospholipid syndrome (APS). 
 
Coronary artery disease in the setting of HIV seems to be a heterogenous disease having 
a multifactoral aetiology, including effects of the virus itself and the metabolic and 
immunorestorative effects of HAART. These aspects will be described in detail in section 
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5.2.  Some controversy still exists as to whether or not the rate of coronary events is 
increased in HIV patients and whether or not the increase is caused solely by HAART.  
 
The main studies addressing this question are summarised in Table 1.4.  
Table 1.4:   Coronary event rates in HIV patients according to protease inhibitor status  
Study Patients,n Age,y 
Follow 
up Events Findings 
        
DAD study 
group 23 468 39 (median) 
1.6y on 
PI's 126 MI's Risk of MI ↑ with increased 
(18)      exposure to PI combination therapy p<0.001 
        
Bozette et 
al. 36 766 NA 40 mo 1207 admissions for CVD No ↑ in CVD admissions with PI's 
 (89)       
      or with ↑ in duration of PI treatment 
Mary-
Krause et al. 34 976 37.7 (mean) 33 mo 60 MI's Risk of MI ↑in PI vs. non-PI treated 
 (90)     patients. OR 2.56;95% CI, 1.03-6.34  
       
Coplan et al. 10 986 37 (mean) 1y 29 MI's Risk of MI not ↑ in PI vs. non-PI treated 
 (91)     patients. OR 1.69; 95% CI, 0.54-7.48 
        
Holmberg et 
al. 5672 42.6 (mean) 3.1y 21MI's Risk of MI ↑ in PI vs non-PI treated   
 (92)     patients. OR, 7.1; 95% CI, 1.6-44.3 
        
Klein et al. 4159 42.6 (mean) 3.6y 72 CAD events, incl 47 MI's No difference in event rates between regimens 
 (93)     but ↑event rates in HIV patients vs. controls 
        
Barbaro et 
al. 1551 35.5 (median) 36mo 25 coronary events  Risk of MI ↑ in PI vs. non-PI treated patients 
 (94)    including 13 MI's RR, 11.5; CI, 2.7-48.5 
        
Frankfurt 
HIV-cohort 
study  4993 NA 58 29 MI's ↑MI rates in patients after the introduction  
 (95)         of HAART 
 
NA= not reported 
CAD=coronary artery disease; CI= confidence interval; CVD= cardiovascular disease; HAART= 
highly active antiretroviral therapy; HIV= human immunodeficiency virus; MI= myocardial 
infarction; OR= odds ratio; PI= protease inhibitor 
[Source: adapted from (6)] 
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In a large prospective observational benchmark study of 23 437 patients with HIV, 
conducted by Friis-Moller et al. in Denmark [D:A:D study group: Data Collection on 
Adverse Events of Anti-HIV Drugs (18)], which looked specifically at the long term 
effects of different ART regimens on coronary events, increased exposure to PI’s was 
associated with an increased risk of MI. The relative rate of MI per year of PI exposure 
was 1.16 (95% confidence interval 1.10 to 1.23), whereas the relative risk per year of 
exposure to non-nucleoside reverse transcriptase inhibitors was 1.05 (95% confidence 
intervals 0.98 to 1.13). Adjustment for dyslipidaemia eliminated any CAD risk associated 
with non-nucleoside reverse transcriptase inhibitor use, but the association with PI’s 
remained significant.  
 
Considering the collective data, the suggestion is that the rate of MI is higher in patients 
taking protease inhibitors and that the risk increases with treatment duration.  
 
1.5.2   CLINICAL AND ANGIOGRAPHIC FEATURES OF CORONARY 
ARTERY DISEASE IN HIV PATIENTS OF THE DEVELOPED WORLD 
 
Various studies have looked at whether the clinical expression, angiographic features and 
management of HIV patients with CAD differs from the general population. The results 
of the main studies are presented in Table 1.5. 
 
 
In general, HIV patients tend to be younger at first presentation of ACS compared to HIV 
negative patients. In this reviewed series of eight studies, the age ranged from a mean or 
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median of 42 to 50 years. This was 11 years younger than the HIV negative population 
with ACS found in the study done by Hsue et al. (96). There was a higher percentage of 
men compared to women (91% vs. 9%). In terms of coronary risk factors, the majority of 
patients (61%) were active smokers at the time of their coronary event.  
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  Table 1.5:   Clinical and angiographic features of coronary artery disease in HIV patients of the developed world 
 
Study Patients 
n 
Age, y Smoking
(%) 
CD4 count 
cells/mm3 
PI use 
(%) 
MI on 
presentation 
n(%) 
Coronary 
angiogram 
n(%) 
Single vessel 
disease 
 n(%) 
PCI, n(%) Stent ,n(%) Overall 
restenosis n(%) 
In-Stent 
restenosis n(%) 
CABG 
n(%) 
                      
                
Hsue et 
al. (96) 
68 50 ± 8 68 341 (3-
4360)* 
49 37/68(54) 56/68(82) 20/56(36) 29/68(43) 22/68(32) 15/29(52) 11/22 (50) 6/68(9) 
                
Matetzky 
et al. (97) 
24 47 ± 9 58 318 ± 210 71 24(100) 21/24(88) 5/21(24) 17/24(71) 17/24(71) 6/14(43)† 6/14(43) 3/24(13) 
                
Escaut et 
al. (98) 
17 46 ± 6 71 272 ± 185 65 11/17(65) 17/17(100) 9/17(53) 14/17(82) 11/17(65) 5/14(35) 5/11(45) 0/17(0) 
                
Mehta et 
al. (99) 
129†† 42 ± 10 NA 313 ± 209 NA 82/106(77) 76/129(59) 26/76(35) 32/129(25)‡ NA NA NA NA 
                
Ambrose 
et al. 
(100) 
51 48 ± 9 55 426 ± 290 59 34/51(67) 45/51(88) 21/45(47) 25/51(49) 21/51(41) NA NA 9/51(18) 
                
Varriale 
et al. 
(101) 
29 46 ± 10 55 >500 in 
18/29 
66 29(100) 13/29(45) NA 10/29(35) NA NA NA 3/29(10) 
                
Boccara 
et al. 
(102) 
50 43 ± 
6.5 
NA 456 (18-
1220)* 
76 49/50(98) 50/50(100) NA 38/50(76) 38/50(76) 5/38(14) 5/38(14) 0/50(0) 
                
Segev et 
al. (103) 
12 48 ± 9 58 <500 in 
12/12 
92 2/12(17) 12 NA 12/12(100) 12/12(100) 7/12(58) 7/12(58) 0/12(0) 
Data presented as mean ± standard deviation, percentages or median (range) * 
N/A= not reported, PI=Protease Inhibitor, PCI= Percutaneous Coronary Intervention, CABG= Coronary Artery Bypass Graft 
  † 14 patients available for relook angiography; †† Patients drawn from 25 previous reports; ‡ Includes total no. revascularised by PCI or CABG. 
  [Source: adapted from (6)] 
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The proportion of patients receiving PI’s ranged from 49% to 92%. Mean HDL 
cholesterol  levels were significantly lower in HIV patients compared to HIV negative 
controls in the four studies in which they were reported, with levels of  0.9 ± 0.3 mmol/L 
(96), 0.8 ± 0.3 mmol/L (97) and 0.7 ± 0.3 mmol/L (98), with the fourth study quoting a 
higher percentage of HIV patients with low HDL cholesterol (88% vs. 42%, p<0.001) 
and hypertriglyceridaemia (78% vs. 46%, p=0.001) (102). Mean LDL cholesterol levels 
were lower in HIV patients compared to HIV negative controls in one study (97), but this 
was not found in another study (96).   
 
In terms of angiographic features, as might be expected from a young cohort, single 
vessel CAD is commonly found in  HIV patients and the TIMI risk score is low if an 
ACS is present (96). Percutaneous coronary intervention (PCI) has been used safely and 
effectively as a revascularisation strategy in HIV positive patients with ACS (96, 98, 100, 
102, 103), with excellent angiographic success.  
 
In terms of short term outcomes, in the eight studies reviewed (Table 1.5), only nine 
deaths (3.8%) occurred in hospital among 235 HIV positive patients. Several studies have 
raised a concern about a much higher than expected incidence of restenosis in HIV 
patients undergoing PCI with either angioplasty or bare metal stenting. Significantly 
higher rates of restenosis were shown in four of the five studies (Table 1.5) reporting data 
on restenosis (96-98, 103).  
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In the series by Hsue et al., restenosis developed in 15 of 29 HIV patients, compared with 
3 of 21 non-HIV patients (52% vs. 14%, p=0.006) (96). For patients receiving stents, the 
restenosis rate was 11 of 22 HIV patients vs. 2 of 11 control subjects (50% vs. 18%, 
p=0.078). Similarly in the series by Matetzky et al (97), restenosis requiring target vessel 
revascularisation (TVR) occurred in 6 of 14 HIV patients, compared with 4 of 38 
uninfected controls (43% vs. 11%, p=0.02)(97). The 6 HIV infected patients who 
underwent TVR, as compared to the 8 HIV patients who did not, had: a higher incidence 
of detectable HIV RNA load (5/6[83%] vs. 3/8[38%]; p=0.140 and lower CD4 count 
(280 ± 45 vs. 388 ± 185 x10 -3µL; p=0.4), although the differences were not statistically 
significant.  
 
In the series by Escaut et al. (98), restenosis occurred in 43% of HIV patients treated with 
angioplasty alone and in 57% of patients who underwent bare metal coronary stenting 
(98). Segev et al (103) reported on 12 HIV patients who all received at least one bare 
metal stent for either an acute or chronic coronary indication. Seven (58%) patients 
developed angiographic restenosis, clinical restenosis or progression of CAD. All five 
patients with documented angiographic in-stent restenosis had a diffuse proliferative form 
of the disease (103). Boccara et al. (102) failed to show an increased incidence of 
restenosis in his series of 50 patients presenting with an ACS. Clinical restenosis, 
including TVR, was not statistically different between HIV positive and negative patients 
(14% vs. 16%, p=0.78).  
 
35 
 
The mechanism by which HIV may predispose to restenosis is thought to be related to a 
heightened inflammatory milieu. Patients with higher levels of inflammatory markers, 
such as C-reactive protein (CRP), at the time of PCI, have higher restenosis rates (104). 
Chronic low level inflammation in HIV patients may, therefore, contribute to their high 
rate of restenosis.  
 
By inducing adhesion molecule expression on endothelial cells (105) and LDL 
cholesterol uptake by macrophages (106), CRP may contribute directly to atherogenesis 
and restenosis. No data regarding the safety and efficacy of drug eluting stents (DES) in 
the setting of HIV are currently available and, similarly, no data exists on the incidence 
of stent thrombosis.  
 
Several patients in these studies underwent coronary artery bypass surgery (CABG), but 
no large series of HIV patients with long term follow up after bypass surgery have been 
reported (6). Initial concerns about the immunosuppressive effects of surgery and, in 
particular, cardiopulmonary bypass (CPB) and risk of postoperative infection seem to be 
unfounded (107). In a series of 37 HIV positive patients who were followed up for a 
mean of 28 months after cardiac surgery, 29 of whom  received coronary bypass grafts, 
event free survival was 81% at 3 years (108). In recent years it has become apparent that 
the prognosis is strongly influenced by the patient’s baseline condition (108). Patients 
with clinical AIDS, bacterial endocarditis and a history of intravenous drug abuse have a 
much worse outcome after cardiac surgery than patients who are simply HIV carriers 
(107).    
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1.5.3   PATHOGENESIS OF ATHEROSCLEROSIS IN HIV PATIENTS 
 
1.5.3.1  INTRODUCTION 
 
Atherosclerosis is characterised by a complex multifactorial pathophysiology. 
Inflammation in the vessel wall is now considered to play an essential role in the 
initiation, progression and final steps of atherosclerosis, namely destabilisation and 
plaque rupture (109). Classical pathologic studies show the abundant presence of 
inflammatory cells, like monocyte-derived macrophages and T-lymphocytes, at the site of 
rupture, or superficial erosions, especially at the shoulder area of the plaque cap.  
 
These morphological characteristics are preceded by dysfunction of activated endothelial 
cells, which produce adhesion molecles that interact with inflammatory cells. The ability 
of monocyte-derived macrophages to secrete various cytokines, chemokines, growth 
factors and disintegrins, then leads to: activation and proliferation of smooth muscle cells, 
lesion progression and finally to weakening of a vulnerable plaque by matrix degradation 
of its fibrous cap (110). Endothelial cells play a fundamental role in the basal and 
dynamic regulation of the circulation and are constantly exposed to potentially noxious 
circulating agents, such as cholesterol, cigarette by-products and infective agents. 
Endothelial cells play an important role in the generation of the inflammatory response 
directed against such noxious stimuli.  
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Inflammation caused by infection has been recognised for a long time (111). In contrast, 
the sub-clinical inflammatory changes in the arterial wall because of cardiovascular risk 
factors have only recently emerged as an important pathogenic factor in atherosclerosis. 
Inflammatory markers such as CRP and IL-6 have strong and independent prognostic 
implications in patients with atherosclerotic vascular disease (109).  
 
1.5.3.2  EFFECTS OF HIV ON ATHEROSCLEROSIS 
 
Although HIV infection causes immunosuppression with an attenuated inflammatory 
response to certain opportunistic infections, HIV infection causes profound functional 
alterations of the endothelium resembling the sub-clinical inflammation in atheroscleosis. 
The mechanism of HIV-related endothelial dysfunction is not clear, but may include: 
lipid disorders associated with HIV infection (112), viral protein-related endothelial 
activation (113), effects of systemic inflammatory cytokine or chemokine dysregulation, 
or direct HIV infection of the endothelium and vascular smooth muscle cells (114). HIV-
associated systemic inflammation may contribute to endothelial dysfunction and it has 
been shown that treatment of HAART-naïve HIV patients with the anti-inflammatory 
agent Salsalate improved endothelial dysfunction (115). HIV-associated activation of 
macrophages may predispose patients to endothelial dysfunction and enhance atheroma 
formation (12). In addition, activated endothelial and vascular smooth muscle cells can 
contribute to a prothrombotic milieu (116).  
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Progressive HIV disease is associated with accelerated T-cell proliferation, heightened T-
cell activation and high levels of pro-inflammatory markers (117) that persist even after 
the introduction of HAART (118). The level of immune activation has been 
independently associated with CD4 T-cell nadir (106). Both immunodeficiency and 
immune reconstitution may be pro-atherogenic.  
 
T lymphocytes play a key role in atherogenesis (119). CD4 activation promotes 
atherosclerosis through elaboration of pro-inflammatory cytokines, including Tumour 
necrosis factor-α (TNF- α) and the interleukins (120). Analogously, T-cell lymphocytes 
are also involved in the arteriosclerosis that develops in immune-suppressed patients after 
cardiac transplantation (121). Chronic low grade inflammation contributes to accelerated 
atherosclerosis (122). CRP levels are higher in HIV patients than in control subjects (16) 
and subjects with levels of this marker in the upper quartile or quintile have an elevated 
risk of cardiovascular events (123) . Some experimental data indicate that CRP is an 
active participant in the process of atherogenesis (124).  
 
Leukocyte adherence to the endothelium is enhanced as the expression of cell adhesion 
molecules increase as part of the inflammatory process. Monocyte chemoattractant 
protein-1 (MCP-1) is a potent activator of macrophages and monocytes, stimulating them 
to migrate to the sub-endothelial space, where they begin phagocytosis of modified 
lipoproteins to become lipid-laden foam cells - an early step in atherogenesis. The data 
obtained from clinical and experimental studies provide support for a role of MCP-1 in 
the initiation and progression of atherosclerosis (125). Among HIV patients with sub-
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clinical atherosclerosis by carotid and femoral ultrasound, MCP-1 plasma levels were 
higher and the frequency of a mutation in the promoter gene was also higher compared to 
HIV patients without atherosclerosis (126). Elevated circulating levels of von Willebrand 
factor (vWF), a glycoprotein facilitating platelet adhesion, synthesised in endothelial cells 
and megakaryocytes, are elevated  in untreated HIV patients compared to HIV negative 
patients, reflecting endothelial activation. This correlates with circulating levels of 
inflammatory cytokines, such TNF-α , IL-6 and interferon γ (IFNγ). Plasma  levels of 
vWF have prognostic relevance in CAD (111) and tend to decrease towards normal with 
HAART treatment (127).  
 
Platelet activation is also enhanced in HIV patients (127). Cigarette smoking, rates of 
which are particularly high in HIV patients (6), activates platelets and increases 
coagulability. In  addition, abnormalities of lipid metabolism, such as 
hypertriglyceridaemia and low levels of HDL have been described in patients infected 
with HIV before the advent of HAART (11, 12). Endothelial dysfunction, inflammation, 
platelet activation and hypercoagulability interact to enhance the atherogenic and 
thrombotic milieu of the arterial wall. The effects of HIV on atherosclerosis are 
summarised in Table 1.6. 
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Table 1.6:  Effects of HIV on atherosclerosis  
 
1. Endothelial dysfunction: 
    - viral protein-related endothelial cell activation 
    - direct infection of endothelium and vascular smooth muscle cells 
    - effect of HIV-associated lipid disorders 
2. Lipid disorders associated with HIV infection- hypertryglyceridaemia and low HDL 
3. Systemic inflammatory cytokine-chemokine dysregulation 
4. Enhanced atheroma formation by activated macrophages 
5. Platelet activation 
6. Prothrombotic state 
 
 
[Source: adapted from (128)] 
 
1.5.3.3  EFFECTS OF ANTI-RETROVIRAL THERAPY ON 
ATHEROSCLEROSIS 
 
The first report of premature CAD in a patient treated with protease inhibitors (PI’s) was 
published in 1998 (83). PI’s have increasingly been linked to the occurrence of CAD by 
inducing dyslipidaemia, insulin resistance, increased levels of C peptide and 
lipodystrophy (129). Insulin resistance occurs in as much as 25% to 60% of patients 
treated with PI’s (130). PI’s lead to typical alterations in lipid metabolism commonly 
associated with insulin resistance i.e. decreased HDL cholesterol, increased LDL 
cholesterol, hypertriglyceridaemia and hyperinsulinaemia. As a consequence, there is 
reduced uptake of serum lipids by fat cells, increased lipolysis in the sub-cutaneous 
adipose tissue and increased production of lipids by hepatocytes.  
 
Protease inhibitors are designed to target the catalytic region of two proteins that regulate 
lipid metabolism, namely cytoplasmic retinoic acid binding protein-1 and low density 
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lipoprotein-receptor-related protein (131). It has been hypothesised, although without 
strong experimental support, that this homology may allow PI’s to interfere with these 
proteins and cause the metabolic and somatic alterations that develop in PI-treated 
patients (131). Recent data indicate that dyslipidaemia may be caused, at least in part, 
either by PI-mediated inhibition of proteasome activity and accumulation of the active 
portion of sterol regulatory element-binding-protein 1c in liver cells and adipocytes (132) 
or by apoprotein-CIII polymorphisms in HIV-infected patients (133).  
 
The effects of PI’s on lipid metabolism appear to be drug specific. For example: 
Ritonavir increases triglycerides and lowers HDL slightly, with no increase in LDL 
(134); whereas indinavir has no effect on lipoproteins but causes insulin resistance (135). 
Amprenavir has no effect on lipoproteins (134), but lopinavir/ritonavir increases 
triglycerides with no effect on LDL, HDL or insulin resistance (136). These studies were 
of short duration and involved HIV-negative subjects to isolate the effects of the drugs.  
 
Abnormalities in body composition are frequent in HIV patients and have been reported 
in 20% to 30% of patients after one to two years of combination HAART (137). The type 
and duration of ART are strongly associated with the development and severity of 
lipodystrophy. Combination therapy with a PI and two NRTI’s, particularly stavudine 
with didanosine, is most likely to induce severe lipodystrophy (112).  The redistribution 
of body fat is manifest as fat wasting of the extremities, buttocks and face and/or central 
fat accumulation, including visceral adiposity, enlargement of breasts or gynaecomastia, 
increased neck circumference, dorsocervical fat pads (buffalo humps) and lipomas.  
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Although dyslipidaemia and abnormal glucose tolerance are not observed in every patient 
with fat redistribution, most studies describe an association between fat redistribution and 
a cluster of metabolic abnormalities including: insulin resistance, hypertryglyceridaemia 
and low serum levels of HDL (138).  Untreated HIV-infected patients have endothelial 
dysfunction that improves with ART but that does not return to normal in the short term 
(139).  
 
In contrast, one early study documented severe endothelial dysfunction in patients 
receiving long term, PI-based ART, but not in those receiving ART without a PI (129). 
Half of the patients received the older and now seldomly used PI indinavir. More 
contemporary studies, in which few patients received indinavir, have not confirmed a role 
for PI-containing ART regimens causing endothelial dysfunction (140). Studies in HIV 
uninfected patients show a marked effect of indinavir inducing endothelial dysfunction 
(141), but suggest a beneficial (142) or neutral (143) effect with the protease inhibitor 
combination lopinavir-ritonavir, or with atazanavir (143) on endothelial function.  
 
In the South African context, indinavir is also no longer recommended due to problems 
with toxicity; atazanavir, lopinavir and saquinavir are the preferred PI’s, generally used 
as second line ART (Appendix). The effects of PI’s on the endothelium, therefore, 
depend on the specific agent used and there does not seem to be a class effect. 
Experimental models suggest that PI-induced endothelial dysfunction is mediated by 
reduced nitric oxide production or release, based on both clinical (144) and experimental 
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models (145). Specific mechanisms include reduced expression of endothelial nitric 
oxide synthase (145) and increased reactive oxygen species (146). Experimental data 
suggest that PI’s may promote atherosclerosis by effects other than those on circulating 
lipoprotein levels or endothelial dysfunction. These include impaired cholesterol efflux 
from foam cells (147) and increased macrophage cholesterol ester accumulation through 
upregulation of the CD36 scavenger receptor (148). Impaired endothelial regrowth, due 
to ART after experimental arterial injury, is another potential mechanism whereby ART 
may predispose to cardiovascular disease (149).  
 
PI-containing ART, therefore, seems to directly promote atherosclerosis independently of 
the metabolic effects described above. The mechanisms by which ART may adversely 
affect the vasculature are shown in Table 1.7. 
 
Table 1.7:  Effects of ART on atherosclerosis 
 
1. Endothelial dysfunction 
2. Increased endothelial permeability 
3. Increased oxidative stress 
4. Increased mononuclear cell adhesion 
5. Persistent arterial inflammation and immune activation 
6. Accelerated lipid accumulation in the vessel wall 
7. Impaired response to vascular injury 
8. ART-associated lipodystrophy leading to :    - metabolic syndrome 
                                                                           - insulin resistance 
                                                                           - mixed dyslipidaemia 
                                                                           - hypertension 
                                                                           - systemic inflammation 
                                                                           - ↓ circulating adiponectin 
 
 
[Source: adapted from (128)] 
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Carotid intima media thickness, an independent risk factor for MI and stroke (150), has 
been shown to be increased in patients treated with PI’s compared to patients on non-PI 
containing regimens (151) (Figure 1.4). There is now good evidence to suggest that HIV 
patients on PI-containing ART regimens have a higher incidence of ACS compared to 
patients on non-PI containing regimens. In a prospective observational study of 23 437 
patients with HIV, conducted by Friss-Moller et al. in Denmark [D:A:D study group: 
Data Collection on Adverse Events of Anti-HIV Drugs (18)], increased exposure to PI’s 
was associated with an increased risk of  MI. The relative rate of MI per year of PI 
exposure was 1.16 (95% confidence interval 1.10 to 1.23), whereas the relative risk per 
year of exposure to non-nucleoside reverse transcriptase inhibitors was 1.05 (95% 
confidence intervals 0.98 to 1.13). Adjustment for dyslipidaemia eliminated any CAD 
risk associated with non-nucleoside reverse transcriptase inhibitor use, but the association 
with PI’s remained significant.  
 
Figure 1.4:  The effect of protease inhibitors on carotid intima-media thickness in HIV 
positive patients 
Seminari et al. Atherosclerosis 2002; 162: 433-8 
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The pathogenesis and clinical manifestations of HIV-associated atherosclerosis may be 
different to common atherosclerosis. The disease seems to progress more rapidly in HIV 
patients, as evidenced by a specific histopathological form of the disease reported in post 
mortem studies (85) and evidence of rapid progression of carotid intima-media thickness 
(IMT) in HIV positive patients receiving PI-containing regimens compared to HIV 
negative controls matched for traditional risk factors (152). The reasons for this 
observation may be explained by the fact that HIV infection and ART act synergistically 
in the atherosclerotic process, which is multifactoral in HIV patients.  
 
1.5.4   ASSESSMENT OF ENDOTHELIAL FUNCTION 
 
The endothelium plays a key role in HIV-associated CAD in treatment-naïve patients and 
in those receiving HAART. The complex associations between infection, inflammation 
and the endothelium have long been known, but the underlying mechanisms are still not 
yet completely understood. Measures of endothelial function have been investigated to 
better understand the pathophysiology of endothelial dysfunction and (more recently) to 
investigate the actions of anti-retroviral drugs and estimate cardiovascular risk in HIV 
positive patients (153).  
 
Endothelial function assessment can be performed either invasively or non-invasively 
(154). Non-invasive models include the study of biomarkers that are present on the 
surface of endothelial cells or are expressed in response to several stimuli and which have 
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an important role in the process of leukocyte rolling, firm adhesion and transendothelial 
migration (155). Soluble cellular adhesion molecules (CAMS) are considered reliable 
biomarkers of atherosclerosis development and severity and to add to the predictive value 
of classic risk factors for CAD in healthy individuals and in patients (156). Another non-
invasive technique is the use of ultrasonography to assess the degree of flow mediated 
dilatation (FMD) of the brachial artery following an ischaemic stimulus, which provides 
a surrogate measure of the coronary circulation and a correlate of the severity of CAD 
(157). Another approach to studying endothelial function is to assess it invasively, by 
studying blood flow responses, either intracoronary or intra-arterial, to infusions of 
nitroglycerine and NG-mono-methyl-L-arginine (L-NMMA) (158).  
 
The use of non-invasive tests is clearly desirable and a recent approach to studying 
endothelial function in vivo in human beings has been to measure endothelial biomarkers, 
such as soluble CAMS, the assessment of which is non-invasive, relatively inexpensive 
and reproducible with low inter-operator variability. 
 
1.5.4.1  ENDOTHELIAL CELL ADHESION MOLECULES 
 
The adhesion to and subsequent transmigration of leucocytes across the vascular 
endothelium are early inflammatory events; these are mediated by endothelial CAMS and 
other counter-adhesive molecules present on leucocytes and other blood cells. Table 1.8 
lists the main adhesion molecules and their functions. 
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Initial rolling of leucocytes on the vascular endothelium is mediated by members of the  
Selectin family (159) by creating loose contacts with the endothelial layer. P-selectin 
(Platelet-selectin) is stored in the Weibel-Palade bodies of endothelial cells (EC’s) and is 
rapidly redistributed on the cell surface after agonist stimulation. E-selectin (endothelial-
selectin) derives from de novo synthesis by EC’s activated by inflammatory cytokines, 
such as IL-1 and TNF-α. E-selectin is maximally expressed 2 - 4 hours after cell 
activation. Within the next 24 - 48 hours, E-Selectin is again eliminated from the 
cytoplasmic membrane by shedding into the circulation, resulting in the  circulating form 
or soluble (sE-selectin) (160).  
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Table 1.8:  Endothelial cell adhesion molecules and their function 
Molecules Origin and expression Function 
     
Selectins:    
P-selectin 
Stored in EC and platelet granules; 
expressed on stimulation 
Loose contact of leucocytes on EC 
and platelets 
     
E-selectin Induced by cytokines on EC Loose contact of leucocytes on EC  
     
Immunoglobulins:    
ICAM-1 Upregulated by cytokines on EC and  Firm adhesion and transmigration 
  leucocytes   
ICAM-2 Constitutive on EC and platelets Firm adhesion  
VCAM-1 Upregulated by cytokines on EC  Firm adhesion and transmigration 
PECAM-1 Constitutive on EC, platelets and  Transmigration 
  leucocytes   
     
TNF family:    
CD40 
Constitutive on EC, leucocytes; 
expressed on leucocytes on stimulation 
CD40Ligand is proinflammatory for 
EC and a platelet agonist 
     
CD40 Ligand 
     
 
[Source: Adapted from (153)] 
 
CD= cluster of differentiation; EC = endothelial cells; ICAM-1= intercellular adhesion molecule-
1; VCAM-1 = vascular cell adhesion molecule-1; PECAM-1= platelet endothelial cell adhesion 
molecule-1 
 
Adhesion molecules involved in firm adhesion and subsequent transmigration are 
intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 (VCAM-
1), both belonging to the immunoglobulin super-family. E-selectin is the most specific 
endothelial CAM, while both VCAM-1 and ICAM-1 are also produced by other cell 
types (lymphocytes, epithelial cells, monocytes and smooth muscle cells) (153). Since P-
selectin is also contained in the platelet α-granules, from where it is released on 
activation, plasma P-selectin could partly indicate platelet activation (161). A significant 
association between increasing concentrations of soluble ICAM-1, VCAM-1 and E-
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selectin and future cardiac events was shown in apparently healthy individuals in the 
ARIC (Atherosclerosis Risk In Communities) study (162). 
 
1.5.4.2  HIV AND ENDOTHELIAL ADHESION MOLECULES  
 
In the past decade, although measured by different laboratory methods, most  reports 
agreed on increased rates of soluble adhesion molecules in HIV positive patients (153). 
As discussed in section 5.3.2, endothelial activation in HIV is multifactoral. The link 
between in-vitro findings and clinical data is still lacking, however. A capacity to 
transiently infect EC’s, either directly or indirectly, would suggest that this is the main 
mechanism of the raised plasma concentrations.  
 
The possible link between HIV immunological status and the concentrations of soluble 
CAMS as biomarkers of the severity of endothelial injury have been explored in several 
small cross-sectional studies. Seigneur et al. (163) conducted a study on  90 HIV-infected 
patients, around half of whom were taking an anti-retroviral drug (monotherapy) and half 
of whom were treatment-naïve. Increased levels of E-selectin (as well as thrombomodulin 
(TM) and vWF were seen in HIV positive individuals compared to HIV negative 
controls. In particular, TM was strongly raised in those with the lowest CD4 counts, 
whereas vWF progressively increased with each incremental drop in CD4 count, 
correlating with the concentrations of TNF-α and interferon-α. E-selectin; TM and vWF 
strongly correlated both with ß2-microglobulin (an indicator of immunological 
activation) and with p24 antigen (a marker of viral replication), showing that endothelial 
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injury was associated with progression and severity of HIV infection (163). There was 
also a correlation between triglycerides and VCAM-1, ICAM-1and TM levels, implying 
that endothelial injury may be, in part, related to certain disease-related biochemical 
abnormalities.  
 
Larranaga et al. (164) looked at endothelial markers and HIV infection in the era of 
HAART. Endothelial markers were measured in 38 treatment-naïve patients and 63 
patients receiving HAART, 33 of whom had lipodystrophy and 30 not. All endothelial 
markers (sVCAM-1, vWF and soluble thrombomodulin [sTM]) in the treatment-naïve 
group were higher compared to the patients receiving HAART. The 30 HIV patients 
receiving HAART with no lipodystrophy had significantly lower levels of sVCAM-1 and 
a trend towards lower levels of vWF and sTM. The 33 HIV patients receiving HAART 
with lipodystrophy had increased levels of endothelial markers compared to the HAART  
group with no lipodystrophy, implying that HAART decreases concentrations of 
endothelial activation markers but that its benefits may be offset by the metabolic 
syndrome that then confers a higher atherothrombotic risk (164). The use of non-invasive 
tools such as endothelial adhesion molecules, to assess endothelial function, although not 
validated, may be a useful tool in conjunction with standard risk assessments in further 
risk stratifying HIV patients who might benefit from more aggressive primary prevention.   
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1.5.5  HIV AND THROMBOSIS 
 
Haematologic abnormalities amongst individuals infected with HIV are well described 
and although the cytopaenia’s are the most common, there is evidence that HIV induces a 
hypercoagulable state, resulting in thromboembolic complications, with an incidence 
ranging from 0.26-7.6% (165). Autopsy studies have also revealed high rates of 
previously undiagnosed thromboembolism among patients with AIDS (166, 167). The 
mechanisms responsible for this hypercoagulable state are thought to be multifactoral in 
nature and involve thrombosis in both the venous and arterial beds. Thrombotic 
complications may arise as a direct result of the virus or indirectly through associated 
opportunistic infections, malignancies or the effects of HAART (14). Furthermore, it has 
been shown that HIV negative black Americans  appear to have a greater predisposition 
to venous thromboembolism compared to white patients despite having less traditional 
risk factors for the disorder, suggesting a possible role of unrecognised heritable factors 
(168)    
 
In HIV positive patients, thrombotic potential seems to correlate with the degree of 
immunosuppression measured by CD4 cell count as well as with the presence of 
opportunistic manifestations of AIDS (14). Thrombophilic states can be classified 
according to the vascular bed affected and the abnormality within that vascular bed, 
modelled on Virchow’s triad (169). There may be defects within the vessel wall, defects 
with the blood constituents or abnormal flow i.e. stasis or combinations of all three. Table 
1.9 summarises the thrombophilic state of HIV/AIDS according to this schema.  
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The endothelium is fundamental in the maintenance of non-thrombotic vascular surfaces 
and is a logical starting point when discussing thrombosis. Endothelial activation and its 
role in atherogenesis has been discussed in section 4.3.2, but the link between 
inflammation, endothelial activation and thrombosis needs elaboration.  
 
Table 1.9:  HIV and risk factors for thrombosis 
Abnormality  Affected Vascular Beds  
    
 Venous Venous and Arterial Arterial 
    
Defects in vessel wall:  Chronic inflammation (117),(120) Atherosclerosis         (129) 
  Vasculitis                               (14) Metabolic syndrome (129) 
                 - Hypertension 
                 - Diabetes 
                 - Dyslipidaemia 
   Smoking                   (170) 
    
Defects in coagulation  Deficiency of PC     (171)   
factors: Deficiency of PS     (172)   
 Deficiency of AT     (173)   
 Deficiency of HCII  (173)   
 ↑ Microparticles      (174)   
    
Defects in fibrinolysis:  ↑ PAI-1                                 (171)  
    
Platelet defects:  TTP                                        (14) ↑Platelet activation   (175) 
    
Stasis: Immobilisation          (14)   
 CCF                          (14)                 
    
Other: Malignancy Antiphospholipid syndrome  (176)  
 Opportunistic infections Protease inhibitors               (177)  
                         (14)                 Nephrotic syndrome   
 AIHA                           
    
 
[Source: Adapted from (169)] 
 
PC = Protein c; PS = Protein s; AT = Antithrombin; HCII = Heparin co-factor II; PAI-1 = 
Plasminogen activator inhibitor-1; TTP = Thrombotic thrombocytopaenic purpura; CCF = 
Congestive cardiac failure; AIHA = Autoimmune haemolytic anaemia  
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HIV infection is characterised by a profound inflammatory response, with elevated levels 
of a number of pro-inflammatory cytokines, including TNF-α, IL-1, IL-6 and CRP (117, 
120, 152). In addition to activating endothelial cells, these pro-inflammatory cytokines 
induce tissue factor expression in macrophages and endothelial cells (178). Tissue factor 
(TF) is a 46kD (kiloDalton) transmembrane glycoprotein that serves as a cell surface 
receptor and essential co-factor for coagulation factor VII and its active form VIIa (179). 
It is a critical factor in the initiation of coagulation in both physiologic and pathologic 
conditions (178). It is not normally expressed by resting endothelial cells, but can be 
induced by various stimuli, including vascular endothelial growth factor , TNF-α and IL-
1 (180), as well as certain infectious agents.  
 
In terms of HIV infection, there is  evidence that gp120, an HIV-associated membrane 
glycoprotein, is able to activate human arterial smooth muscle cells in vitro, resulting in 
the elaboration of TF (181). The ability of infectious agents, immune complexes and pro-
inflammatory cytokines to activate monocytes for an inflammatory response and at the 
same time to induce TF expression on their membrane is of great interest, as it could 
represent the biological basis to explain the strong relationship existing between 
inflammation and coagulation (178). In a recent study by Funderburg et al (182),  it was 
shown that monocyte TF expression could be induced in vitro by lipopolysaccharide and 
flagellin , but not IL-6 . Monocyte expression of TF was correlated with HIV levels in 
plasma, with indices of immune activation, and with plasma levels of soluble CD14, a 
marker of in vivo lipopolysaccharide exposure. TF levels also correlated with plasma 
levels of D-dimers, reflective of in vivo clot formation and fibrinolysis. Thus, drivers of 
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immune activation in HIV disease, such as HIV replication, and potentially, microbial 
translocation, may activate clotting cascades and contribute to thrombus formation and 
cardiovascular morbidities in HIV infection.  
 
Other biochemical markers of endothelial injury in HIV, besides the CAMS that have 
been discussed in section 5.4.2, which have important regulatory functions in haemostasis 
are vWF and soluble thrombomodulin (sTM). These have both been shown to be 
increased in HIV patients (171, 174, 183). The levels of these markers of endothelial 
damage correlate with the degree of immunosuppression, as measured by CD4 count. 
vWF is a large endothelium-derived protein with binding sites for glycoprotein Ib, 
glycoprotein IIb/IIIa, collagen and vitronectin, mediating platelet adhesion to other 
platelets and to the sub-endothelium, which is the first step in haemostasis. 
Thrombomodulin plays a crucial role in maintaining homeostasis of the coagulation 
system. It has an intracellular tail that anchors it to the endothelial cell, as well as a lectin-
like domain and 6 extracellular growth factor domains (184). TM binds to and activates 
PC via thrombin binding regions 5 and 6 of the growth factor domains. The lectin-like 
domain inhibits neutrophil interaction with the endothelial cell and may, therefore, play 
an anti-inflammatory role. sTM is created by the proteolytic cleavage of the membrane 
bound molecule and increased levels indicate endothelial cell membrane injury due to 
neutrophil derived proteolytic enzymes and inflammatory cytokines, such as TNF-α 
(180).  
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Another triggering factor of the coagulation cascade in HIV patients could be stimulation 
of microparticles, i.e. small cellular remnants originating from platelets and endothelial 
cells found circulating in the plasma (174). Elevated levels of microparticles have been 
reported in HIV infected individuals (185), possibly as a reflection of CD4 lymphocyte 
apoptosis (186), which is associated with activation of the coagulation cascade (185). The 
procoagulant properties of microparticles are thought to be due to their ability to cluster 
coagulation proteins on the surface of activated phospholipids and act as catalysts of 
coagulation reactions (174).  
 
In terms of the coagulation cascade, Antithrombin (AT) is a hepatocyte derived serine 
protease inhibitor that irreversibly neutralizes all the serine proteases (Factors IIa, IXa, 
Xa, XIa and XIIa) and is the most important physiological inhibitor of activated 
coagulation factors. Inhibition occurs by the formation of an equimolar complex between 
AT and the serine protease, a process accelerated by heparin. AT deficiency in HIV 
patients with thrombotic events has been described (173). The deficiency may be due to 
decreased hepatic synthesis from malnutrition or liver disease, protein losing enteropathy 
or nephropathy or consumptive states, including malignancies, disseminated intravascular 
coagulopathy (DIC) and surgery. Heparin cofactor 2, a specific thrombin inhibitor whose 
activity is enhanced by heparin, is also decreased in HIV positive individuals compared 
to age and sex matched healthy individuals, which correlates with the degree of 
immunosuppresion and confers a heightened thrombotic risk (173).  
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Protein C (PC) is a vitamin K-dependent protein that acts as an anti-coagulant by 
inactivating cofactors Va and VIIIa. Decreased levels of both functional and antigenic PC 
have been described in HIV patients, correlating positively with degree of 
immunosuppression, as measured by CD4 count (171). Factor V Leiden, which confers 
activated PC resistance has not been reported to date in HIV infected patients (14).  
 
Protein S (PS) is also a vitamin K dependent plasma protein synthesized by endothelial 
cells, hepatocytes and megakaryocytes. It acts as a non-enzymatic co-factor of protein C 
(PC) in the proteolysis of activated factors V and VIII. PS circulates in 2 forms: a free 
active moiety (40%) and an inactive moiety that binds to C4b-binding protein (60%). PS 
deficiency has been reported in patients infected with HIV and is associated with a 
heightened thrombotic risk (172, 187). The incidence of PS deficiency seems to correlate 
with the degree of immunosuppression (187). The aetiology of PS deficiency is thought 
to be multifactorial, involving decreased synthesis and abnormal distribution between 
bound and free moieties. C4b binding protein is an acute phase reactant whose levels are 
elevated during acute inflammatory processes, reducing the active free moiety; this may 
partly explain the hypercoagulable state seen during acute inflammatory conditions (187).  
 
Disorders of fibrinolysis have also been described in HIV positive patients. TNF-α has 
been shown to cause increased expression of PAI-1 in endothelial cells (171, 188). 
Coexistence of other medical conditions, such as concurrent opportunistic infections, 
malignancy, autoimmune haemolytic anaemia and DIC can also predispose to thrombosis 
(14). A review of the literature suggests that thrombosis in HIV patients is frequently 
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associated with the presence of opportunistic infections, particularly Pneumocystis carinii 
pneumonia (PCP) and cytomegalovirus (CMV) infection (15). The possible link between 
thrombosis and low grade DIC is supported by the fact that AIDS patients have elevated 
D-dimer levels and decreased levels of both antigenic and functional PC, which is 
thought to be due to a consumptive coagulopathy (14).  
 
Circulating concentrations of fibrin D-dimer reflect the extent of fibrin turnover in the 
circulation and it has been suggested that modestly elevated circulating D-dimer values 
reflect minor increases in blood coagulation, thrombin formation and turnover of cross-
linked intravascular fibrin, and that these increases may be relevant to coronary heart 
disease (189). Cigarette smoking rates have been shown to be higher in HIV infected 
patients compared to the general population (170) and an association between smoking 
and spontaneous thrombosis in HIV patients has been documented (76). Protease 
inhibitors (PI’s) as part of highly active anti-retroviral therapy (HAART) have been 
associated with venous thromboembolic disease (177, 190).  
 
It is hypothesized that PI’s interfere with hepatic regulation of thrombotic proteins, which 
leads to a prothrombotic state in some patients (177). Platelet dysfunction has been 
described in HIV patients. A report by Blann et al. provided evidence for increased 
platelet activation, based on elevated P-selectin levels (175). 
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1.5.5.1  HIV AND ANTIPHOSPHOLIPID ANTIBODIES  
 
Antiphospholipid antibodies (aPL) are a group of heterogeneous autoantibodies that have 
been reported in many autoimmune diseases and in the antiphospholipid syndrome 
(APS), which is characterised by raised levels of aPL, in association with thrombosis, 
recurrent foetal loss, thromboctopaenia and a number of other less commonly found 
complications (169). In the course of many acute infections, such as HIV, syphilis, 
hepatitis C, leprosy and malaria, raised levels of anticardiolipin (aCL), anti-ß2-
glycoprotein (anti-ß2-GPI) and anti-prothrombin (aPT) antibodies have been reported. 
They are often transient and can disappear after treatment of the infection (191).  
 
In HIV infection, aCL (IgG and IgM) have been reported to be present in 0-94%, anti-ß2-
GPI (IgG and IgM) in 4-47%, aPT (IgG and IgM) in 2-12% of patients and lupus anti-
coagulant (LA) in 0-53.5%. The variations found in HIV are most likely due to the 
composition of the patient group and the disease stage studied, i.e. asymptomatic to full-
blown AIDS and the associated presence of opportunistic infections (191). These studies 
were performed on predominantly white or mixed race populations.  
 
Very little data exists on the prevalence of the IgA aPL isotype and to aPT in the setting 
of infections including HIV(192). Loizou et al. (192) reported on the prevalence of aPL 
in 100 black South African HIV positive patients. There was a low prevalence of: anti-
ß2-GPI (6%), all exclusively belonging to the IgA isotype; as well as aCL (7%), which 
were mainly positive for IgG. A prevalence of 43% (mainly IgG) aPT was found, 
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showing that the pattern of aPL in black South Africans differs from that found in 
Caucasians (192). The difference is thought to be due to infection with HIV-1 sub-types 
B or C, which are the viruses infecting black South Africans, as opposed to HIV-1 sub-
type B, which is the predominant HIV virus found in white subjects (193).  
 
The aetiopathogenic link between aPL and thrombosis in HIV positive patients is tenuous 
(191) and limited to case reports. The association of LA with thrombosis in HIV has 
rarely been shown (15, 176). aCL’s have been associated with multiple transient 
ischaemic attacks and stroke (194), avascular necrosis of bone (195) and skin necrosis 
(196).  However, in 63 HIV infected patients, Palomo et al. (197) could not find a 
correlation between the presence of aPL’s and development of thrombosis. The clinical 
correlates of aPL in black South African patients with HIV are unknown. Despite this, 
aPL, which are often present in infectious diseases, are not usually associated with 
thrombotic and other complications attributed to them in patients with systemic lupus 
erythematosis (SLE) and APS. These infectious aPL could be induced by immune 
dysregulation as a consequence of the infectious process; alternatively their induction 
might result from the exposure of cell wall phospholipids, after breakdown on damaged 
body cells, as a consequence of inflammation due to the infection. The current 
hypothesis, therefore, is that infections (including HIV) may be a trigger for the induction 
of “pathogenic” aPL in predisposed or compromised subjects (192).      
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1.6   GAPS IN OUR KNOWLEDGE AND OBJECTIVES OF THE THESIS 
 
Epidemiologic and disease specific data are particularly scarce in Africa. The majority of 
medical literature comes from the developed world, where disease patterns are different, 
and information regarding certain disease states cannot be extrapolated to the developing 
world. There is currently a paradox in that sub-Saharan Africa has the highest incidence 
of HIV in the world (5) and yet local data on the subject is limited, which prevents 
effective health care planning and ultimately health care outcomes.  
 
HIV is a heterogeneous disease, both biologically (193) and in the way it manifests 
clinically, which depends on the socio-economic climate of the country, access to anti-
retroviral treatment (ART) and general supportive and nutritional care. A major concern 
in South Africa was the view that the South African government had adopted a denialist 
attitude towards HIV/AIDS (38) thus impeding attempts to tackle the epidemic. 
 
In light of this background, gaps in our knowledge need to be considered on a population 
based epidemiological level and on a specific disease related level. The research 
questions aimed at addressing the gaps in our knowledge to be addressed by this thesis 
are outlined below. 
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EPIDEMIOLOGIC TRANSITION: 
 
While there are preliminary reports of epidemiologic transition in the developing world 
(198) and in South Africa particularly, there has been no formal epidemiologic study 
done in South Africa to document this conclusively and to provide information on the 
incidence and prevalence of cardiovascular disease in South Africa. 
 
Research Question 1: (Addressed in chapters 3 and 4) 
1a)    What is the current spectrum of cardiovascular disease seen in a large urban 
population of black South Africans, including prevalence, incidence and associated risk 
factors? 
1b)    Is this pattern consistent with epidemiologic transition? 
 
ACUTE CORONARY SYNDROMES IN THE SETTING OF HIV INFECTION 
 
The relationship between HIV, HAART and coronary artery disease remains a highly 
controversial issue. Furthermore, no data exists on patients who are HAART-naïve, 
which makes extrapolation to the South African context inaccurate as the majority of 
HIV positive South Africans do not have access to HAART (38). No data currently exists 
on the characteristics and treatment outcomes of HIV positive black South Africans with 
acute coronary syndromes.   
 
The remaining research questions will be aimed at addressing these specific issues. 
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Research Question 2: (Addressed in chapter 5) 
2)   Are their differences in the demographic, clinical and angiographic features, as well 
as the treatment outcomes, in black South Africans presenting with ACS, according to 
HIV status? 
 
Research Question 3: (Addressed in chapters 6 and 7) 
3)   Do thrombotic profiles in black South Africans with ACS differ according to HIV 
status? 
 
Research Question 4: (Addressed in chapter 8) 
4)   Do markers of inflammation and endothelial cell activation differ in black 
South Africans with ACS according to HIV status; and what is their role in the 
pathogenesis of ACS? 
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CHAPTER TWO: METHODS 
 
All the studies contained in this thesis were conducted in the Department of Cardiology, 
CHB hospital and all adhere to the Declaration of Helsinki. Ethical clearance for all 
studies was granted by the Human Research Ethics Committee of the University of the 
Witwatersrand. 
 
2.1   EPIDEMIOLOGICAL STUDIES 
 
The “Heart of Soweto” (HOS) study (Chapter 3) was a prospectively designed registry 
that recorded epidemiologic data relating to the presentation, investigation and treatment 
of 1593 patients with newly diagnosed cardiovascular disease presenting to CHB hospital 
between January 1, 2006 and December 31, 2006. The second epidemiological study, 
“Emerging epidemic of cardiovascular disease among urban Africans: Acute coronary 
syndrome at Baragwanath hospital, Soweto” (Chapter 4), was a cross sectional study of 
patients with ACS admitted to the Baragwanath coronary care unit over the year 2004 
compared to the years 1975-1980. For all patients presenting with ACS in 2004, we 
collected data on demographic factors (age, gender, ethnicity), cardiovascular risk 
factors, blood pressure and electrocardiogram, exercise stress test and coronary 
angiography. A detailed description of the methodology for these two studies is found in 
the corresponding publications that follow.  
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2.2   ACUTE CORONARY SYNDROMES IN BLACK SOUTH AFRICANS 
WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION STUDY 
 
2.2.1   STUDY GROUPS 
 
Three study groups were used for analysis, as depicted below in Table 2.0: 
 
Table 2.0:  Study groups used for analysis 
Group 1: 
30 consecutive treatment-naïve black HIV positive patients with an Acute 
Coronary Syndrome  
(ACS+ : HIV+ group) 
Group 2: 
30 consecutive black HIV negative patients with an Acute Coronary 
Syndrome 
   (ACS+ : HIV- group) 
Group 3:  
30 asymptomatic treatment-naïve black HIV positive patients without 
coronary disease 
matched for age, sex and viral load with the patients in Group 1  
(ACS- : HIV+ group) 
 
2.2.1.1  STUDY DESIGN AND PATIENT RECRUITMENT 
 
The study was designed as a prospective, single centre, observational study conducted in 
the Department of Cardiology at CHB hospital, Soweto, South Africa. The protocol was 
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approved by the Human Research Ethics Committee of the University of the 
Witwatersrand (Protocol no. M040702) and adheres to the Declaration of Helsinki. All 
patients gave informed consent before study entry. Between March 2004 and February 
2008, 30 consecutive black HIV patients presenting with ACS (ACS+: HIV+ group) were 
enrolled. For each HIV patient with ACS, we selected the first presenting black non-HIV 
patient with ACS as a case-control comparator (ACS+: HIV- group). In addition, a 
second control group, consisting of 30 asymptomatic black HIV patients matched for age 
and sex (ACS- : HIV+ group), were recruited from the HIV clinic.  
 
STUDY GROUP 1 (ACUTE CORONARY SYNDROME +: HIV+ GROUP) 
RECRUITMENT AND INCLUSION CRITERIA 
 
All patients presenting with an ACS to CHB hospital during the study period were 
identified by our Cardiac Unit and offered HIV testing after receiving pre-test 
counselling. All black patients with an ACS, who were found to be HIV positive and 
fulfilled the inclusion criteria (Table 2.1), were recruited for the study after signing 
informed consent. The patients were recruited either from the medical admissions ward 
(ward 20) or the Coronary Care Unit (CCU) at CHB hospital. 
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Table 2.1:   Inclusion criteria for Group1 (Acute Coronary Syndrome +: HIV+ group) 
 
 
STUDY GROUP 2 (ACUTE CORONARY SYNDROME +: HIV- GROUP) 
RECRUITMENT AND INCLUSION CRITERIA 
 
For each patient in the ACS+:HIV+ (Group1) group recruited, the next available HIV 
negative black patient, with an ACS that fulfilled the inclusion criteria (Table 2.2), was 
recruited for this group. In terms of group 1, this group was also recruited either from the 
medical admissions ward (ward 20) or the Coronary Care Unit (CCU) at CHB hospital. 
 
Table 2.2:  Inclusion criteria for Group 2 (Acute Coronary Syndrome +: HIV- group) 
 
 
1. Informed consent 
2. Age ≥ 18 years 
3. Black ethnicity 
4. HIV seronegative (Screening ELISA + confirmatory Western Blot) 
5. Confirmed ACS (Unstable Angina/Non-ST elevation Myocardial 
Infarction/ ST-elevation Myocardial Infarction) 
6. No contra-indications for coronary angiography  
 
 
   
1. Informed consent 
2. Age ≥18 years 
3. Black ethnicity 
4. HIV seropositive (Screening ELISA + confirmatory Western Blot) 
5. Confirmed ACS (Unstable Angina/Non-ST elevation Myocardial 
Infarction/ ST-elevation Myocardial Infarction) 
6. No contra-indications for coronary angiography  
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DEFINITION OF ACUTE CORONARY SYNDROME 
 
Acute Coronary Syndrome was defined as either ST-elevation myocardial infarction 
(STEMI), non-ST-elevation myocardial infarction (NSTEMI) or unstable angina (UA). 
Myocardial infarction (MI) was diagnosed in patients with compatible symptoms with 
elevated troponin T measurements. Patients with persistent ST elevation >0.1 mV in 2 
contiguous leads were categorized as having STEMI and those without this criterion as 
having NSTEMI. Unstable angina was diagnosed in patients hospitalized with worsening 
angina or new-onset angina at rest without troponin T elevations. 
 
STUDY GROUP 3 (ACUTE CORONARY SYNDROME -: HIV+ GROUP) 
RECRUITMENT AND INCLUSION CRITERIA 
 
The patients in group 3 (ACS-: HIV+) were selected as a second control for group 1, 
matched with respect to age, sex and ethnicity. The patients were screened and selected 
from the HIV Clinic at CHB hospital. For each patient in group 1, a patient in group 3 
was selected if the patient met the criteria stipulated in Table 2.3 and if the patient was of 
the same sex and age (to ± 5 years) of the index patient in group 1. All patients in this 
group had a detailed history and examination, including resting and effort 
electrocardiograms (where indicated), which were used to exclude underlying coronary 
artery disease. 
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Table 2.3:  Inclusion criteria for Group 3 (Acute Coronary Syndrome -: HIV+ group) 
 
2.2.1.2   CLINICAL DATA COLLECTION 
 
Clinical data was obtained in all patients by taking a detailed history, clinical examination 
and accessing available clinical records. Patients were categorized as having diabetes, 
hypertension or dyslipidemia when being treated chronically for these conditions or when 
diagnosed with the condition on admission. Patients were classified as having “other” 
coronary risk factors if any of the following conditions were present: i) Family history of 
premature CAD (men <55 yrs, women <65 yrs); ii) chronic kidney disease; iii) post 
menopausal state, and; iv) abdominal obesity (abdominal circumference > 102cm in men 
and 88cm in women) . “Multiple” risk factors was defined as ≥ 2 of: hypertension, 
diabetes mellitus, hyperlipidaemia, smoking or family history.  
 
The TIMI  risk score for STEMI and NSTEMI / UA was calculated in all patients with an 
ACS as a clinical assessment of risk and prognosis. Demographic data was recorded for 
each patient and anthropometric measurements, including weight, height, body mass 
index (BMI), waist to hip ratio and abdominal circumference (AC) were measured on 
1. Informed consent 
2. Age> 18 years 
3. Black ethnicity 
4. HIV seropositive (Screening ELISA + confirmatory Western Blot) 
5. No evidence of coronary artery disease  
6. No history of thrombotic events 
7. No evidence of acute infectious disease 
8. Not receiving antiretroviral therapy  
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admission. HIV positive patients were staged according to the CDC staging system, 
which uses two parameters, i.e.:  
• Clinical category [A: Asymptomatic HIV infection; B: Non-AIDS defining 
symptomatic conditions; C: AIDS defining conditions]  
• CD4 count (cells/ml3) [1: ≥500; 2: 200-499; 3: <200].  
 
2.2.2   CLINICAL BLOOD TESTS 
 
Infection with HIV was diagnosed with the standard enzyme linked immunosorbent assay 
(ELISA) and Western blot techniques, after obtaining consent and offering pre-test 
counselling. In the HIV group, Plasma HIV RNA level was determined by quantitative 
polymerase chain reaction. CD4 count was determined by flow cytometry. In addition, all 
patients had venous blood drawn (in the fasting state) for glucose and a lipogram.  
 
2.2.3   CORONARY ANGIOGRAPHY AND PERCUTANEOUS CORONARY 
INTERVENTION (PCI) 
 
All patients in groups 1 and 2 (ACS group) were managed in the Coronary Care Unit at 
CHB hospital by the attending cardiology staff according to standard ACS guidelines 
recommended by the European Society of Cardiology. All patients underwent coronary 
angiography at some stage during their acute stay in the unit, the timing being left to the 
judgement of the attending cardiology staff.  
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Coronary angiography and PCI were performed in the CHB cardiac catheterisation 
laboratory, utilising a Philips Allura, single plane system (Koninklijke Philips 
Electronics, Netherlands) with standard catheters. Intravascular ultrasound (IVUS) was 
performed in patients found to have normal appearing infarct related arteries (IRA) at the 
time of angiography and in patients with evidence of in-stent restenosis at the time of 
follow up angiography.  
 
All IVUS studies were performed with a commercially available system (Clearview 
Ultra, Boston Scientific, Boston, Massachusetts). A 40 MHz IVUS catheter was 
advanced distal to the culprit lesion and imaging performed in a retrograde fashion to the 
aorto-ostial junction. The IVUS images were recorded on VHS videotape for off-line 
analysis. The results of all diagnostic angiograms and PCI were assessed by two 
independent interventional cardiologists blinded to the patients’ HIV status. 
Angiographic follow-up was planned for all patients receiving a coronary stent at a 
minimum of six months post-procedure to assess for the development of in-stent 
restenosis.  
 
Single vessel disease was defined as a single major epicardial coronary artery with a 
stenosis ≥50% and multi-vessel disease ≥2 major epicardial arteries with stenoses ≥50%. 
The IRA was defined by reviewing each patient’s angiogram, electrocardiogram and/or 
echocardiogram. An artery was considered to be infarct related if an obvious thrombus or 
ruptured plaque was present, or if two of the aforementioned diagnostic tests implicated 
the same coronary territory. The IRA was defined as angiographically normal if the 
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contour was smooth with no angiographic features of atherosclerotic disease in any of the 
coronary arteries. IRA thrombus burden, when present, was classified angiographically as 
small or large, according to a previously published descriptive model with 5 grades 
(Table 2.4). 
 
Table 2.4:   Angiographic classification of intracoronary thrombus burden 
 
 
 
 
 
 
 
 
 
 
 
 
Gibson et al. Circulation 2001; 103:2550-2554 
 
Initial flow in the IRA was defined by the TIMI flow grade scoring system, which is a 
widely adopted scoring system (199): 0-3 referring to levels of coronary blood flow. 
TIMI 0 flow (no perfusion) refers to the absence of any antegrade flow beyond a 
coronary occlusion. TIMI 1 flow (penetration without perfusion) is faint antegrade 
coronary flow beyond the occlusion, with incomplete filling of the distal coronary bed. 
TIMI 2 flow (partial reperfusion) is delayed or sluggish antegrade flow with complete 
filling of the distal territory. TIMI 3 flow (complete perfusion) is normal flow that fills 
the distal coronary bed completely.  
 
• Grade 0: No cineangiographic characteristics of thrombus 
• Grade 1: Possible thrombus present 
• Grade 2: Definite thrombus, with greatest dimensions ≤ ½ the vessel diameter 
• Grade 3: Definite thrombus, but with greatest linear dimension >½, but <2 vessel 
diameters 
• Grade 4: Definite thrombus, with the largest dimension ≥ 2 vessel diameters 
• Grade 5: Total occlusion (unable to assess thrombus burden due to total vessel 
occlusion). Reclassified after flow established with guide wire or small deflated 
balloon passage 
 
Small thrombus burden (STB) <Grade 4 
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Successful PCI was defined as achievement of normal (TIMI 3) coronary flow with a 
residual stenosis of ≤ 50% and no periprocedural complications. Stent thrombosis was 
defined according to the Academic Research Consortium (ARC) criteria (200), which 
considers the timing and probability of occurrence of stent thrombosis. With respect to 
timing, stent thrombosis was defined as: acute if it occured between 0 and 24 hours; sub-
acute when occurring between 25 hours and 30 days; late when occurring between 31 
days and 1 year, and; very late when occurring beyond 1 year after stent implantation.  
 
With respect to probability, stent thrombosis was defined as definite, probable or 
possible. Definite stent thrombosis was considered to have occurred on the basis of either 
angiographic or pathological evidence. Probable stent thrombosis was considered to have 
occurred in the case of: 1) unexplained death within the first 30 days after stent 
implantation, or; 2) MI in the territory of the implanted stent, in the absence of another 
obvious cause, without angiographic confirmation of stent thrombosis and regardless of 
its timing after the index procedure. Possible stent thrombosis was considered to have 
occurred as a cause of any unexplained death past 30 days after stent implantation.  
 
Binary angiographic in-stent restenosis was defined as a >50% diameter stenosis at 
follow up. In-stent restenosis was further defined as focal or diffuse according to a 
previously proposed classification (Table 2.5, Methods Appendix). Target lesion 
revascularization (TLR) was defined as any repeat revascularization of the IRA involving 
the stent and/or its 5mm proximal or distal edges. Major adverse cardiovascular events 
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(MACE) were defined as death, non-fatal myocardial infarction or TLR. All patients 
were followed up at the CHB cardiac clinic. 
 
Table 2.5:   Classification of in-stent restenosis (ISR) 
 
 
 
 
 
 
 
 
 
 
 
Mehran et al. Circulation 1999; 100:1872-1878 
 
 2.2.4   RESEARCH BLOOD TESTS 
 
The list and timing schedule of research blood tests performed for each group is listed in 
Table 2.6. 
• Class 1: Focal ISR group. Lesions are ≤ 10mm in length and are positioned at the 
unscaffolded segment (i.e. articulation or gap), the body of the stent, the proximal or 
distal margin (but not both), or a combination of these sites (multifocal ISR). 
 
• Class 2: “Diffuse intrastent” ISR. Lesions are >10mm in length and are confined to 
the stent(s), without extending outside the margins of the stent(s). 
 
• Class 3: “Diffuse proliferative” ISR. Lesions are >10 mm in length and extend beyond 
the margins(s) of the stent(s). 
 
• Class 4:  ISR with “total occlusion”. Lesions have a TIMI flow grade of 0. 
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Table 2.6:   Research blood schedule according to study group 
           (TIMING ACCORDING TO GROUP† ) 
RESEARCH BLOOD TESTS BASELINE 6 WEEKS 6 MONTHS 
        
1) Markers of inflammation and endothelial activation       
Tumour necrosis factor-α (TNF-α) 1, 2, 3   1, 2 
Interleukin-6 (IL-6) 1, 2, 3   1, 2 
High sensitivity C-reactive protein (hs-CRP) 1, 2, 3   1, 2 
Intercellular adhesion molecule-1 (ICAM-1) 1, 2, 3   1, 2 
Vascular cellular adhesion molecule-1 (VCAM-1) 1, 2, 3   1, 2 
Endothelial-selectin (E-selectin) 1, 2, 3   1, 2 
Macrophage chemoattractant protein-1 (MCP-1) 1, 2, 3   1, 2 
        
2) Coagulation assays       
Protein C  3 1, 2   
Protein S  3 1, 2   
Fibrinogen 3 1, 2   
Antithrombin 3 1, 2   
Factor VIII 3 1, 2   
Activated protein C resistance  3 1, 2   
D Dimer 3 1, 2   
von Willebrand factor antigen  3 1, 2   
von Willebrand factor activity  3 1, 2   
Lupus anti-coagulant  3 1, 2   
Platelet aggregometry 3 1, 2   
        
3) Antiphospholipid antibodies (aPL)       
Anticardiolipin (IgG) 1, 2, 3   1, 2 
Anticardiolipin (IgM) 1, 2, 3   1, 2 
Anticardiolipin (IgA) 1, 2, 3   1, 2 
Beta-2 Glycoprotein (IgG) 1, 2, 3   1, 2 
Beta-2 Glycoprotein (IgM) 1, 2, 3   1, 2 
Beta-2 Glycoprotein (IgA) 1, 2, 3   1, 2 
Anti-Prothrombin (IGG) 1, 2, 3   1, 2 
Anti-Prothrombin (IGM) 1, 2, 3   1, 2 
Anti-Prothrombin (IGA) 1, 2, 3   1, 2 
 
†Group 1 = ACS+: HIV+ group; Group 2 = ACS+: HIV- group; Group 3 = ACS-: HIV+ group 
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2.2.4.1   BLOOD COLLECTION 
 
For all coagulation assays and platelet studies, which were performed within 1 hour of 
collection, twenty ml of venous blood was obtained by clean venipuncture and drawn into 
plastic tubes containing sodium citrate in a ratio of 1 volume trisodium citrate to 9 
volumes of blood. The samples were transported to the coagulation laboratory of the 
National Health Services Laboratory (NHLS), Johannesburg hospital, at ambient 
temperature. The samples were then centrifuged at 3500 rpm for 15 minutes prior to 
analysis.  
 
For the markers of inflammation and endothelial activation, as well as antiphospholipid 
antibody analysis, blood was drawn, centrifuged and frozen for analysis at a later stage. 
Twenty ml of blood was obtained by clean venipuncture, with seated subjects and non-
fasting venous blood drawn into plain tubes (for the evaluation of antiphospholipid 
antibodies and hs-CRP) and plastic tubes [containing ethylenediaminetetraacetic acid 
(EDTA)] to obtain plasma for the inflammatory cytokine and endothelial activation 
marker analysis. Plasma was separated by centrifugation at 3500 rpm for 15 minutes 
within 15 minutes of collection. Aliquots were stored at -70 degrees Celcius. All plasma 
samples used in these studies were thawed only once for analysis.  
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2.2.4.2   COAGULATION ASSAYS 
 
All coagulation studies were performed in the Coagulation Laboratory of the National 
Health Services Laboratory (NHLS), Johannesburg hospital. The assays were performed 
on an Automated Coagulometer (ACL) [Instrument Laboratories, Milan, Italy], according 
to the standard operating procedures of the NHLS.  
 
PROTEIN C (CHROMOGENIC ASSAY) 
 
Principles of the assay: Protein C (PC) in plasma is activated by a specific enzyme from 
the Southern Copperhead snake venom. The amount of activated PC is determined by the 
rate of hydrolysis of a synthetic substrate S-2366, releasing a substance called p-
Nitroanalin (pNA). The pNa released is measured at 405 nanometres (nm) using a 
spectrophotometer and this is proportional to the PC level in the range of 0-120% of 
normal plasma. 
 
Calculations: Patients’ values are calculated automatically by comparison with a 
standard curve. Reference ranges are 70-160%, as obtained from the package insert of the 
kit (Instrument Laboratories, Milan, Italy). 
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PROTEIN S (FUNCTIONAL ASSAY) 
 
Principles of the assay: The functional activity of Protein S (PS), co-factor of PC, is 
proportional to the prolongation of the prothrombin time (PT) of a PS deficient plasma, to 
which diluted sample has been added. Activated PC (APC) is generated by activation of 
PS deficient plasma with Protac (1 part PS deficient plasma with 1 part Owrens buffer). 
Levels of activated PS in patients’ plasma are measured automatically on the ACL, using 
bovine thromboplastin as reagent. 
 
Calculations: The results obtained from the ACL are reported in percentage. All values 
are obtained from a calibration curve that is generated by the analyser for each batch. 
Reference ranges are 60-140%, as obtained form the package insert of the kit (Instrument 
Laboratories, Milan, Italy). 
 
FIBRINOGEN (CLAUSS METHOD) 
 
Principles of the assay: Calcium thrombin solution is added to patients’ plasma; this 
converts fibrinogen to fibrin. The optical density of the clot is read at 470nm on a 
spectrophotometer. The resultant turbidity of normal fibrinogen is proportional to the 
fibrinogen concentration of the plasma. 
 
Calculations: Reference range 2-4 g/l, as obtained from the package insert of the kit 
(Instrument Laboratories, Milan, Italy). 
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ANTITHROMBIN (CHROMOGENIC ASSAY) 
 
Principles of the assay: Plasma is incubated with an excess of Factor Xa in the presence 
of heparin. The residual quantity of Factor Xa is determined by the rate of hydrolysis of a 
synthetic substrate, releasing a substance called p-Nitroanalin (pNA). The pNA release, 
measured at 405nm spectrophotometrically, is inveresely proportional to the antithrombin 
(AT) level, in the range of 0-125% of normal plasma. 
 
Calculations: Patients’ values are calculated automatically by comparison with a 
standard curve. The ACL calculates the activity of the tested parameters on the basis of 
the relative calibration curve. The patient’s AT value has to be corrected on the ACL, 
depending on the AT value for the standard (Instrument Laboratories, Milan, Italy). The 
patient’s’ value is then multiplied by the correction factor. 
 
ACTIVATED PROTEIN C RESISTANCE (APCR) 
 
Principles of the assay: The kit is used for the determination of resistance to activated 
protein C (APC), caused by the FV: Q506 (Factor V Leiden mutation) in plasma from 
untreated individuals and from patients on oral anti-coagulant or heparin therapy. Sample 
plasma is incubated with the activated partial thromboplastin time (aPTT) reagent for a 
standard period of time. Coagulation is triggered by the addition of calcium chloride 
(CaCl2), in the absence and presence of APC, and the time for clot formation is recorded.  
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Calculations: APC ratio= Clot time APC+ CaCl2                                                    
                                           Clot time CaCl2            
                                                  
Typical Median Values: >2 Normal 
                                     : 1.7 Heterozygous (FV:Q506 ) 
                                     : 1.2 Homozygous  (FV:Q506 ) 
 
D- DIMER (QUANTITATIVE METHOD) 
 
Principles of the assay: This assay utilises a D-dimer latex reagent (Instrument 
Laboratories, Milan, Italy), which is a suspension of polystyrene latex particles of 
uniform size (coated with a monoclonal antibody highly specific for the D-dimer domain) 
included in fibrin soluble derivatives. When a plasma containing D-dimer is mixed with 
latex reagent and a reaction buffer, the coated latex particles agglutinate. The degree of 
agglutination is proportional to the concentration of D-dimer in the sample and is 
determined by measuring the decrease of the transmitted light at 405nm caused by the 
aggregates (turbidometric immunoassay). 
 
Calculations: Patients’ values are calculated automatically by comparison with a 
standard curve. The ACL calculates the activity of the listed parameters on the basis of 
the relative calibration curve. Reference range <0.2mg/L. 
 
VON WILLEBRAND ANTIGEN ASSAY (vWF:Ag) 
 
Principles of the assay: The Instrument Laboratories vWF:Ag assay (Instrument 
Laboratories, Milan, Italy) involves a latex particle enhanced immuno-turbidometric 
80 
 
assay to quantify vWF:Ag in plasma. When plasma containing vWF:Ag is mixed with the 
latex reagent and a reaction buffer, the coated particles agglutinate. The degree of 
agglutination is directly proportional to the concentration of the vWF:Ag in the sample 
and is determined by measuring the transmitted light caused by the aggregates.  
 
Calculations: Patients’ values are calculated automatically by comparison with a 
standard curve. The ACL calculates the activity of the listed parameters on the basis of 
the relative calibration curve. Reference range: 50-150%. 
 
VON WILLEBRAND FACTOR ACTIVITY (RISTOCETIN COFACTOR 
ACTIVITY) 
 
Principles of the assay: This is a functional assay of von Willebrand factor activity that 
measures the ability of the antibiotic ristocetin to induce platelet agglutination in the 
presence of von Willebrand factor. Thus, the rate and extent of platelet agglutination is a 
function of the concentration and functional integrity of von Willebrand factor. Von 
Willebrand factor mediates platelet adhesion to subendothelial collagen following 
vascular injury. Ristocetin is an antibiotic which causes platelet agglutination only in the 
presence of large multimers of von Willebrand factor. 
 
Calculations: The titre of the specimen is given by the dilution in which there is distinct 
agglutination compared to the blank. The ristocetin cofactor content (as a percentage of 
normal) is obtained by multiplying the titre of the specimen with the limit of detection 
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that is stated on the vial label. For example: if agglutination is detected in the 1:120 
dilution and not the 1:160 dilution (120x0.7=84; 160x0.7=112, where 0.7 is the 
sensitivity of the von Willebrand reagent), the result is >84 <112%. Reference range 50-
150%. 
 
LUPUS ANTI-COAGULANTS (KAOLIN CLOTTING TIME) 
 
Principles of the assay: Lupus anti-coagulants (LA) are naturally occuring 
immunoglobulins, which react against anionic phospholipids in vitro.  LA inhibit the 
formation of the prothrombinase complex  by interfering with the interaction between 
anionic phospholipids and clotting factors thereby causing prolonged times in 
phospholipid-dependant coagulation tests [Prothrombin time (PT), Partial thromboplastin 
time (PTT) and factor assays.See Methods Appendix]. Kaolin, which is a naturally 
occuring clay, initiates clotting through the contact factors and subsequently involves 
other factors in the intrinsic pathway of coagulation. The kaolin clotting time (KCT) is 
essentially an activated partial thromboplastin time test but without any added 
phospholipid. The test relies on residual cell membrane fragments and plasma lipids to 
provide a phospholipid surface for coagulation reactions. Kaolin is used to test for the 
presence of LA, as it does not contain phospholipid. In this assay, decreasing amounts of 
normal plasma (NP) are mixed with increasing amounts of test plasma (TP) and a KCT 
performed on each mixture. Clotting times are plotted against increasing concentrations 
of TP on arithmetic graph paper. The test is sensitive to the presence of LA and is able to 
identify the coexistence of a factor deficiency. 
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Results: The results are plotted on a graph with: time on the y axis; relative 
concentrations of TP to NP on the x axis. Results are reported as the time at 0.2TP:0.8NP. 
Plasma with KCT’s above the reference range are then subjected to further confirmatory 
tests for LA using dilute Russell’s viper venom. 
 
LUPUS ANTI-COAGULANTS (RUSSELL’S VIPER VENOM) 
 
Principles of the assay: Plasma with a KCT above the reference range is subjected to 
further testing using the following protocol to exclude the presence of LA. RVV 
(Russell’s Viper Venom), phospholipids and calcium are added to the test plasma (LA1 
screening test) to directly activate factors X and V, thereby triggering the joint cascade of 
the intrinsic and extrinsic coagulation pathways (Methods Appendix). Any LA contained 
in the sample prolongs the coagulation time as they block the phospholipids necessary for 
the coagulation process. If the clotting time from the LA1 screening test is above the 
reference range, the LA2 test is used for confirmation as it contains an excess of 
phospholipids, which neutralise the LA.  
 
Results: If the LA1 screening reagent clotting time is within the normal range, no further 
testing is required and the presence of LA is excluded. If the LA1 screening reagent 
clotting time is more than 2 standard deviations (SD) longer than the mean of normal 
plasma, the result should be considered abnormal and investigated further with the LA2 
confirmatory test..The final result is best expressed as a ratio of the clotting times of LA1 
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screen: LA2 confirm. LA1 screen: LA2 confirm >2 (strong LA presence); 1.5-2.0 
(moderate LA presence); 1.3-1.5 (weak LA presence); <1.3 (No LA present).   
 
2.2.4.3  PLATELET AGGREGOMETRY 
 
Platelet aggregometry was performed in the Coagulation Laboratory of the NHLS. The 
assays were performed on an APACT-2 light transmission platelet aggregometer 
[Instrument Laboratories, Milan, Italy], according to the standard operating procedures of 
the NHLS.  
 
Principle of assay: The absorbance of platelet-rich plasma decreases as platelets 
aggregate. The amount and rate of fall is dependent on platelet reactivity to the added 
agonist, if other variables (such as temperature, platelet count and mixing speed) are 
controlled. Aggregation responses to the agonist’s arachidonic acid (1,5 mM), ADP 
(adenosine diphosphate, 10uM), collagen (2ug/mL) and adrenaline (10mg/mL) are 
measured by absorbance changes monitored on a chart recorder.  
 
Results: Results are reported as “normal”, “flat” or “reduced”, depending on the degree 
of aggregation with each agonist:  ≥ 50% aggregation in the face of an agonist defined as 
“normal”, <20% aggregation defined as “flat” and >20 but <50% , defined as “reduced” .  
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PLATELET SENSITIVITIES 
 
Principle of assay: Platelet sensitivities are performed on a range of decreasing 
concentrations of the agonist to assess for the presence of hypersensitive platelets, which 
aggregate at low concentrations of agonists. Full aggregation responses to <0.5mM 
arachidonic acid, <2µg/ml collagen and <1µg/ml ADP is defined as platelet 
hyperactivity. 
 
2.2.4.4  MARKERS OF INFLAMMATION AND ENDOTHELIAL 
ACTIVATION 
 
BIOPLEX CYTOKINE ASSAY  
 
Principle of the assay (Methods Appendix): Bioplex cytokine assays are multiplex bead-
based assays designed to quantitate multiple cytokines in diverse matrices, including 
serum samples, plasma samples and tissue culture supernatants. The system allows for 
the simultaneous analysis of up to 100 different cytokines in a single microplate well. 
The multiplexing bead technology is based on the colour coding of tiny beads, or 
microspheres. Each bead is dyed with a different ratio of two spectrally distinct 
fluorophores to create 100 distinct sets of beads. The Bioplex principle uses a bead 
format with the capture antigen whereas ELISA uses a plate format with the antigen in 
each well. 
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Antibody specifically directed against the cytokine of interest is covalently coupled to 
colour-coded 5.6µm polystyrene beads. The antibody-coupled beads are allowed to react 
with a sample containing an unknown amount of cytokine (test sample) or with a 
standard solution containing a known amount of cytokine. After performing a series of 
washes to remove unbound protein, a biotinylated detection antibody, specific for a 
different epitope on the cytokine, is added to the beads. The result is the formation of a 
sandwich of antibodies around the cytokine. The reaction mixture is detected by the 
addition of streptavidin-phycoerythrin (Streptavidin-PE), which binds to the biotinylated 
detection antibodies. The constituents of each well are drawn up into the flow-based 
Bioplex suspension array system, which identifies and quantitates each specific reaction 
based on bead colour and flourescence. Unknown cytokine concentrations are 
automatically calculated by Bioplex manager software, using a standard curve derived 
from a recombinant cytokine standard.  
 
Assays performed: 
By making use of this technology we were able to combine (“plex”) the following related 
cytokines together in 3 different assays: 
1)  TNF-α / IL-6 (Pro-inflammatory cytokines)                                  
2) ICAM-1 / VCAM-1 (Soluble cellular adhesion molecules)        (Bio-Rad Laboratories, 
                                                                                                            Hercules, CA, USA) 
3) MCP-1 / RANTES* (Chemokines) 
* Data regarding RANTES was not used in the thesis. 
Details for the measurements of the above cytokines can be found in the Methods 
Appendix at the end of this chapter. 
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E-SELECTIN (Human sE-selectin immunoassay kit, Invitrogen Corporation, Carlsbad, 
CA) 
 
Principle of the assay: The sE-selectin ELISA is an enzyme-linked immunosorbent 
assay for quantitative detection of soluble E-selectin levels in human sera. An anti-sE-
selectin monoclonal coating antibody is adsorbed onto microwells. sE-selectin present in 
the sample or standard binds to antibodies adsorbed to the microwells; an horse radish 
peroxidase (HRP)-conjugated monoclonal anti-sE-selectin antibody is added and binds to 
sE-selectin captured by the first antibody. Following incubation, unbound enzyme 
conjugated anti-sE-selectin is removed during a wash step and substrate solution reactive 
with HRP is added to the wells. A coloured product is formed in proportion to the amount 
of soluble E-selectin present in the sample. The reaction is terminated by addition of acid 
and absorbance is measured at 450nm. A standard curve is prepared from seven sE-
selectin standard dilutions, and sE-selectin sample concentration determined. Results are 
expressed as ng/mL. 
 
HIGH SENSITIVITY C-REACTIVE PROTEIN ASSAY (CRP Vario, Sentinal 
Diagnostics, Milano, Italy) 
 
Principle of the assay: CRP Vario is a latex immunoassay developed to accurately and 
reproducibly measure blood CRP levels in serum and plasma.When an antigen-antibody 
reaction occurs between CRP in a sample and anti-CRP antibody, which has been 
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adsorbed to latex particles, agglutination results. This agglutination is detected as an 
absorbance change (572nm), with the change being proportional to the quantity of CRP 
in the sample. Results are expressed as mg/L. 
 
2.2.4.5  ANTIPHOSPHOLIPID ANTIBODIES 
 
Antiphospholipid antibodies (aPL), including anticardiolipin antibodies (aCL), anti-ß2-
glycoprotein-I (anti- ß2-GP-1) and anti-prothrombin (aPT) [IgG, IgM, IgA], were 
measured at baseline in all patients and at 6 months post-event in the ACS groups, using 
commercial enzyme linked immunosorbent assay (ELISA) kits (Orgentec Diagnostika, 
Mainz, Germany). The principle of the ELISA assay has been described in section 2.4.4.  
 
The results are expressed in units, according to the manufacturer’s instructions. IgG, IgM 
and IgA aCL are expressed as U/mL. Results for each of the three isotypes of the three 
types of aPL measured were considered positive when the optical density obtained for 
each patient exceeded that of the mean value plus 2 standard deviations (SD) of the 100 
sera from black South African normal healthy subjects. The Antiphospholipid Syndrome 
(APS) was diagnosed in patients with ACS where the presence of aPL (aCL IgG/ IgM 
and/or anti- ß2-GP-1 IgG/ IgM) in titres was greater than the mean plus 2SD from normal 
healthy subjects on two occasions, at least 12 weeks apart, as per the Sappora 
classification (201).  
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2.2.5   STATISTICAL ANALYSIS 
 
Statistical analysis was performed using SAS 9.1 software (SAS, Cary, NC, USA). 
Normally distributed continuous data are presented as the mean (± standard deviation), 
and variables, with non-Gaussian distribution as the median (min-max range). 
Categorical data are presented as frequencies and percentages. The initial analysis 
compared variables between the three groups using: the one way Anova test for 
continuous variables with normal distribution; and the Kruskal Wallis test in the case of 
non-normal distribution. For categorical variables, the Chi square test was performed 
with a Fisher exact test used when necessary. Significant differences between variables in 
the three groups was assumed at p<0.05. Sub-group analysis with multiple pairwise 
comparisons was then performed by applying the Bonferroni correction, with a p value< 
0.0166 considered significant. 
 
With specific respect to the analysis of groups 1 and 2, changes in TIMI flow rates pre 
and post-PCI between HIV positive and negative groups were calculated, using the 
Wilcoxon rank sums test. Significance was assumed at a two-tailed value of p<0.05. 
Univariate logistic regression was performed to determine predictors of the variables: 
normal infarct related artery, large thrombus burden and death and data presented as odds 
ratios (OR) with 95% confidence intervals (CI). Multivariate logistic regression was then 
performed, but due to the small sample size, it was not possible to include all potential 
explanatory variables were significantly different between the groups (age, smoking, 
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hypertension, total cholesterol, LDL cholesterol, HDL cholesterol and “other risk 
factors”); thus a limited analysis using age and smoking was performed. 
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2.2.6   METHODS APPENDIX  
 
Figure 2.1:  Patterns of in-stent restenosis 
 
Mehran et al. Circulation 1999; 100:1872-1878 
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Figure 2.2:  Coagulation and antithrombotic pathways 
     Intrinsic Pathway              Extrinsic Pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Explanation: Coagulation is initiated by extrinsic tenase, which forms when factor VIIa binds to 
TF. Extrinsic tenase activates factors IX and X. In the presence of calcium, factor IXa binds to 
negatively charged phospholipid surfaces, where it interacts with factor VIIIa to form intrinsic 
tenase, a complex that efficiently activates factor X. Factor Xa binds to factor Va on negatively 
charged phospholipid surfaces to form prothrombinase, the complex that activates prothrombin to 
thrombin, which converts fibrinogen to fibrin. The four main antithrombotic mechanisms and 
their site(s) of action are depicted in red.  
 
Key: APC - activated protein C; AT - antithrombin ; FDP - fibrin degradation products; PA - 
plasminogen activators; PC - protein C; PS - protein S; TF - tissue factor; TFPI - tissue factor 
pathway inhibitor; TM - thrombomodulin. 
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Figure 2.3:  Prothrombin time (PT) and partial thromboplastin time (aPTT)  
 
A             B 
 
THROMBOPLASTIN           PARTIAL THROMBOPLASTIN 
               Contact Factors 
        VIIa (Extrinsic       XII   XIIa (Intrinsic 
   pathway)      pathway)   
            XI  XIa 
 
             IX  IXa 
    X          Xa         VIIIa 
      Va     X                     Xa  
    II          IIa                        Va 
        II                      IIa 
FIBRINOGEN   FIBRIN    FIBRINOGEN           FIBRIN 
 
Explanation: A: PT (Prothrombin time). Thromboplastin reagent containing tissue factor (TF) 
and calcium is added to citrated plasma. Formation of extrinsic tenase results in rapid fibrin 
formation via extrinsic and common pathways. B: aPTT (activated partial thromboplastin 
time). Partial thromboplastin reagent, consisting of surface activator and dilute phospholipids, is 
added to citrated plasma. After incubation, to allow activation of contact factors and generation of 
factor IXa, calcium is added to induce clotting via intrinsic and common pathways. 
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Figure 2.4:  Bioplex cytokine measurement 
 
 
Cytokine assay kits (2-Plex) for TNF-α / IL-6, ICAM-1 / VCAM-1 and MCP-1 / 
RANTES (Bio-Rad Laboratories, CA, USA) were used in the analysis. The kits included 
beaded 96 well plates, standard and serum diluent, wash buffer, cytokine standard, 
detection antibody and Streptavidin-PE solution. 
 
1)  Patient plasma samples, which had been stored at -70 degrees Celcius, were 
allowed to thaw overnight, but were kept at 4 degrees Celcius until the first 
incubation.  
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2)  The cytokine standard samples and serum were serially diluted four-fold with the 
use of diluent into sterile 1.5ml microcentrifuge tubes, using multi-channel 
micropipettes. 
3)  The standard and serum samples were then added to the 96 well plates and 
incubated for 30 minutes at room temperature. 
4)  The samples were then washed three times with 100µL of Bioplex wash buffer.              
Excess buffer was removed by vacuum filtration after each wash cycle. 
5)  The plate was stored in a dark environment, while the detection antibody vial was 
centrifuged prior to pipetting to collect the entire volume at the bottom of the vial. 
6)  The detection antibody was then diluted to a 1x concentration using detection 
antibody diluent added to the wells. Following this, the samples were incubated at 
room temperature for 30 minutes and washed in a similar fashion. 
7)  The samples were then washed again (three times) with 100µL of Bioplex wash 
buffer. Excess buffer was removed by vacuum filtration after each wash cycle. 
8)  Streptavidin-PE was then diluted to a 1x concentration with Bioplex assay buffer 
and added to the wells, incubated at room temperature for 30 minutes and then 
washed. 
9)  The plates were then read using the Bioplex manager software, which allows for 
the calculation of concentrations to be done based on the generation of standard 
curves.  
10)  Concentrations for TNF-α, IL-6, ICAM-1 and VCAM-1 were expressed as ng/mL 
and MCP-1 as ng/L. 
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CHAPTER THREE: SPECTRUM OF HEART DISEASE AND RISK FACTORS 
IN A BLACK URBAN POPULATION IN SOUTH AFRICA: THE “HEART OF 
SOWETO” STUDY 
Lancet. 2008; 371:915-22. 
 
Summary: This publication investigates the clinical range of disorders related to 
cardiovascular disease in patients from Soweto, presenting for the first time to a tertiary 
health care facility, in an attempt to improve our understanding of the characteristics and 
burden imposed by heart disease in an urban African community in probable 
epidemiologic transition. 
 
Statement of originality document: Please see Appendix.
Articles
www.thelancet.com   Vol 371   March 15, 2008 915
Spectrum of heart disease and risk factors in a black urban 
population in South Africa (the Heart of Soweto Study): 
a cohort study
Karen Sliwa, David Wilkinson, Craig Hansen, Lucas Ntyintyane, Kemi Tibazarwa, Anthony Becker, Simon Stewart
Summary
Background The Heart of Soweto Study aims to increase our understanding of the characteristics and burden imposed 
by heart disease in an urban African community in probable epidemiological transition. We aimed to investigate the 
clinical range of disorders related to cardiovascular disease in patients presenting for the fi rst time to a tertiary-care 
centre. 
Methods From Jan 1 to Dec 31, 2006, we recorded data for 4162 patients with confi rmed cases of cardiovascular 
disease (1593 newly diagnosed and 2569 previously diagnosed and under treatment) who attended the cardiology unit 
at the Chris Hani Baragwanath Hospital in Soweto, South Africa. We developed a prospectively designed registry and 
gathered detailed clinical data relating to the presentation, investigations, and treatment of all 1593 patients with 
newly diagnosed cardiovascular disease.
Findings Most patients were black Africans (n=1359 [85%]), and the study population contained more women (n=939 
[59%]) than men. Women were slightly younger than were men (mean 53 [SD 16] years vs 55 [15] years; p=0·031), 
with 399 (25%) patients younger than 40 years. Heart failure was the most common primary diagnosis (704 cases, 
44% of total). Moderate to severe systolic dysfunction was evident in 415 (53%) of 844 identifi ed cases of heart failure, 
577 (68%) of which were attributable to dilated cardiomyopathy or hypertensive heart disease, or both. Black Africans 
were more likely to be diagnosed with heart failure than were the rest of the cohort (739 [54%] vs 105 [45%]; odds ratio 
[OR] 1·46, 95% CI 1·11–1·94; p=0·009) but were less likely to be diagnosed with coronary artery disease (77 [6%] vs 
88 [38%]; OR 0·10, 0·07–0·14; p<0·0001). Prevalence of cardiovascular risk factors was very high, with 897 
(56%) patients diagnosed with hypertension (190 [44%] of whom were also obese). Only 209 (13%) patients had no 
identifi able risk factors, whereas 933 (59%) had several risk factors.
Interpretation We noted many threats to the present and future cardiac health of Soweto, including a high prevalence 
of modifi able risk factors for atherosclerotic disease and a combination of infectious and non-communicable forms of 
heart disease, with late clinical presentations. Overall, our fi ndings provide strong evidence that epidemiological 
transition in Soweto, South Africa has broadened the complexity and spectrum of heart disease in this community. 
This registry will enable continued monitoring of the range of heart disease.
Introduction
The causes and consequences of an epidemic of 
cardiovascular disease and its major component, heart 
disease, in developed countries have been well documented. 
Conversely, few data exist in low-income and middle-
income countries to describe the eff ect of cardiovascular 
disease emerging as a threat in addition to malnourishment 
and infectious disease,1–3 especially in vulnerable popu-
lations for whom modifi able risk factors have previously 
been rare4 and health-care resources already over burdened. 
The potential eff ect of diff erent stages of epi demiological 
transition is especially evident in South Africa; this coun-
try of great diversity extends from highly indus trial ised 
cities with an urban advanced-economy lifestyle to 
remote rural regions with more traditional lifestyles. 
Although the sustained epidemic of HIV/AIDS causes 41% 
and 64% of deaths in men and women aged 15–44 years, 
respectively, coronary artery disease, hyper tensive heart 
disease, and stroke already account for more than a third 
of deaths in people older than 65 years.5,6
We therefore established the Heart of Soweto Study7 to 
monitor, describe, and respond to the evolving burden of 
heart disease within the largest urban concentration of 
black Africans in South Africa. We investigated the 
clinical spectrum of disorders related to cardiovascular 
disease (with a particular focus on heart disease) in 
people presenting for the fi rst time to a tertiary-care 
centre.
Methods
Study setting and design
The Heart of Soweto Study is a large-scale study of 
emergent heart disease and its antecedents in the 
geographically compact townships that comprise Soweto 
(estimated population of 1·1 million).7 This inter-
nationally renowned community has one of the largest 
urban populations of black Africans on the African 
continent.7 We investigated people presenting between 
Jan 1, 2006, and Dec 31, 2006, for the fi rst time to a 
tertiary-care centre (the Chris Hani Baragwanath 
Lancet 2008; 371: 915–22
See Comment page 876
Soweto Cardiovascular 
Research Unit, Chris Hani 
Baragwanath Hospital, 
University of the 
Witwatersrand, Johannesburg, 
South Africa (Prof K Sliwa MD, 
Prof D Wilkinson DSc, 
L Ntyintyane MD, 
K Tibazarwa MD, A Becker MD, 
Prof S Stewart PhD); School of 
Medicine, University of 
Queensland, Brisbane, 
Australia (Prof D Wilkinson, 
C Hansen PhD); and 
Preventative Cardiology, Baker 
Heart Research Institute, 
Melbourne, Australia 
(Prof S Stewart)
Correspondence to:
Prof Simon Stewart, Soweto 
Cardiovascular Research Unit, 
Chris Hani Baragwanath 
Hospital, University of the 
Witwatersrand, P.O. Bertsham, 
Johannesburg 2013, South Africa
simon.stewart@baker.edu.au
Articles
916 www.thelancet.com   Vol 371   March 15, 2008
Hospital), which provides specialist cardiac care to 
patients in Soweto and surrounding communities. 
Importantly, this 3500-bed hospital also provides referral 
services to individuals from a broad range of ethnic 
backgrounds including Europeans, Asians, and those of 
mixed ancestry (Khoi San European-African-Malay 
South Africans).
We developed a prospectively designed registry via 
dedicated facilities and staff  (with a strong focus on local 
capacity building) that included all individuals presenting 
with confi rmed or suspected cardiovascular disease to 
the cardiology unit. We gathered detailed clinical data 
relating to the presentation, investigations, and treatment 
of all patients with newly diagnosed cardiovascular 
disease. Patients with previously established 
cardiovascular disease were entered into a simpler 
version of the study’s clinical registry. Data were collected 
for age, sex, ethnic group, and primary diagnosis for 
previously established cases. 
The study was approved by the relevant local ethics 
committee and administrative bodies. The study 
conformed to the principles outlined in the Declaration 
of Helsinki. Every patient in the registry was assigned a 
unique identifying code (nine digits), and all documents 
were labelled accordingly to maintain anonymity. All 
participating patients provided oral consent to become 
part of the clinical registry. 
Participants
Since the population of Soweto and surrounding 
communities rely on the Chris Hani Baragwanath 
Hospital to provide all cardiac services and treatment via 
the cardiology unit, clinical data from the unit’s activities 
are highly representative of the underlying spectrum of 
cardiovascular disease (mild to severe). In 2006, the 
hospital managed 129 633 inpatients (45 400 [35%] of 
whom were managed by the Department of Medicine). 
In 2006, the case load for the cardiology unit included an 
estimated 5000 patients with a total of 21 000 patient 
contacts.
The cardiology unit is staff ed by internal medicine 
specialists (with a minimum of 4 years’ specialist training) 
undergoing specialist cardiology training and supported 
by experienced cardiologists. With gold-standard 
cardiological expertise and advanced diagnostic technical 
capacity (eg, coronary angiography and nuclear imaging), 
the cardiology unit provides defi nitive diagnostic and 
treatment services to the region. These services include 
all patients being seen at the dedicated cardiology 
outpatient department in addition to the hospital’s 
coronary-care unit. The cardiology outpatient department 
population includes all patients seen at 12 local Soweto 
primary-care clinics who were referred directly for a 
suspected cardiac disorder; all patients requiring more 
defi nitive investigation or treatment of suspected or 
confi rmed cardiovascular disease, who were seen initially 
at the general medical outpatient facilities, the specialist 
medical registrar clinic, and the diabetic clinic; and 
patients being initially admitted to the general medical or 
any other ward at Chris Hani Baragwanath Hospital who 
need a cardiological consultation.
Study data
Data were collected on a consecutive patient basis that 
was designed to keep selection bias to a minimum, and 
collection was limited only by the volume of cases at peak 
clinical activity. Overall, less than 10% of the adminis-
trative listing of patient case load by the cardiac-clinic 
clerk could not be accounted for (mainly because patients 
left the clinic before assessment during busy clinic days). 
The panel shows the sociodemographic and clinical data 
that the registry obtained for every new patient with 
cardiovascular disease.
Dependent on the clinical diagnosis and subsequent 
routine management of the patient, additional clinical 
variables that were entered into the clinical registry 
included: serum glucose concentration and haemo-
globin A1c ratio, lipid profi le, full blood count (eg, platelet 
and white cell counts and haemoglobin), renal function 
(creatinine and urea concentrations), cardiac enzymes 
(eg, cardiac troponin concentrations), and results of HIV 
Panel: Sociodemographic and clinical data obtained for every new case of 
cardiovascular disease
• Self-reported cultural, sociodemographic, and risk-factor profi le, which included ethnic 
origin, length of residence in Soweto, education status, and previous clinical history 
• Averaged seated systolic and diastolic blood pressure (mm Hg) and heart rate (beats 
per min), with measurements via a calibrated Dynamap (Critikon [GE Medical Systems 
Information Technologies]; Johannesburg, South Africa) monitor
• Height and weight with calculation of body-mass index (kg/m2); data available for 
ambulatory patients only
• Results of an advanced cardiological assessment including heart and lung sounds 
and documentation of any other clinically relevant signs and symptoms on dedicated 
study forms
• Functional status according to the New York Heart Association (NYHA) classifi cation 
of dyspnoea
• 12-lead electrocardiogram (ECG) subject to blinded coding according to published 
Minnesota criteria8 to document any clinical abnormalities relating to wave-form 
abnormalities (eg, changes indicative of left ventricular hypertrophy), conduction (eg, 
left bundle-branch block), or cardiac rhythm (eg, atrial fi brillation). Data were available 
in 1431 (90%) patients and fi nal determination was made by SS
• Two-dimensional targeted M-mode echocardiography with doppler colour fl ow mapping 
with a Hewlett Packard (Johannesburg, South Africa) Sonos 5500 echocardiograph 
attached to a 2·5 or 3·5 MHz transducer. Left ventricular dimensions and parameters 
(average of more than three beats) were measured according to the American Society of 
Echocardiography guidelines.9 Diastolic mitral fl ow was assessed by pulsed-wave doppler 
echocardiography from the apical four-chamber view. If no abnormalities were detected 
during the initial echocardiographic assessment, no further specifi c measurements were 
recorded. In all other cases, echocardiographic assessment consisting of a detailed 
assessment of ventricular function, valvular integrity, and function and regional wall 
abnormalities was undertaken. For patients in atrial fi brillation, echocardiographic 
measures were taken at least three times and the average documented
Articles
www.thelancet.com   Vol 371   March 15, 2008 917
testing if consent was given. In addition to the prescribed 
treatments, the registry also captured all advanced clinical 
investigative procedures (eg, coronary angiography, 
which was undertaken in all people diagnosed with 
coronary artery disease) and therapeutic procedures (eg, 
valve repair surgery).
All clinical diagnoses were independently reviewed by 
KS and SS following contemporary guidelines published 
online by the European Society of Cardiology10 to fi nalise 
each individual’s list of diagnoses within the clinical 
registry by consensus.
Statistical analysis
All study data were documented on specifi c study forms 
and then entered into a dedicated database (Microsoft 
Access) by the same designated data coordinator, who was 
a cardiac nurse with extensive clinical experience. Data 
were then verifi ed (with resolution of data queries) and 
transferred to SAS version 9.1 for all analyses. Normally 
distributed continuous data are presented as the mean 
(SD), and variables with non-Gaussian distribution as the 
median (IQR). Categorical data are presented as 
percentages with 95% CIs when appropriate. To compare 
groups of patients according to demographic and clinical 
profi le, we used χ² analysis with calculation of odds ratios 
(OR) and 95% CI for discrete variables, Student’s t test, 
and analysis of variance for normally distributed 
continuous variables. p values were two sided.
Role of the funding source
The sponsors of the study had no role in the design of the 
study, data collection, data analysis, data interpretation, 
or the writing of the report. The corresponding author 
had full access to all the data in the study and had fi nal 
responsibility for the decision to submit the report for 
publication.
Results
Figure 1 shows the clinical profi le of the study population. 
Of the 4506 patients who were assessed and entered into 
the registry, 344 (8%) did not have underlying 
cardiovascular disease: these patients had a similar sex 
and racial profi le to those with cardiac disease, but were, 
on average, a decade younger (data not shown). Thus the 
study population consisted of 4162 confi rmed patients 
with cardiovascular disease, 1593 (38%) of whom were 
newly diagnosed and 2569 (62%) were previously 
diagnosed and under treatment (fi gure 1). On average, 
patients with established disease were 1·7 (95% CI 
0·7–2·7) years older than were those with newly 
diagnosed disease (p=0·0012). 
The table shows the demographic and clinical profi le of 
the 1593 patients with newly diagnosed cardiovascular 
disease according to their primary diagnosis. Most 
patients were black Africans and the study population 
included more women than men (table). The age profi le 
of women was slightly younger than that for men (mean 
age 53 [SD 16] years vs 55 [15] years; p=0·031), with 862 
(54%) patients younger than 55 years and 399 
(25%) younger than 40 years. Just over half of patients 
reported living in Soweto itself (table), with only 42 
(5%) indicating they had lived there for less than 5 years. 
Black Africans were signifi cantly more likely to report 
low education levels than were other races combined 
(381 [28%] vs 35 [15%]; p<0·0001).
Figure 2 shows the broad spectrum of cardiovas-
cular disease and risk factors identifi ed within the study 
cohort. Apart from patients with a primary diagnosis of 
hypertension, most cases represented late clinical 
presentations with established heart disease of more 
than one cause. Overall, the four most common diag-
noses were hypertension, heart failure, valvular heart 
disease/dysfunction, and coronary artery disease 
(fi gure 2). Patients diagnosed with valvular heart disease 
were on average more than a decade younger than were 
those with heart failure or hypertension (table). 
Concurrent diabetes (predominantly type 2), renal 
disease, and anaemia were also diagnosed in some 
patients (table), and 74 (5%) were confi rmed as HIV 
positive (previous diagnosis or specifi cally tested for the 
virus).
In the 146 miscellaneous cases (9% of all cases), the 
most common diagnosis was pericardial eff usion 
(fi gure 2) as a complication due to tuberculosis, 
HIV/AIDS, or a combination of both diseases (n=80 
[5% of all cases]). Overall, rheumatic valvular heart 
disease, the cardiomyopathies, and tuberculous peri-
cardial eff usion combined, accounted for 639 (40%) of 
these newly diagnosed cases. A clinically important but 
4506 patients assessed and entered into the registry
1937 newly diagnosed patients
Detailed clinical registry Simple clinical registry
2569 patients with established disease
2569 with previously treated CVD
1330 cases of hypertension
1116 cases of heart failure
976 cases of valvular heart disease
451 cases of coronary artery disease
231 cases of diabetes
1593 with newly diagnosed CVD344 with non-cardiac
disease
897 cases of hypertension
844 cases of heart failure
360 cases of valvular heart disease
165 cases of coronary artery disease
165 cases of diabetes
Figure 1: Clinical profi le of the study cohort
CVD=cardiovascular disease.
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rare diagnosis was stroke. Overall, 145 (9%) patients 
reported a family history of stroke but only 64 (4%) were 
diagnosed with an acute stroke (16 cases) or as a secondary 
contributor to their presentation.
Black Africans accounted for most cases in all major 
diagnostic groups—eg, 739 of 844 (88%) cases of heart 
failure were in black African patients. Black Africans 
were signifi cantly more likely to be diagnosed with heart 
failure than were the rest of the cohort (739 [54%] vs 
105 [45%]; OR 1·46, 95% CI 1·11–1·94; p=0·009). 
However, they were far less likely to be diagnosed with 
coronary artery disease than were all other racial groups 
(77 [6%] vs 88 [38%]; OR 0·10, 0·07–0·14; p<0·0001). 
Although the overall proportions of men and women 
diagnosed with hypertension and diabetes were much 
the same, proportionately more women were diagnosed 
with valvular heart disease than were men (240 [26%] vs 
120 [18%]; OR 1·30, 1·11–1·52; p=0·001). By contrast, 
All (n=1593) Hypertension 
(n=310)
Heart failure 
(n=704)
Valve disease 
(n=268)
CAD (n=165) Other (n=146)
Sociodemographic profi le
Age (years) 52·8 (17·1) 58·3 (15·3) 55·1 (16·2) 45·7 (18·2) 56·7 (12·4) 38·8 (16·6)
Black African 1359 (85%) 265 (86%) 640 (91%) 243 (91%) 77 (47%) 134 (92%)
Women 939 (59%) 199 (64%) 409 (58%) 179 (67%) 68 (41%) 84 (58%)
No or standard education 416 (26%) 76 (26%) 204 (31%) 69 (27%) 29 (21%) 38 (27%)
Live in Soweto 842 (53%) 169 (55%) 418 (59%) 126 (47%) 42 (25%) 87 (60%) 
Years living in Soweto 41 (27–50) 46 (35–54) 43 (30–52) 36 (20–50) 44 (40–55) 28 (17–39)
Risk factor profi le
Positive family history 405 (25%) 67 (22%) 168 (24%) 75 (28%) 60 (36%) 35 (24%)
Hypercholesterolaemia* 159 (22%) 54 (38%) 45 (17%) 16 (21%) 37 (35%) 7 (20%)
History of smoking 661 (41%) 112 (36%) 327 (46%) 84 (31%) 84 (51%) 54 (37%)
Risk factors
None 209 (13%) 0 71 (10%) 78 (29%) 8 (5% ) 52 (36% )
One 451 (28%) 72 (23%) 203 (29%) 77 (29%) 40 (24%) 59 (40%)
More than one 933 (59%) 238 (77%) 430 (61%) 113 (42%) 117 (71%) 35 (24%)
Clinical presentation
NYHA class III or IV 486 (31%) 84 (27%) 255 (36%) 63 (24%) 32 (19%) 52 (36%)
Heart rate (min) 86 (21·5) 82 (19·2) 90 (20·3) 83 (18·3) 77 (19·2) 97 (37·6)
Systolic BP (mm Hg) 130 (27·1) 144 (29·0) 129 (26·1) 123 (24·4) 124 (27·1) 120 (23·4) 
Diastolic BP (mm Hg) 73 (16·6) 78 (16·8) 75 (16·7) 68 (15·0) 70 (13·5) 71 (17·3)
Angina pectoris/chest pain 451 (28%) 89 (29%) 182 (26%) 70 (26%) 82 (50%) 28 (19%)
Oedema (pulmonary/peripheral) 494 (31%) 78 (25%) 275 (39%) 75 (28%) 35 (21%) 31 (21%) 
Co-morbidity
Renal dysfunction† 115 (10%) 23 (10%) 51 (10%) 20 (8%) 16 (11%) 5 (5%)
Anaemia‡ 156 (13%) 30 (12%) 64 (11%) 22 (12%) 7 (6%) 33 (28%)
Diabetes 165 (10%) 41 (13%) 66 (9%) 13 (5%) 35 (21%) 10 (7%)
HIV positive 74 (5%) 4 (1%) 35 (5%) 10 (4%) 2 (1%) 23 (16%)
ECG profi le§
Sinus rhythm 1321 (92%) 267 (98%) 574 (90%) 222 (90%) 140 (98%) 118 (93%)
Atrial fi brillation 102 (7%) 12 (4%) 48 (8%) 32 (13%) 4 (3%) 6 (5%)
Arrhythmia 487 (34%) 79 (29%) 252 (40%) 74 (30%) 31 (22%) 51 (40%)
Bundle block 127 (9%) 11 (4%) 76 (12%) 23 (9%) 11 (8%) 6 (4%)
Echocardiographic profi le§
Mean LVEF 53·0 (17·4) 65·0 (10·8) 45·7 (18·3) 57·1 (13·4) 51·6 (15·9) 61·8 (8·8)
Systolic heart failure¶ 415 (29%) 0 341 (52%) 37 (14%) 37 (31%) 0
Preserved heart failure¶ 373 (26%) 0 316 (48%) 35 (13%) 22 (18%) 0
Data are number (%), mean (SD), or median (IQR). CAD=coronary artery disease. NYHA=New York Heart Association. BP=blood pressure. LVEF=left ventricular ejection 
fraction. ECG=electrocardiogram. *Hypercholesterolaemia defi ned as fasting total cholesterol serum concentration greater than 5·5 mmol/L (clinical data collected in 
728 cases). †Renal dysfunction defi ned as a serum creatinine concentration greater than 160 µmol/L (clinical data in 1182 cases). ‡Anaemia defi ned as haemoglobin 
concentration less than 110 g/L in men and less than 100 g/L in women (clinical data in 1185 cases). §Echocardiographic data were available in 1431 and 1433 cases, 
respectively. ¶Systolic or preserved (diastolic) heart failure defi ned by the presence or absence of a left ventricular ejection fraction of 45% or less (measured on presentation 
to the cardiology unit) when clinical symptoms or signs of heart failure were present.
Table: Sociodemographic and clinical profi le according to primary diagnosis
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proportionately fewer women were diagnosed with heart 
failure (478 [51%] vs 366 [56%]; OR 0·89, 0·79–0·99; 
p=0·047) or coronary artery disease (68 [7%] vs 97 [15%]; 
OR 0·66, 0·58–0·77; p<0·0001); in absolute terms, 
however, 112 more women than men were diagnosed 
with heart failure.
On presentation, many patients had evidence of 
advanced disease with signifi cant dyspnoea (New York 
Heart Association class III or IV), chest pain or angina 
pectoris, and peripheral oedema as common presenting 
symptoms across all diagnostic groups (table). 
Electrocardiographic (ECG) and echocardiographic 
fi ndings were indicative of a cohort with predominantly 
advanced and complex disease, with 487 (34%) patients 
having tachycardia, or underlying cardiac dysfunction or 
structural disease. Of the 844 cases of heart failure, 
203 (24%) had a mixed underlying aetiology, 332 (39%) had 
developed valvular dysfunction (eg, secondary to mitral 
regurgitation), and 67 (8%) had a primary diagnosis of 
valve disease (eg, predominantly rheumatic heart disease 
or degenerative valve disease) (fi gure 2). The three most 
common forms of heart failure were the dilated 
cardiomyopathies (35% [95% CI 32–38]), which included 
peri-partum cardiomyopathy, heart failure second to 
hypertensive heart disease (33% [30–36]), and right heart 
failure (27% [24–30]), which was commonly associated 
with underlying cor pulmonale (99 [44%] patients) 
(fi gure 2). Overall, 415 (53%) of patients with heart failure 
had moderate to severe systolic dysfunction and 
225 (27%) had impaired diastolic function; mean left 
ventricular ejection fraction being 34% (SD 13) in those 
with dilated cardiomyopathy and 39% (SD 15) in those 
with ischaemic cardiomyopathy. Patients with heart 
failure related to underlying hypertensive heart disease 
(157 [56%] of 281 cases) and valvular disease (24 [36%] of 
67 cases) were most likely to have impaired diastolic 
function. Similarly, 733 (97%) of 756 12-lead ECGs in 
patients diagnosed with heart failure had some form of 
abnormality, with 115 (16%) patients having ECG evidence 
of left ventricular hypertrophy.
In all diagnostic groups, the rate of common risk 
factors for cardiovascular disease was very high; overall, 
only 209 (13%) had no risk factors, whereas 933 (59%) had 
several risk factors. For example, 70 (47%) patients with a 
primary diagnosis of hypertension were also obese 
and 84 (51%) with coronary artery disease had a history of 
smoking. In those for whom we recorded body-mass 
index (BMI) data (ambulatory cases), women were 
signifi cantly heavier than were men (mean BMI 29·6 
[SD 7·7] kg/m² vs 25·2 [5·9] kg/m²; p<0·0001).
Discussion
Consistent with a call for the development of high quality, 
contemporaneous data to combat the global eff ect of 
cardiovascular disease,11 this fi rst report from the Heart 
of Soweto Study provides a detailed perspective on the 
spectrum of heart disease arising from a large urban 
African community. We noted that heart failure was the 
most common primary diagnosis in this population, with 
moderate to severe systolic dysfunction evident in around 
half the cases. Black Africans were more likely to be 
diagnosed with heart failure than were others, but far 
less likely to be diagnosed with coronary artery disease. 
Almost two-thirds of patients had multiple risk factors 
for cardiovascular disease. 
Our data have important public-health and clinical 
implications for the prevention and treatment of heart 
disease both within this internationally renowned 
community and possibly for other urban communities 
on the African continent that are undergoing 
epidemiological transition. Specifi cally, we note that the 
present spectrum of heart disease in Soweto ranges from 
the so-called traditional forms of infectious diseases that 
are usually expected in African populations12–14 to newer 
non-communicable diseases (predominantly associated 
with advanced clinical presentations) that are often 
reported in high-income countries.15,16
These baseline data now provide us with the opportunity 
to establish whether epidemiological transition in Soweto 
has broadened the spectrum of clinical cardiovascular 
disease beyond the traditional threats of rheumatic 
valvular heart disease, the cardiomyopathies, and 
1593 new cases of cardiovascular disease
310 cases
(19% [95% CI 17–21])
897 hypertension (56%)
         310 lone hypertension (35%)
844 heart failure (53%)
         296 dilated cardiomyopathy (35%)
         281 hypertensive heart failure (33%)
         225 right heart failure (27%)
         77 ischaemic cardioyopathy (9%)
        67 valvular heart failure (8%)
360 valvular heart disease/dysfunction (23%)
         208 rheumatic valvular disease (58%)
         103 functional valvular disease (29%)
         78 degenerative failure (22%)
165 coronary artery disease (10%)
         28 coronary artery disease without
         risk factor (17%)
146 other diagnoses (9%)
         67 pericardial effusion (46%)
         25 cardiac arrythmia (17%)
         22 congenital heart disease (15%)
         16 stroke (11%)
704 cases
(44% [95% CI 42–47])
268 cases
(17% [95% CI 15–19])
165 cases
(10% [95% CI 8–12])
146 cases
(9% [95% CI 8–11])
Primary diagnosis
Figure 2: Clinical spectrum of disease 
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tuberculous pericardial eff usion (aff ecting 40% of 
patients in 2006).12 The presence of a large component of 
non-communicable cardiovascular disease (eg, 
hypertensive heart disease and coronary artery disease) 
and its common antecedent, type II diabetes, is consistent 
with a broadening spectrum of cardiovascular disease in 
this urban population.17 In view of its near historical 
absence in black Africans,7,18 the number of documented 
cases of atherosclerotic disease (14% overall including 
stroke cases) is consistent with our recent 
community-based survey that showed a high prevalence 
of modifi able risk factors in black African adults living in 
Soweto.19 The clinical spectrum of heart disease within 
this population is further broadened by cardiac compli-
cations relating to tuberculosis and HIV/AIDS (eg, 
tuberculous pericardial eff usion, HIV-cardiomyopathy, 
and diseases related to highly active antiretroviral 
therapy). The burden of patients presenting for the fi rst 
time with symptoms of chronic rheumatic heart disease 
and idiopathic cardiomyopathy still exceeds the number 
of patients presenting with coronary artery disease. 
Importantly, these data also show that many patients had 
developed signifi cant clinical disease before their fi rst 
presentation (suggesting little awareness of heart disease 
and diffi  culty in accessing appropriate health care). 
Almost half of people being treated for hypertension in 
the absence of clinical heart disease were obese. That 
black African women were most likely to be obese both 
in this hospital cohort and the general community,19 and 
that they are also the predominant sex within this ethnic 
cohort, is especially noteworthy in view of the typical 
male dominance seen in cohorts from developed 
countires.15,16 Similarly, the fairly young age of the cohort 
also contrasts substantially with reports from high-income 
countries.
For decision-making and planning processes in health 
care, a consistent and comparative description of the 
spectrum and burden of diseases and their associated 
risk factors is essential. All broad indications, whether 
specifi c to the region6,20 or derived from a range of 
developing countries,21 indicate an increasing burden 
imposed by cardiovascular disease. For example, a 
South African survey of 10 000 households has identifi ed 
a worsening risk profi le for cardiovascular disease in 
the country.6 Similarly, a report from Columbia 
University’s Earth Institute showed that cardiovascular 
mortality rates in working-age people in South Africa 
were 1·5 times higher than were those of working-age 
people in the USA, and 41% of cases occurred in those 
aged 35–64 years.20 However, probable error rates 
relating to estimates of all-cause mortality 
(range 15–20%) and prevalence of ischaemic heart 
disease (25–35%) for sub-Saharan Africa are 
substantial.22 Few data for the spectrum and 
characteristics of heart disease and other major forms 
of cardiovascular disease in Africa exist.11–13,23 Many 
studies were undertaken before echocardiography was 
used as standard, or many cases did not use this 
technique. By contrast with our report, studies usually 
focus on a particular disease and only seldom investigate 
the entire spectrum of cardiovascular disease.13 Overall, 
comprehensive clinical data supported by results of 
appropriate investigations (ECG, echocardiography, 
and biochemical studies) are not available from 
sub-Saharan African, and our study addresses this 
important gap.
We noted that most patients presented with advanced 
disease and the most frequent primary diagnosis was 
heart failure. The likely reasons for these fi ndings are 
complex. An absence of screening programmes for 
rheumatic or congenital heart disease in schoolchildren 
means that many individuals will present late with 
symptoms of heart failure in adulthood. This problem 
could be addressed with the emergence of portable 
technologies that provide cost-eff ective and pragmatic 
options for screening when resources are scarce. 
Similarly, underlying hypertension and diabetes are often 
identifi ed only when signifi cant end-organ damage has 
occurred. Little community awareness of the signs and 
symptoms of advanced heart disease undoubtedly 
contributes to a systematic delay in health seeking 
behaviours and patterns of referral. The disease profi le is 
clearly diff erent to the so-called traditional spectrum of 
disease; our data identifi ed a large burden of newly 
diagnosed patients with rheumatic heart disease but not 
one case of acute rheumatic fever, which was previously a 
common disease.24,25 Although this fi nding potentially 
shows improved living circumstances and access to 
antibiotic therapy for throat infections in children living 
in Soweto, it could also indicate an underestimation of 
acute rheumatic fever by parents or fi rst-line health-care 
workers. Moreover, our data might not be representative 
for rural regions or other sub-Saharan countries (eg, the 
prevalence of rheumatic heart disease in Mozambique 
was reported to be 2·3 cases per 1000 on the basis of 
clinical screening and 30·4 cases per 1000 on the basis of 
echocardiographic screening).26
Consistent with data from other parts of Africa 
suggesting a broadening pattern of cardiovascular disease 
involving a component of greater burden imposed by 
atherosclerotic disease,27,28 we recorded a small but 
potentially signifi cant number of cases of coronary artery 
disease. Our data need careful examination in view of a 
cost-eff ectiveness analysis on the application of multidrug 
regimens for the primary and secondary prevention of 
cardiovascular disease from the perspective of six 
developing World Bank geographical regions, which 
favoured populations with high absolute risk for future 
cardiovascular events.29 Our data would lend support to 
the application of this form of strategy on a primary 
prevention basis in sub-Saharan Africa, but not (as of yet) 
on a secondary prevention basis. More applicable, 
perhaps, would be culturally adapted programmes for 
the management of chronic diseases, particularly in 
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relation to the management of heart failure.30 Clearly, 
these issues need to be addressed via appropriately 
designed and powered clinical trials in addition to 
sustainable community programmes for screening and 
awareness.
Notwithstanding a range of issues (including few 
health-care resources, the complexity of disease states, 
and need to build local research capacity), we support a 
call for an appropriate research agenda to better 
understand and respond to the evolving burden of 
cardiovascular disease in Africa on the basis of our 
fi ndings.13 Further to this study and other substantive 
attempts to investigate changes in the lifestyles and 
cardiovascular risk in African children,31 similar reports 
from other parts of Africa are needed. We plan to continue 
this registry to monitor potential changes in the spectrum 
of cardiovascular disease presentations over the next 
decade.
Our study has several limitations. First, since not all 
patients being managed by the cardiology unit were 
captured by our registry, selection bias might exist. 
Furthermore, our focus on patients being managed by a 
tertiary centre to describe the spectrum of disease 
within the region could also have been biased. We 
acknowledge that individuals with subclinical disease, 
milder forms of cardiovascular disease, or those 
suff ering sudden fatal events (eg, fatal haemorrhagic 
stroke or myocardial infarction) would not be captured 
by our registry; the few cases of stroke could partly be 
explained by the fact that haemorrhagic strokes 
diagnosed via CT scans with an obvious non-cardiac 
origin are often not referred to a cardiology centre in 
South Africa. Alternative cardiac services for those 
living in Soweto and surrounding communities are few, 
and the use of private facilities in black South Africans 
is very low.32 Similarly, since the registry was based on 
routine clinical practice (albeit under the direction of 
trained cardiologists), we did not capture identical 
clinical data for all patients and have relied on clinical 
diagnoses. However, our ability to provide compre-
hensive 12-lead ECG and echocardiographic data for 
most patients is a major strength of our study, and 
wherever possible, we have adhered to the recently 
published STROBE guidelines relating to the reporting 
of this type of study.33
Despite some important limitations, our data provide 
preliminary evidence to show the eff ect of epidemiological 
transition in this population who face many threats to 
their present and future cardiac health, including a high 
prevalence of modifi able risk factors for atherosclerotic 
disease, a combination of infectious and non-
communicable forms of heart disease, and late clinical 
presentations. The combination of common preventable 
risk factors and late clinical presentations (especially 
heart failure) represents a particular challenge to improve 
primary and secondary prevention strategies to not only 
reduce the number of new cases of cardiovascular disease 
but also improve health outcomes for those with 
pre-established disease. Long-term surveillance systems 
are also needed to monitor the success or failure of such 
initiatives.
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Summary: This publication, the second of the epidemiological studies, presents data on 
the presentation of acute coronary syndromes in modern Soweto compared to a study 
carried out in the same hospital between the years 1975 and 1980. A comparison is made 
in order to quantify the magnitude of change in the presentation of acute coronary 
syndromes in Soweto over the past 25 years. 
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ABSTRACT
Objectives:
To describe the recent increase in acute coronary syndromes among urban black South Africans in Soweto. 
Design:
Cross-sectional study in 2004 and comparison with data from 1975-80.
Setting:
Chris Hani Baragwanath Hospital, Soweto.
Participants:
Patients admitted with a diagnosis of troponin positive acute coronary syndrome (ACS) in 2004, to Coronary Care Unit
(CCU) and patients admitted with a diagnosis of acute myocardial infarction (AMI) in 1975-80. 
Results: 
We identified 154 patients with ACS in 2004. Of these 64 (42%) were black, 50 (32%) were white and 40 (26%) Asian.
Between 1975 and 80, 54 patients were diagnosed with AMI (50 were black). Mean age in 2004 was 56 years and most
were men (110; 71%). Risk factor prevalence was high in 2004. Black patients tended to be younger, less likely to have
diabetes than Asians, and much less likely to have a family history of coronary artery disease. Black patients were more
likely to have only one coronary artery affected by atherosclerosis than were white patients (48% vs 26%, p=0.07).
Eight patients died in 2004 (5%) and eight in 1975-80 (15%). 
Conclusion:
The annual incidence of ACS among black Africans has increased rapidly in Soweto. There seem to be significant dif-
ferences in risk factor profile and extent of coronary arteries involved among the different ethnic groups studied.
Continued emergence of coronary artery disease implies a significant additional burden to the health system. 
KS and CA conceived of the study, supervised data collection, and drafted the paper. CA, LN and AB collected data. DW and SS con-
tributed to data analysis and paper drafting. EL analysed data. All authors reviewed the final paper.
No funding was used to support this study.
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Introduction
The burden and spectrum of non-communicable diseases
differs considerably between Africa and more developed
countries. Doctors working in rural African settings observe
the virtual absence of coronary artery disease. The frequen-
cy of ischaemic heart disease has been documented as being
very low among black South Africans1 with an average of
three patients each year admitted to Baragwanath Hospital,
Soweto, South Africa with acute myocardial infarction
(AMI) in the 1950s. However, it is now widely recognised
that, in association with urbanisation and its associated epi-
demiological transition,2,3 Africa is facing a significant bur-
den of non-communicable diseases, many of which act as
risk factors for cardiovascular disease. It has been suggested
that the prevalence of coronary artery disease is increasing in
sub-Saharan Africa4,5 but there is limited data to confirm this,
and what is available suggests regional variation.
Furthermore, ethnicity, a construct that encompasses both
cultural (e.g. language, habits, diet) and possibly genetic fac-
tors,2,3 is a potentially important additional factor explaining
such variation. 
Between 1975 and 1980 at Baragwanath Hospital, serving
the (then) almost exclusively black African population of
Soweto only 54 cases of AMI were reported (50 black
Africans; average eight each year in a community of
approximately one million in size).6 We have recently
observed a significant change in the burden and spectrum of
cardiovascular disease at Baragwanath Hospital, including
the increased presentation of ischaemic heart disease. The
population served by the hospital has however also changed
to include Africans of European and Asian ancestry. This
paper characterises acute coronary syndrome (ACS) at this
hospital and compares the results with a study on acute
myocardial infarction carried out in the same hospital
between 1975 and 1980. A comparison is made in order to
quantify the magnitude of change in the presentation of ACS
in Soweto over the past 25 years. 
Methods
Setting
Baragwanath Hospital has 3 300 beds and is the largest hos-
pital in the southern hemisphere, with about 100 medical
admissions each day. In 1975 the hospital had 2 734 beds
with an average of 70 general medical admissions daily.6 The
hospital historically served the (essentially black African)
population of Soweto, reportedly comprising around one
million people6 situated in the outskirts of Johannesburg.
Since the re-organisation of South Africa’s health services
along non-racial lines in 1994, Baragwanath now serves a
mixed population, drawing Africans of Asian (Indian) ances-
try from Lenasia, and Africans of European ancestry from
Vereeniging. The total population served is estimated at 1.5
million, of which 1 million of these are black Africans
(www.statssa.gov.za). The coronary care unit at
Baragwanath Hospital now routinely cares for black, Asian
and white patients. 
The above-mentioned population groups in the given geo-
graphical regions are also served by a network of primary
care clinics and secondary care level hospitals. However, the
Department of Cardiology at Baragwanath Hospital is the
only source of specialist cardiology care in the public health
system in Soweto. The cardiology outpatient clinic, which
cares for about 100 patients each day (20-30 new patients)
sees mainly non-referred patients (hence effectively provid-
ing a primary care service), but also sees patients admitted to
the medical wards with a cardiac diagnosis. Furthermore the
coronary care unit in the department is the only one serving
this population, as is the coronary angiography service (in
the public system). Patients have access to private health
care if they can afford it.7
The study was approved by the University of the
Witwatersrand Ethics Committee. The cohort of patients
studied were part of a larger group that participated in the
on-going acute coronary syndrome study. 
Methodology
We carried out a cross-sectional study of patients admitted to
the coronary care unit (CCU) in 2004, with ACS and posi-
tive troponin T test in accordance with the current European
Society of Cardiology guidelines (www.escardio.org). All
patients presenting with ACS are routinely admitted to the
CCU for further evaluation and treatment. This syndrome
comprises the following specific diagnoses:
• ST elevation myocardial infarction: characterised by
typical symptoms of acute myocardial ischaemia in addi-
tion to a positive serum troponin T concentration and
evolving ST-segment elevation of ≥ 0.1 mV in two or
more contiguous ECG leads.
• Non-ST elevation myocardial infarction: characterised
by typical symptoms and a positive troponin T concen-
tration, but with ECG changes indicative of acute
myocardial ischaemia (i.e. ST-segment depression in two
or more contiguous ECG leads).
• Unstable angina pectoris: characterised by typical
symptoms of worsening angina pectoris or occurring at
rest with ECG changes indicative of myocardial
ischaemia. All patients included in the study presenting
with unstable angina, ST elevation or non-ST elevation
infarction needed to have a positive troponin T concen-
tration to be included. Acute coronary syndromes share
the same common pathophysiologic mechanism, namely
disruption of atherosclerotic plaque with different
degrees of superimposed intra-coronary thrombus and
distal embolisation.8 For all patients admitted with this
diagnosis in 2004, we collected data on demographic fac-
tors (age, gender, ethnicity), cardiovascular risk factors
(previously diagnosed hypertension, diabetes, hypercho-
lesterolaemia, current smoking, family history), blood
pressure and electrocardiogram, standard Bruce stress
test, coronary angiography, and left ventricular angiogra-
phy. All diagnoses and results of investigations were ver-
ified by a qualified cardiologist and independently
reviewed by KS.
SA HEART • Spring 2006 ARTICLE
8
SAHJ Journal Spring 06  10/12/06  3:37 PM  Page 8
Statistical analysis
Data for this study were entered into an Excel spreadsheet.
Values are expressed as means ± standard deviation and
percentages. Mean values were compared using ANOVA
for normally distributed data. Percentages were compared
using Chi-square test. A p value less than 0.05 was regard-
ed as significant. 
Results
Characteristics
In total, 154 patients with a diagnosis of ACS were admit-
ted to the CCU of Baragwanath Hospital in 2004. The
mean age was 56 years and there were more male (110;
71%) than female patients (Table I). Most patients were
black (64; 42%), with 50 (32%) white and 40 (26%) Asian
(Indian). The gender distribution was similar for each eth-
nic group. 
The prevalence of risk factors was high (Table I) and
similar in each ethnic group. However, black patients were
significantly younger, less likely to have diabetes or dys-
lipidaemia than Asian patients, and much less likely to
have a family history of coronary artery disease than either
Asians or whites (Table II). 
Coronary disease patterns, intervention 
and outcomes
There were significant differ-
ences in the type and extent of
coronary artery disease among
these patients (Table III). Black
patients were more likely to
have single vessel disease than
were white patients (48 vs 26%,
p=0.07), while the distribution
of vessels affected by athero-
sclerosis was similar among
black and Asian (Indian)
patients. In all, 76 patients
(53%) had PTCA and 35 (24%)
had coronary artery bypass
graft surgery. At index admis-
sion eight patients died in 2004
(5%) and eight in 1975-80
(15%). 
Temporal trends
Between 1975 and 1980 only 54
patients were admitted to the
intensive care unit of
Baragwanath Hospital with a
diagnosis of AMI, 50 of whom
were black Africans (eighth per
annum)6 and in the 1950s an aver-
age of three patients per annum
with AMI were identified.9
In those years the hospital served an almost exclusively black
African population. We identified 64 black Africans with acute
coronary syndrome in 2004 alone (Figure 1). The population
of Soweto has almost certainly increased since that time and
the 2001 Census determined the population to be 890 000. If
we assume that all black Africans identified in our study lived
in Soweto then the annual incidence of hospitalised ACS is
7/100 000. The population was estimated to be 1 million in the
late 1970s, providing an annual incidence of 0.5/100 000. 
Table I: Baseline characteristics (n = 154)
Characteristic Measure
Age (years) (SD) 56.4 (11.8)
Gender (male) (%) 110 (71%)
Smoker (n = 145) (%) 83 (57%)
Hypertension (n = 143) (%) 84 (59%)
Family history (n = 149) (%) 53 (36%)
Dyslipidaemia (n = 148) (%) 61 (41%)
Diabetes (n = 149) (%) 49 (33%)
LV dysfunction, EF < 40% (%) 39 (34%)
LV: left ventricular; EF: ejection fraction
Table II: Frequency of coronary artery risk factors in patients from
different ethnic groups (p-value refers to the comparison
between blacks vs other ethnic groups)
Ethnicity
Risk factor Whites Asian Blacks p-value
Number 50 40 64
Age (years) (sd) 57.7 (11.4) 59.5 (13.1) 53.6 (10.9) 0.03
Smoker (%) 24/49(29%) 25/39 (30%) 34/57 (41%) 0.32
Hypertension (%) 33/49 (39%) 18/35 (21%) 33/59 (39%) 0.29
Diabetes (%) 15 (31%) 20 (41%) 14 (29%) 0.02
Family history (%) 26 (49%) 18 (34%) 9 (17%) <0.0001
Dyslipidaemia (%) 22 (36%) 22 (36%) 17 (28%) 0.02
Table III: Distribution of number of coronary arteries with athero-
sclerotic lesions in patients from different ethnic groups 
Extent of coronary Whites Asian Blacks Total 
artery disease
Single vessel (n,%) 12 (26%) 16 (43%) 29 (48%) 57 (40%)
Two vessel (n,%) 17 (37%) 7 (19%) 18 (30%) 42 (29%)
Triple vessel (n,%) 17 (37%) 14 (38%) 13 (22%) 44 (31%)
Total (n,%) 46 37 60 143
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However, if we assume that the population estimate in the
1970s was a significant overestimate then the annual incidence
was probably higher – perhaps 1/100 000 if the population was
actually 0.5 million then. Nevertheless the annual incidence
seems to have increased considerably in recent years.
Discussion
The rising prevalence of cardiovascular diseases is an emer-
gent trend in the African continent.4,5 In this study we report on
acute coronary syndromes among urban black South Africans
in Soweto. Our data demonstrates a substantial increase in the
number of patients diagnosed with ACS at Baragwanath
Hospital, South Africa in recent years. While about 50 years
ago, three such patients were identified each year,9 and about
25 years ago, five such patients were identified each year,6 in
2004 there were 64 black Africans with ACS. These data are
important because they may herald the emergence of a signifi-
cant epidemic of ischaemic artery disease in South Africa. 
It is worth noting that reports from physicians working in the
rural areas of South Africa have reported very low rates of
ACS.10 Anecdotal observations from one of our colleagues
(DW) who had worked on stroke in the rural Agincourt area of
South Africa for 12 years showed that ACS was rare as only
one case was seen during the study period.10 Such observations
raise the important question of an epidemiologic transition due
to urbanisation, adoption of western life style and changes
from the traditional African diet to a diet high in saturated fats
consistent with a population in epidemiologic transition: Is an
urban epidemic of ischaemic heart disease emerging, second-
ary to the “westernisation” of the traditional (cardio-protective)
African lifestyle in Soweto, and potentially, other urban areas? 
Our data need cautious interpretation. Comparative data
comes from historical publications that inevitably used differ-
ent diagnostic criteria and methods which are less sensitive
than current methods employed. Troponins have the greatest
sensitivity and specificity in detecting myocardial infarction
compared with clinical diagnosis and use of cardiac enzymes.
In our study, we used very strict criteria for diagnosis of
ACS in 2004 using current European Society of
Cardiology guidelines and it is unlikely that our 2004 data
are inflated. Although there are differences in diagnostic
criteria used in our study and the two previous studies, the
current data suggest an epidemiologic transition among
the black population from infectious diseases to non-com-
municable diseases. Also, as unstable angina and AMI
were so rarely diagnosed 25 and 50 years ago, and are of
such clinical interest, it seems unlikely that the authors of
those reports missed significant numbers of patients.
However, a detailed prospective study is necessary to
determine the future emergence of ACS in this population.
Overall, in 2004 we noted the typical preponderance of
male cases and the high underlying prevalence of risk fac-
tors for coronary artery disease. Clearly, there were some
ethnic-based differences with, for example, Asian patients
demonstrating a significantly higher prevalence of dia-
betes. Conversely, black Africans were less likely to have
a positive family history of dyslipidaemia. These observa-
tions raise two important issues. Firstly, it appears that the
former likely reflects a “new” generation of coronary
artery disease in the local population with the emergence
of new “triggers” including the adoption of western
lifestyles. Secondly, the concurrent differences in dyslipi-
daemia and preponderance of single vessel disease in
black Africans suggest a different pathology in this group
of patients. One possibility is an association with HIV
infection which we are currently studying. There are
reports on AMI in HIV-positive subjects11,12 in the litera-
ture. The possible mechanisms proposed are the use of
protease-inhibitor drugs which is associated with
increased levels of triglycerides, total cholesterol, and
low-density lipoprotein cholesterol and also its association
with advanced HIV disease.11,12 Finally we note that the
mortality rate among patients with ACS at this hospital has
fallen from 15% substantially to 5%, associated with the
use of modern therapy including thrombolysis and PTCA. 
In conclusion, this study has highlighted a rising preva-
lence of coronary artery disease among South African
blacks which is in keeping with the observed epidemio-
logic transition phase in most African countries.4,5
Although ethnic variation in risk factors was noted, most
of these factors are modifiable and efforts must be geared
towards promoting a healthy life style among the general
population in order to stem the impending epidemic of
chronic diseases in developing countries.
Age
Figure 1: Comparison of the relative annual
number of patients by age group presenting
with ACS in 2004 and AMI during the 
period 1975-80, for black Africans only
These data are important because they 
may herald the emergence of a significant 
epidemic of ischaemic artery disease 
in South Africa
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Louis Vogelpoel Travelling Scholarship
Applications are invited for the first annual Louis Vogelpoel Travelling Scholarship.
An amount of up to R15 000 towards the travel and accommodation costs of a local or international congress will be offered
annually by the Cape Western branch of the South African Heart Association in memory of one of South Africa’s outstand-
ing cardiologists, Dr Louis Vogelpoel.
Louis Vogelpoel was a pioneer of cardiology in South Africa who died in April 2005. He was one of the founding members
of the Cardiac Clinic at Groote Schuur Hospital and University of Cape Town. He had an exceptional career over more than
5 decades as a distinguished general physician, cardiologist and horticultural scientist. His commitment to patient care, teach-
ing and personal education is remembered by his many students, colleagues and patients. Medical students, house officers,
registrars and consultants benefited from exposure to his unique blend of clinical expertise, extensive knowledge, enthusiasm
and gracious style. 
A gifted and enthusiastic teacher he was instrumental in the training of generations of under-graduates by regular bedside
tutorials. He served as an outstanding role-model for postgraduates and many who have achieved prominence nationally and
internationally acknowledged his contribution to the development of their careers. 
The scholarship will be awarded for the first time in 2007 after all applications have been received and reviewed by the
executive committee of the Cape Western branch of the South African Heart Association. Preference will be given to practi-
tioners or researchers in the field of cardiovascular medicine who are members of the South African Heart Association and
are resident in the Western Cape. 
Applications should include:
1) a brief résumé of the work the applicant wishes to present at the congress, and 
2) a brief letter of what the applicant hopes to gain by attending the relevant congress. 
The applicant should submit an abstract for presentation at the relevant national or international meeting.  Should such an
abstract not be accepted by the relevant congress organising committee, the applicant will forfeit his or her sponsorship
towards the congress. (Application can however be made well in advance of the relevant congress but will only be awarded
on acceptance of the abstract).  A written report on the relevant congress attended will need to be submitted by the success-
ful applicant within six weeks of attending the congress. The congress report will be published in the South African Heart
Association Newsletter.
Applications should be sent to Prof Johan Brink, President of the Cape Western branch of the South African Heart
Association, Chris Barnard Division of Cardiothoracic Surgery, Cape Heart Centre, Faculty of Health Sciences, University of
Cape Town, Anzio Road, Observatory, 7925 or alternatively e-mail: johan.brink@uct.ac.za. 
Applications for the first round of awards close on 15 December 2006.
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CHAPTER FIVE: ACUTE CORONARY SYNDROMES IN TREATMENT-
NAÏVE BLACK SOUTH AFRICAN PATIENTS WITH HUMAN 
IMMUNODEFICIENCY VIRUS INFECTION 
Journal of Interventional Cardiology 2010; 23:70-77 
 
Summary: This publication presents data on the clinical and angiographic features of 
treatment-naïve HIV positive black South Africans presenting with acute coronary 
syndromes compared to HIV negative patients in the large urban population of Soweto, 
where rates of coronary artery disease have traditionally been low. This comprises the 
first published data on acute coronary syndromes in treatment-naïve HIV patients.  
 
Statement of originality document: Please see Appendix. 
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Acute Coronary Syndromes in Treatment-Naı¨ve Black South Africans
with Human Immunodeficiency Virus Infection
A.C. BECKER, M.B.B.CH., F.C.P.,1 K. SLIWA, M.D., PH.D., F.E.S.C.,1
S. STEWART, PH.D., F.C.S.A.N.Z., N.F.E.S.C., F.A.H.A.,1,2 E. LIBHABER, PH.D.,1
A.R. ESSOP, M.B.B.CH., M.R.C.P., M.SC., F.C.P., F.A.C.C.,1 C.A. ZAMBAKIDES, M.B.B.CH., M.M.ED.,1
and M.R. ESSOP, M.B.B.CH., M.R.C.P., F.C.P., F.A.C.C., F.R.C.P.1
From the 1Division of Cardiology, Chris Hani Baragwanath Hospital and University of the Witwatersrand, Johannesburg, South Africa; and
2Preventative Cardiology, Baker IDI Heart and Diabetes Research Institute, Melbourne, Australia
Background: HIV patients on protease inhibitors have greater risk of acute coronary syndromes (ACS) but little
is known about treatment-naı¨ve patients.
Methods and Results: Authors conducted a prospective single-center study from Soweto, South Africa, comparing
the clinical and angiographic features of treatment-naı¨ve HIV positive and negative patients with ACS. Between
March 2004 and February 2008, 30 consecutive treatment-naı¨ve HIV patients with ACS were compared to the next
HIV-negative patient as a 1:1 control. HIV patients were younger (43 ± 7 vs. 54 ± 13, P = 0.004) and, besides
smoking (73% vs. 33%, P = 0.002), had fewer risk factors than the control group with less hypertension (23% vs.
77%, P = 0.0001), diabetes (3% vs. 23% , P = 0.05), LDL hyperlipidemia (2.2 ± 0.9 vs. 3.0 ± 1.2, P = 0.006), and
other coronary risk factors (7% vs. 53%, P = 0.0001). HDL was lower in the HIV group (0.8 ± 0.3 vs. 1.1 ± 0.4,
P = 0.001). Atherosclerotic burden was lower in the HIV group with more normal infarct-related arteries (47%
vs. 13%, P = 0.005) but a higher degree of large thrombus burden (43% vs. 17%, P = 0.02). Stents were used to a
similar degree in HIV and control patients (30% vs. 37%, P = 0.78) with more target lesion revascularization in
the HIV group (56% vs. 0%, P = 0.008).
Conclusion: Treatment-naı¨ve HIV patients with ACS are younger and have fewer traditional risk factors than
HIV-negative patients. HIV patients have less atherosclerotic but higher thrombotic burden which may imply a
prothrombotic state in the pathogenesis of ACS in these patients. (J Interven Cardiol 2010;23:70–77)
Background
South Africa is a country in epidemiologic tran-
sition facing an epidemic of cardiovascular disease.1
The Heart of Soweto Study2 provided a detailed per-
spective on the spectrum of heart disease arising from
the large urban community of Soweto, South Africa,
ranging from the so-called traditional forms of infec-
Address for reprints: Dr. Anthony Becker, M.B.B.Ch., F.C.P.,
Division of Cardiology, Chris Hani Baragwanath Hospital, P.O.
Bertsham, Johannesburg 2013, South Africa. Fax: +2711 938 8945;
e-mail: abecker@worldonline.co.za
Funding Sources: HE Griffin CharitableTrust. SS is funded by the
National Health & Medical Research Council of Australia.
tious diseases to newer non-communicable diseases,
with a high prevalence of modifiable risk factors of-
ten reported in high income countries.3,4 Rates of is-
chemic heart disease in the predominantly black pop-
ulation of Soweto, which have traditionally been low,
are on the increase,5 and this “double burden” of dis-
ease is particularly concerning considering the current
human immune deficiency virus (HIV) pandemic with
an estimated 5.5 million South Africans infected and
five hundred thousand HIV-related deaths annually.6
While cardiac complications of HIV infection are well
described,7 controversy still exists as to whether HIV
seropositive subjects have a higher incidence of acute
coronary syndromes (ACS). Autopsy studies in HIV-
positive patients have shown unexpectedly high rates
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of atherosclerotic coronary artery disease (CAD) com-
pared to aged-matched HIV-negative patients.8
The phenomenon of HIV-related premature CAD
and ACS can be directly attributed to the virus-
and/or treatment-related factors. Theoretically, HIV
infection itself may independently predispose to
premature atherosclerosis through endothelial dys-
function,9 a heightened proinflammatory state10,11 and
dyslipidemia characterized by reductions in high den-
sity lipoprotein (HDL) cholesterol and elevations in
triglycerides.12,13 HIV patients are also prone to var-
ious abnormalities of the coagulation and fibrinolytic
systems resulting in a prothrombotic state.14–16 Alter-
natively, protease inhibitors (PIs) as part of highly ac-
tive antiretroviral therapy (HAART) have the potential
to induce an adverse metabolic phenotype including
dyslipidemia and insulin resistance, endothelial dys-
function, and a prothrombotic state.7,15,17 Following an
earlier report suggesting a strong link between HAART
and premature CAD,18 the subsequent evidence has
been conflicting.7 It seems, however, that the risk of
ACS is increased by prolonged exposure to PIs.19 The
historical lack of data for HAART-naı¨ve patients pre-
senting with concurrent HIV and CAD has, therefore,
hindered attempts to understand the fundamental role
of HIV status (and by its very absence HAART) in the
development of premature CAD.
Study Aims
It is within this context that we have taken the unique
opportunity to study a HAART-naı¨ve population in
Soweto at historically low risk for CAD to determine
whether their risk factors, clinical presentation, and
coronary angiographic features differ from the paral-
lel HIV-negative population. We hypothesized that the
risk profile and clinical characteristics of HIV-positive
patients presenting with ACS would markedly differ
from their HIV-negative counterparts, particularly in
respect to the underlying morphology of coronary le-
sion(s) and thrombus formation.
Methods
Study Design and Patient Enrollment. We con-
ducted a prospective single center study at Chris Hani
Baragwanth Hospital, Soweto. The protocol was ap-
proved by the ethics committee of the University of
the Witwatersrand and adheres to the Declaration of
Helsinki. All patients gave informed consent before
study entry. Between March 2004 and February 2008,
all presenting patients with ACS were screened for
HIV and 30 consecutive HIV-positive patients were
enrolled. For each HIV patient with ACS we se-
lected the first presenting non-HIV patient with ACS
as a case-control comparator. Consistent with current
guidelines,20,21 ACS was defined as either ST eleva-
tion myocardial infarction (STEMI), non-ST elevation
myocardial infarction (NSTEMI), or unstable angina
(UA). Myocardial infarction (MI) was diagnosed in
patients with compatible symptoms with elevated tro-
ponin T measurements. Patients with persistent ST el-
evation >0.1 mV in two contiguous leads were cate-
gorized as having STEMI and those without this cri-
terion as having NSTEMI. Unstable angina was diag-
nosed in patients hospitalized with worsening angina or
new-onset angina at rest without troponin T elevations.
HIV was diagnosed with the standard enzyme-linked
immunosorbent assay and Western blot techniques af-
ter obtaining consent and offering pretest counseling.
Plasma HIV RNA level was determined by quantitative
polymerase chain reaction. CD4 count was determined
by flow cytometry. Conventional risk factors for arte-
rial thrombosis were documented including a history of
opportunistic infections and/or HIV-related malignan-
cies and CDC disease stage22 in the HIV group. The
CDC HIV staging classification uses two parameters:
Clinical category [A. Asymptomatic HIV infection; B.
Non-AIDS defining symptomatic conditions; C. AIDS
defining conditions] and CD4 count (cells/mL3) [1.
≥500; 2. 200–499; 3. <200]. Patients were catego-
rized as having diabetes, hypertension, or dyslipidemia
when being treated chronically for these conditions or
when diagnosed with the condition on admission. Pa-
tients were classified as having “other” coronary risk
factors if any of the following conditions were present:
(i) Family history of premature CAD (men <55 years,
women <65 years), (ii) chronic kidney disease (CKD),
(iii) postmenopausal state, and (iv) abdominal obesity
(abdominal circumference > 102 cm in men and 88
cm in women). “Multiple” risk factors was defined as
≥2 of: hypertension, diabetes mellitus, hyperlipidemia,
smoking, or family history. The TIMI (thrombolysis
in myocardial infarction) risk score for STEMI23 and
NSTEMI / UA24 were calculated in all patients. An-
thropometric measurements including body mass in-
dex (BMI), waist-to-hip ratio, and abdominal circum-
ference were measured according to guidelines from
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the InterHeart study.25 Patients were managed accord-
ing to standard ACS guidelines.20,21 The results of all
diagnostic angiograms and percutaneous coronary in-
terventions (PCI) were assessed by two independent
interventional cardiologists (AE and CZ) blinded to
the patients’ HIV status. Angiographic follow-up was
planned for all patients receiving a coronary stent at
a minimum of 6 months postprocedure. Single vessel
disease was defined as a single major epicardial coro-
nary artery with a stenosis ≥50% and multivessel dis-
ease ≥2 major epicardial arteries with stenoses ≥50%.
The infarct-related artery (IRA) was defined by re-
viewing each patient’s angiogram, electrocardiogram,
and/or echocardiogram. An artery was considered to
be infarct related if an obvious thrombus or ruptured
plaque was present, or if two of the aforementioned di-
agnostic tests implicated the same coronary territory.
The IRA was defined as angiographically normal if
the contour was smooth with no angiographic features
of atherosclerotic disease in any of the coronary arter-
ies. IRA thrombus burden, when present, was classified
angiographically as small or large according to a previ-
ously published descriptive model.26 Initial TIMI flow
grade in the IRA was defined as previously reported.27
Successful PCI was defined as achievement of nor-
mal (TIMI 3) coronary flow with a residual stenosis
of ≤ 50% and no periprocedural complications. Stent
thrombosis was defined according to the Academic
Research Consortium criteria.28 Binary angiographic
in-stent restenosis was defined as a >50% diameter
stenosis at follow-up. In-stent restenosis was further
defined as focal or diffuse according to a previously
proposed classification.29 Target lesion revasculariza-
tion (TLR) was defined as any repeat revascularization
of the IRA involving the stent and/or its 5 mm proximal
or distal edges. Major adverse cardiovascular events
(MACE) was defined as death, non-fatal myocardial
infarction, or TLR. All patients were followed up at
the Chris Hani Baragwanath cardiac clinic.
Statistical Analysis. Statistical analysis was per-
formed using SAS version 9.1 software (SAS, Cary,
NC, USA). Normally distributed continuous data are
presented as the mean (± standard deviation), and vari-
ables with non-Gaussian distribution as the median
(min-max range). Categorical data are presented as
frequencies and percentages. Differences between the
groups were assessed using a Student’s t-test for con-
tinuous variables with normal distribution and in the
case of non-normal distribution, a Mann-Whitney or
Wilcoxon test. For categorical variables, a chi-squared
test was performed and a Fisher exact test when nec-
essary. Changes in TIMI flow rates pre- and post-PCI
between HIV-positive and -negative groups were cal-
culated using the Wilcoxon’s rank sum test. Signifi-
cance was assumed at a 2-tailed value of P < 0.05.
Univariate logistic regression was performed to deter-
mine predictors of the variables: normal IRA, large
thrombus burden and death and data presented as odds
ratios (OR) with 95% confidence intervals (CI). Multi-
variate logistic regression was then performed but due
to the small sample size we were unable to include
all potential explanatory variables, which were signif-
icantly different between the groups (age, smoking,
hypertension, total cholesterol, LDL cholesterol, HDL
cholesterol, and “other risk factors”) and so performed
a limited analysis using age and smoking.
Results
Between March 2004 and February 2008, we stud-
ied 60 patients presenting with an ACS comprising 30
consecutive patients diagnosed as HIV-positive and 30
HIV-negative patients (1:1 control group) who repre-
sented the next clinical presentation of ACS. Overall,
these 60 study patients represented 9% of the total
caseload of 673 patients presenting with an ACS dur-
ing this period.2 There were no refusals to enter the
study in either group.
HIV Profile. In the HIV-positive group, the me-
dian (range) CD4 count was 231 (30–1,356) cells/mm3
with a median (range) viral load of 29,000 (25–
700,000) RNA copies/mL. All of the HIV patients
were HAART naı¨ve. There were no HIV-related op-
portunistic infections or malignancies and the majority
of patients, 18 of 30 (60%), had early disease being
classified as either CDC stage A1 or A2 with one (3%)
patient classified as stage B1. The criteria for AIDS22
were met in 11 of 30 (37%) patients in the HIV group
based on a CD4 count <200 cells/mL3.
Clinical and Demographic Features According
to HIV Status. The clinical characteristics of the
two groups according to HIV status are summarized in
Table 1. None of the patients had suffered a previous
MI or received prior coronary revascularization. Al-
though the gender distribution was similar with a male
predominance in both groups, HIV patients were sig-
nificantly younger. The odds of an HIV-positive patient
having a history of cigarette smoking (OR 5.5, 95%
CI 1.81–16.68, P = 0.002) was significantly higher
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Table 1. Clinical Features of HIV Patients and Controls with ACS
HIV+ve (n = 30) HIV–ve (n = 30) P Value
Demographic Profile
Black African n (%) 30 (100%) 30 (100%) 1.0
Mean age (years) 43 ± 7 54 ± 13 0.0004
Men (%) 20 (67%) 18 (60%) 0.79
Coronary Risk Factors n (%)
Smoking (%) 22 (73%) 10 (33%) 0.002
Diabetes mellitus (%) 1 (3%) 7 (23%) 0.05
Hypertension (%) 7 (23%) 23 (77%) 0.0001
Total cholesterol (mmol/L) 3.6 ± 1.0 4.6 ± 1.4 0.006
LDL cholesterol (mmol/L) 2.2 ± 0.9 3.0 ± 1.2 0.006
HDL cholesterol (mmol/L) 0.8 ± 0.3 1.1 ± 0.4 0.001
Triglycerides (mmol/L) 1.4 ± 0.8 1.1 ± 0.4 0.35
Multiple risk factors 8 (27) 18 (60) 0.0182
Other coronary risk factors 2 (7%) 16 (53%) 0.0001
Clinical Features
Systolic/ diastolic blood pressure (mmHg) 132 ± 31/ 86 ± 22 145 ± 37/ 89 ± 18 0.18 / 0.32
Pulse rate (beats/min) 91 ± 22 91 ± 29 0.9
Body mass index (kg/m2) 25 ± 5 28 ± 5 0.01
Waist to hip ratio 0.91 ± 0.06 0.95 ± 0.05 0.03
Abdominal circumference (cm) 85 ± 10 100 ± 15 0.0003
Data are presented as the mean ± standard deviation or proportions.
than control patients. Alternatively, HIV-positive pa-
tients were less likely to have a history of other tra-
ditional risk factors for ACS including hypertension
(OR 0.009, 95% CI 0.03–0.31, P = 0.0001), diabetes
mellitus (OR 0.11, 95% CI 0.01–0.99, P = 0.05), ele-
vated LDL cholesterol (2.2 ± 0.9 mmol/L vs. 3.0 ± 1.2
mmol/L, P = 0.006) and other risk factors (OR 0.06,
95% CI 0.01–0.31, P = 0.0001). HDL cholesterol was
significantly lower in the HIV-positive group (0.8 ±
0.3 vs. 1.1 ± 0.4, P = 0.001). Overall 8/30 (27%) and
18/30 (60%) of HIV-positive and control patients had
multiple risk factors (OR 0.24, 95% CI 0.08–0.72, P =
0.018). None of the HIV patients had a history of drug
abuse but one patient in the HIV-negative group admit-
ted to using cocaine. The HIV group had lower BMIs
and AC measurements. The ratio of STEMI (77% vs.
60%, P = 0.27) to NSTEMI / UA (23% vs. 37%,
P = 0.40) in the HIV group vs. the control group
was similar as were the TIMI risk scores (STEMI:
3.7 ± 2.3 vs. 4.1 ± 1.9, P = 0.24; NSTEMI: 2.0 ±
0.8 vs. 2.8 ± 0.8, P = 0.06). In terms of in-hospital
medication, all patients received a 300-mg loading
dose of aspirin followed by 150 mg daily thereafter
and a weight-adjusted antithrombotic (unfractionated
heparin or low molecular weight heparin). Twenty
(67%) HIV patients received clopidogrel on admission
(300 mg loading dose and 75 mg daily) compared to 13
(43%) controls (P = 0.10). Thrombolytic therapy was
utilized as an initial strategy in 9 (30%) HIV patients
compared to 5 (17%) controls. Glycoprotein 2b3a in-
hibitors were used during PCI in 4 (13%) HIV patients
and 7 (23%) controls (P = 0.33). Beta-blockers and
statins were used in 25 (83%) patients in each group
with angiotensin converting enzyme—inhibitors being
utilized in 19 (63%) and 22 (73%) of HIV and control
patients, respectively (P = 0.36).
Initial Angiographic Features. Coronary an-
giography was performed in all patients (Table 2).
There was a trend toward a lower number of affected
coronary vessels in the HIV group (1.3 ± 0.6 vs. 1.6
± 0.8, P = 0.08) and toward the LAD being the most
commonly involved IRA (73% vs. 50%, P = 0.06). An
angiographically normal IRA was significantly more
common in the HIV group and associated with throm-
bus in 8 of 30 (27%) compared to 2 of 30 (7%) controls
(P = 0.04) (Figs. 1 and 2). TIMI 0 flow in the IRA (i.e.,
totally occluded) at presentation was found more com-
monly in the HIV-negative group (60% vs. 23%: OR
0.20, 95% CI 0.07–0.62, P = 0.004). Large throm-
bus burden in the IRA was seen more frequently in
HIV patients (43% vs. 17%, P = 0.02). In addition,
3/30 (10%) patients in the HIV group had thrombus
in a coronary artery other than the IRA compared to
0/30 (0%) control patients (P = 0.24). On univariate
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Table 2. Angiographic Features of HIV Patients and Controls with
ACS
HIV+ve HIV–ve P
(n = 30) (n = 30) Value
Diagnostic angiogram n (%) 30 (100) 30 (100) 1.0
Single vessel disease 24 (80) 18 (60) 0.08
Mean no. of affected vessels 1.3 ± 0.6 1.6 ± 0.8 0.08
Angiographically normal IRA 14 (47) 4 (13) 0.005
Thrombus in multiple arteries 3 (10) 0 (0) 0.24
Large thrombus burden 13 (43) 5 (17) 0.02
Treatment n (%)
PCI (PTCA or stent) 18 (60) 18 (60) 1.0
PTCA alone 9 (30) 7 (23) 0.54
Stent (bare metal) 9 (30) 11 (37) 0.78
Medical therapy only 12 (40) 11 (37) 0.60
CABG 0 (0) 2 (7)∗ 0.49
Data are presented as the mean ± standard deviation or proportions.
IRA = infarct related artery; PCI = percutaneous coronary inter-
vention; PTCA = percutaneous transluminal coronary angioplasty;
CABG = coronary artery bypass surgery.
∗One control patient had CABG following PCI.
logistic regression, HIV infection predicted large
thrombus burden (OR 3.82, CI 1.12–12.7, P = 0.029)
and a normal IRA (OR 5.7, CI 1.6–20.3, P = 0.008). On
multivariate logistic regression, adjusting for age and
smoking, HIV infection was predictive of large throm-
bus burden (OR 5.7 [95% CI 1.1–28.2], P = 0.034)
but not “normal IRA” (OR 3.7 [95% CI 0.8–16.5],
P = 0.09). The only predictor of a “normal IRA” was
age (OR 0.9 [95% CI 0.9–1.0], P = 0.017).
Figure 1. Angiographic image of thrombus in an otherwise an-
giographically normal left anterior descending coronary artery in a
43-year-old HIV-positive male presenting with an ST-elevation MI.
Figure 2. Intravascular ultrasound image of thrombus in an oth-
erwise angiographically normal left anterior descending coronary
artery depicted in Figure 1.
Coronary Intervention. PCI was the most fre-
quently utilized treatment strategy in both groups with
a similar usage of bare metal stents (BMS) and acute
procedural success rates of 9 of 9 (100%) in the HIV
group and 8 of 11 (73%) in the control group (P = 0.36).
Angioplasty alone was performed in 9 of 30 (30%)
HIV patients and 7 of 30 (23%) controls (P = 0.54).
Pre-PCI TIMI flow scores were different between the
two groups with a higher percentage of control patients
having TIMI 0 flow pre-PCI (15/18 [83%] controls vs.
4/18 [22%] HIV, P = 0.0007). There was no difference
in post-PCI TIMI flow scores or the change between
pre- and post-PCI TIMI flow scores. PCI complica-
tions occurred in 7of 30 (23%) patients in both groups.
There was one serious complication (definite sub-acute
stent thrombosis) occurring in an HIV patient (1 of 9
[11%]), 4 days after receiving a BMS resulting in a
non-fatal MI. Medical treatment alone was used in a
similar number of HIV and control patients (12 of 30
[40%] vs. 11 of 30 [37%], P = 0.60) and 2 of 30
(7%) HIV-negative patients underwent surgical revas-
cularization compared to none in the HIV group (P =
0.49).
Angiographic Follow-Up. Follow-up angiogra-
phy was performed in 11 of 20 (55%) patients who
received BMS at a mean duration of 9 months post-
implantation: 5 of 9 (56%) in the HIV group compared
to 6 of 11 (55%) in the control group (P = 0.38).
Overall, 9 of 20 (45%) patients were unable to be
studied owing to 2 deaths and 2 patients lost to follow-
up in the HIV group and 3 deaths and 2 patients lost
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Table 3. Long-Term Outcomes of HIV Patients and Controls with ACS
HIV+ve (n = 30) HIV–ve (n = 30) P Value
Patients n (%) 30 (100) 30 (100) 1.0
Clinical Outcomes at 48 Months
MACE 14 (47)∗ 5 (17) 0.026
Death 9 (30) 5 (17) 0.36
Non-fatal MI 1 (3) 0 (0) 1.0
TLR 5 (17) 0 (0) 0.05
Angiographic Follow-Up
Patients originally receiving BMS 9 (30) 11 (37) 0.78
Patients eligible for follow-up angiography 5/9 (56) 6/11 (55) 0.38
Mean duration of follow-up angiogram (months) 7 ± 5 11 ± 3 0.14
Binary in-stent restenosis 5/5 (100) 3/6 (50) 0.18
Focal 0/5 (0) 1/3 (33) 0.75
Diffuse 5/5 (100) 2/3 (67)
}
Composite TLR† 5/9 (56) 0/11 (0) 0.008
Data are presented as proportions or mean ± standard deviation.
MACE = major adverse cardiovascular events; MI = myocardial infarction; TLR = target lesion revascularization.
∗One HIV patient had a non-fatal MI requiring TLR.
† TLR in patients receiving a bare metal stent.
to follow-up in the control group. Binary angiographic
restenosis in patients who received a BMS with an-
giographic follow-up occurred in 5 of 5 (100%) HIV
patients and 3 of 6 (50%) controls (P = 0.18).
In the HIV group, binary angiographic restenosis of
a diffuse proliferative pattern (type 3)29 was found in
all 5 (100%) patients studied. In the control group, 2
of 6 patients (33%) had a diffuse proliferative pattern
(type 4) and 1 of 6 (17%) had focal body resteno-
sis (type 1C). Ischemia-driven TLR was performed in
all 5 HIV patients with diffuse proliferative resteno-
sis with an angioplasty in 1 of 5 (20%) patients and
drug-eluting stents (DES) in 4 of 5 (80%) patients with
good procedural success. No TLR was performed in
the control group due to lack of objective evidence of
reversible ischemia on nuclear perfusion imaging. The
composite TLR rate for HIV patients and controls who
received a BMS was 5 of 9 (56%) vs. 0 of 11 (0%),
respectively (P = 0.008).
Clinical Outcomes. Follow-up data were avail-
able from the time of admission to last follow-up at
48 months (Table 3). MACE rates were higher in the
HIV group (47% vs. 17%, P = 0.026), driven by in-
creased rates of TLR. Nine of 30 (30%) HIV patients
died compared to 5 of 30 (17%) controls (P = 0.36).
Overall 3 of 9 (33%) fatal events in the HIV group
occurred at the index admission (two from cardiogenic
shock and one from a cardio-embolic stroke). A further
6 patients died after the index event (67% of deaths):
1 from a massive pulmonary embolus and 5 from un-
known causes. In the control group, 1 of 5 fatal events
(20%) occurred during the index admission due to car-
diogenic shock. The remaining deaths (80%) included
a fatal stroke, one recurrent MI, a suicide, and one of
unknown cause.
Discussion
Taking advantage of historically low treatment rates
for HIV in South Africa, we were able to document
clinical presentations of ACS from the predominantly
black African community of Soweto on the basis of
HIV status without the potentially confounding ef-
fects of underlying HAART. As such, in one of the
largest reported series of HAART-naı¨ve HIV-positive
patients presenting with ACS, we found that the major-
ity of HIV patients did not have advanced HIV disease
and were all asymptomatic prior to presentation: only
11/30 (37%) were eligible for HAART therapy accord-
ing to our current guidelines making this an important
group for primary prevention. Classical risk factors for
ACS were more prevalent in the control group with
an older population and more hypertension, diabetes,
hyperlipidemia, abdominal obesity, and other risk fac-
tors. Cigarette smoking was, however, more prevalent
in the HIV group and consistent with other studies.30
HIV patients also had significantly lower HDL levels,
an independent risk factor for CAD, thrombosis, and
ACS.31
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How do we interpret these results relative to previous
reports? Consistent with other studies from the devel-
oped world,30 our HIV group was younger in age and
predominantly male with a high proportion of cigarette
smokers and low HDL which is due, in part, to an
impaired reverse cholesterol transport pathway medi-
ated by the HIV regulatory protein nef.32 In contrast
to findings in the developed world, none of our HIV
patients were intravenous drug abusers and none had
opportunistic infections or HIV-related malignancies,
factors known to confer a higher thrombotic risk.16 De-
gree of immunosuppression did not correlate with risk
of ACS. HIV patients had less atherosclerotic burden
angiographically with significantly more angiographi-
cally normal IRAs probably reflecting the younger age
of the group with less classical risk factors despite the
potentially detrimental effects of a heightened inflam-
matory state. The significantly higher degree of large
thrombus burden in the IRA of HIV patients suggests a
prothrombotic state which is well described and prob-
ably multifactorial14–16 in nature.
What are the potential mechanisms underlying our
findings? A study by Davies and colleagues33 regarding
the causes of MI in young patients without atheroscle-
rosis emphasized the importance of excluding the an-
tiphospholipid syndrome as a potential cause of throm-
bosis in patients with angiographically normal IRAs.
HIV patients are known to have a high incidence of
antiphospholipid antibodies ranging from 46% to 90%
in various studies14,16,34 but the relationship to throm-
botic risk is unclear and further studies are needed.
PCI was the preferred method of revascularization in
both groups with good procedural success rates but a
high incidence of diffuse proliferative in-stent resteno-
sis was found in HIV patients receiving BMS, in keep-
ing with other studies,30,35 the pathogenesis of which is
thought to be due to the heightened inflammatory state
at the time of PCI.36 DES are currently the preferred
treatment for in-stent restenosis requiring revascular-
ization37 but no data exist on their efficacy or safety
in the setting of HIV infection. In this study, four HIV
patients with diffuse proliferative in-stent restenosis re-
ceived DES with good procedural success and no need
for TLR during follow-up.
This study has a number of limitations that require
comment. Although this represents a historically large
cohort of HAART-naı¨ve HIV patients presenting with
ACS, the study cohort overall was small and thus un-
derpowered to detect small differences between the
groups. Although HIV status predicted a normal IRA
and large thrombus burden on univariate logistic re-
gression, the sample size was too small to allow for
multivariate logistic regression using all baseline ex-
planatory variables and thus one cannot conclude that
HIV alone was responsible for these findings. Age-
specific MI rates in black patients from Soweto are not
known and we were thus unable to determine whether
the incidence of ACS is higher in HAART-naı¨ve HIV
patients compared to age-matched HIV-negative pa-
tients. Not all patients receiving BMS underwent re-
peat angiography affecting the reliability of the data
regarding in-stent restenosis but wherever possible we
have adhered to the recently published STROBE guide-
lines in our reporting of study data.38 The potential role
of a hypercoagulable state including antiphospholipid
antibodies in the pathogenesis of ACS in this HAART-
naı¨ve HIV group is currently being investigated.
In summary, in one of the largest studies of its type,
we found that HAART-naı¨ve, HIV-positive black South
Africans presenting with ACS have different clini-
cal and angiographic features compared to the HIV-
negative population. Similar to reports on HIV pa-
tients receiving HAART,7 our patients are younger,
more commonly male with higher rates of smoking,
low HDL and less atherosclerotic burden but a higher
thrombotic burden suggesting a prothrombotic state
which needs further investigation. The exact patho-
genetic role of HIV, independent of associated risk
factors, in ACS and its treatment remains unclear but
may be important as a contributory factor in an al-
ready “vulnerable patient” and needs further elucida-
tion with larger prospective studies. Importantly, we
identified modifiable cardiovascular risk factors in the
HIV group. Smoking may play a crucial role in the
pathogenesis of ACS in these otherwise seemingly
low-risk patients and remains an important target for
cardiovascular risk reduction. The role of HDL in the
pathogenesis and prevention of HIV-associated CAD
needs to be further defined as does the role of DES
in the prevention of restenosis. Cardiovascular risk as-
sessment and appropriate primary prevention should
be an important component in the management of HIV
patients both pre- and post-treatment.
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Summary: This publication attempts to answer some important questions raised in 
Chapter 5 regarding the pathogenesis of acute coronary syndromes in treatment-naïve 
black South Africans by looking, in a detailed fashion, at thrombotic parameters and their 
role in inducing a prothrombotic state. 
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The Thrombotic Profile of Treatment-Naive
HIV-Positive Black South Africans With
Acute Coronary Syndromes
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Abstract
Background: Patients with human immunodeficiency virus (HIV) infection on protease inhibitors (PIs) have a heightened risk of
arterial thrombosis but little is known about treatment-naive patients. Methods/Results: Prospective study from South Africa
comparing thrombotic profiles of HIV-positive and -negative patients with acute coronary syndrome (ACS). A total of 30
treatment-naive HIV-positive patients with ACS were compared to 30 HIV-negative patients with ACS. Patients with HIV were
younger; and besides smoking (73% vs 33%) and low high-density lipoprotein (HDL; 0.8+ 0.3 vs 1.1+ 0.4), they had fewer risk
factors. Thrombophilia was more common in HIV-positive patients with lower protein C (PC; 82+ 22 vs 108+ 20) and higher
factor VIII levels (201+ 87 vs 136+ 45). Patients with HIV had higher frequencies of anticardiolipin (aCL; 47% vs 10%) and
antiprothrombin antibodies (87% vs 21%). Conclusion: Treatment-naive HIV-positive patients with ACS are younger, with
fewer traditional risk factors but a greater degree of thrombophilia compared with HIV-negative patients.
Keywords
acute coronary syndromes, blood coagulation factors, clinical thrombophilia, hypercoagulability, thrombophilia, thrombosis
Background
Hematologic abnormalities among individuals infected with
the human immunodeficiency virus (HIV) are well described,
and although the cytopenias are the most common, there is evi-
dence that HIV induces a hypercoagulable state resulting in
thromboembolic complications.1 Rates of venous thromboem-
bolic (VTE) complications are increased in HIV-positive
patients receiving highly active antiretroviral therapy
(HAART), with an incidence ranging from 0.26% to 7.6%.2
Increased rates of arterial thrombosis have also been described,
but the mechanism of this association remains unclear in the
face of other associated cardiovascular risk factors such as
smoking and dyslipidemia commonly found in HIV-positive
patients.3 The mechanisms responsible for this hypercoagul-
able state are thought to be multifactorial in nature (Table 1).
Thrombotic complications may arise as a direct result of the
virus or indirectly through associated opportunistic infections,
malignancies, or the effects of HAART,1 and the thrombotic
potential seems to correlate with the degree of immuno-
suppression as measured by CD4 cell count as well as with the
presence of opportunistic manifestations of acquired immuno-
deficiency syndrome (AIDS).1 Human immunodeficiency
virus causes endothelial cell and platelet activation, with ele-
vated concentrations of cellular adhesion molecules (CAMs)17
as well as von Willebrand factor (VWF),8,11 all of which
predict future cardiovascular events.18,19 Abnormalities of
coagulation factors include deficiencies of protein C (PC),8
protein S (PS),9,20 antithrombin (AT),10 and heparin cofactor
2 (HC-II).10 Antiphospholipid antibodies (aPL) and lupus
anticoagulants (LAs) are highly prevalent in HIV-positive
patients but their role in thrombosis is unclear.14 Protease inhi-
bitors (PIs) as part of HAART have been associated with VTE
disease15,21 and may lead to hypercholesterolemia, hypertrigly-
ceridemia, and insulin resistance and have been associated with
increased rates of coronary events.22 Whether treatment-naive
HIV-infected patients are also at higher risk of thrombosis
is largely unknown. We have shown that treatment-naive
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HIV-positive black South African patients presenting with
acute coronary syndromes (ACSs) are younger with fewer
traditional risk factors compared to HIV-negative patients and
have less atherosclerotic but higher thrombotic burden on
angiography, suggesting a hypercoagulable state.23
Study Aims
It is within this context that we report on the thrombotic pro-
files of this group of treatment-naive black South African
patients with ACS compared to the parallel HIV-negative pop-
ulation. We hypothesized that the HIV-positive patients would
have evidence of thrombophilia on laboratory testing.
Methods
Study Design and Patient Enrollment
We conducted a prospective single-center study in the Depart-
ment of Cardiology at Chris Hani Baragwanth Hospital,
Soweto, South Africa. The protocol was approved by the
ethics committee of the University of the Witwatersrand and
adheres to the Declaration of Helsinki. All patients gave
informed consent before study entry. Between March 2004
and February 2008, 30 consecutive black HIV-positive
patients presenting with ACS (ACSþ:HIVþ group) were
enrolled. For each HIV-positive patient with ACS, we
selected the first presenting non-HIV black patient with ACS
as a case–control comparator (ACSþ:HIV group). In
addition, a second control group consisting of 30 asympto-
matic HIV-positive patients matched for age, sex, and ethni-
city (ACS:HIVþ group) were recruited from the HIV
clinic. Consistent with current guidelines,24,25 ACS was
defined as ST-elevation myocardial infarction (MI), non-
ST–elevation MI, or unstable angina. Infection with HIV was
diagnosed with the standard enzyme-linked immunosorbent
assay (ELISA) and Western blot techniques, after obtaining
consent and offering pretest counseling. In the HIV group, the
plasma HIV RNA level was determined by quantitative poly-
merase chain reaction. CD4 count was determined by flow
cytometry, and patients were staged according to the Centers
for Disease Control and Prevention (CDC) staging system.26
Patients were categorized as having diabetes, hypertension,
or dyslipidemia when being treated chronically for these con-
ditions or when diagnosed with the condition on admission.
Patients were classified as having ‘‘other’’ coronary risk fac-
tors if any of the following conditions were present: (1) family
history of premature coronary artery disease (CAD; men <55
years, women <65 years), (2) chronic kidney disease, (3)
postmenopausal state, and (4) abdominal obesity (abdominal
circumference >102 cm in men and 88 cm in women). Demo-
graphic data were recorded for each patient and anthropo-
metric measurements including weight, height, body mass
index (BMI), waist-to-hip ratio, and abdominal circumference
(AC) were measured on admission, according to guidelines
set out in the Interheart study.27 Patients with ACS were
managed according to the accepted guidelines set out by the
European Heart Association24,25 and followed up at the Chris
Hani Baragwanath cardiac clinic.
Table 1. HIV and Risk Factors for Thrombosisa
Abnormality
Affected Vascular Beds
Venous Venous and Arterial Arterial
Defects in vessel wall Chronic inflammation4,5 Atherosclerosis6
Vasculitis1 Metabolic syndrome6
Hypertension
Diabetes
Dyslipidemia
Smoking7
Defects in coagulation factors Deficiency of PC8
Deficiency of PS9
Deficiency of AT10
Deficiency of HCII10
" Microparticles11
Defects in fibrinolysis " PAI-112
Platelet defects TTP1 " Platelet activation13
Stasis Immobilization1
CCF1
Other Malignancy1 Antiphospholipid syndrome14
Opportunistic infection1 Protease inhibitors15
Nephrotic syndrome1
AIHA1
NOTES: AIHA¼ autoimmune hemolytic anemia; AT¼ antithrombin; CCF¼ congestive cardiac failure; HCII¼ heparin cofactor II; PAI-1¼ plasminogen activator
inhibitor-1; PC ¼ protein C, PS ¼ protein S; TTP ¼ thrombotic thrombocytopenic purpura; " ¼ increase.
a Adapted from N Engl J Med. 2002;346(10):752-763.16
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Thrombophilic Screening
As part of the thrombophilic workup, all patients had aPL assays
at baseline and further thrombophilic testing at 6 weeks poste-
vent (ACS group), assessing coagulation factors, endothelial
activation markers, and platelet function. The ACS:HIVþ
group had all tests performed at baseline, as this group had not
suffered any thrombotic event. Blood was obtained by clean
venipuncture with seated participants, and nonfasting venous
blood was drawn into plastic tubes containing sodium citrate for
the coagulation studies, EDTA for the full blood count and pla-
telet analysis, and plain tubes for analysis of aPL. The samples
were transported to the National Health Services Laboratory
(NHLS), Johannesburg Hospital, at ambient temperature. All
assays were performed according to the standard operating pro-
cedures of the NHLS laboratory. The analysis of aPL was per-
formed at Lancet Laboratories, Johannesburg.
Laboratory Methods
Coagulation studies including international normalized ratio
(INR), activated partial thromboplastin time (aPTT), PC (chro-
mogenic assay, normal value 70-160 IU/dL), PS (functional
assay, normal value 60-140 IU/dL), AT (chromogenic assay,
normal value 76-125 IU/dL), fibrinogen (Clauss method, nor-
mal value 2-4 g/L),28 factor VIII (normal value 50-150 IU/
dL), and activated PC (APCR) resistance (normal value >2)
were performed on an automated coagulometer (ACL; Instru-
ment Laboratories, Milan, Italy). Lupus anticoagulants were
detected using kaolin clotting time (KCT) with simplified
Dilute Russell’s Viper Venom Test (DRVVT) screening (LAC,
Lupus anticoagulant screen) and confirmation reagent (LAC
confirm; Dade Behring, Milton Keynes, United Kingdom) to
confirm the presence of LAs in patients with prolonged KCT.
Lupus anticoagulants were considered present if the ratio of
LAC screen to LAC confirm was >1.3. Quantitative D-dimer
(normal value <0.5 mg/L) and VWF antigen (VWAG, von
Willebrand factor antigen, normal value 50%-150%) were
measured using a turbidometric Latex immunoassay (Instru-
ment Laboratories). von Willebrand factor activity (VWACT,
von Willebrand factor activity, normal value 50%-150%) was
measured by semiquantitative immunoassay (Dade Behring).
Antiphospholipid antibodies including anticardiolipin (aCL),
anti-b2-glycoprotein-I (anti-b2-GP-1), and antiprothrombin
(aPT; immunoglobulin G [IgG], IgM, and IgA) were measured
at baseline in all patients using commercial ELISA kits (Orgen-
tec Diagnostika, Mainz, Germany).
Results for each of the 3 isotypes of the 3 types of aPL mea-
sured were considered positive when the optical density
obtained for each patient exceeded that of the mean value plus
2 SD of the 100 sera from black South African normal healthy
participants. Platelet aggregometry was performed using an
APACT-2 (Automated platelet aggregation coagulation tra-
cer-2) light transmission aggregometer (LTA; Instrument
Laboratories) using arachidonic acid, adenosine diphosphate
(ADP), collagen, and adrenaline as agonists according to the
standard operating procedures of the NHLS. Where appropri-
ate, platelet sensitivities were performed using decreasing con-
centrations of the appropriate agonist. Full aggregation
responses to <0.5 mmol/L arachidonic acid, <2 mg/mL collagen,
and <1 mg/mL ADP was defined as platelet hyperactivity.
Aspirin resistance was defined as platelet aggregation in the
presence of arachidonic acid of 20%.
Statistical Analysis
Statistical analysis was performed using SAS 9.1 software
(SAS, Cary, North Carolina). Normally distributed continuous
data are presented as the mean (+SD) and variables with
non-Gaussian distribution as the median (min–max range).
Categorical data are presented as frequencies and percentages.
The initial analysis compared variables between the 3 groups
using the 1-way analysis of variance (ANOVA) test for contin-
uous variables with normal distribution and the Kruskal-Wallis
test in case of nonnormal distribution. For categorical
variables, the chi-square test was performed with a Fisher exact
test when necessary. Significant differences between variables
in the 3 groups were assumed at P < .05. Subgroup analysis
with multiple pairwise comparisons was then performed apply-
ing the Bonferroni correction with a P value <.0166 considered
significant.
Results
Acute Coronary Syndrome (ACSþ) Group
The clinical and thrombotic profiles of the ACSþ:HIVþ and
ACSþ:HIV groups are listed in Tables 2 and 3, respectively.
Clinical profile. The HIV-positive patients were younger with
a similar sex distribution. Besides smoking (33% vs 73%, P ¼
.004), coronary risk factors were higher in the ACSþ:HIV
group with more hypertension (P ¼ .0001), low-density lipo-
protein (LDL) hyperlipidemia (P ¼ .003), diabetes mellitus
(P ¼ .03), and ‘‘other coronary risk factors’’ (P ¼ .0001). The
ACSþ:HIVþ group had lower high-density lipoprotein (HDL)
levels (P ¼ .0006) and a lower mean BMI (P ¼ .008).
Thrombotic profile. Thrombotic screens were performed in 21
(70%) of 30 and 24 (80%) of 30 patients in the ACSþ:HIVþ
and ACSþ:HIV groups, respectively. In the ACSþ:HIVþ
group, 9 of 30 (30%) patients were not tested owing to 6 deaths
and 3 patients lost to follow-up. Of 30, 6 (20%) patients in the
ACSþ:HIV group were not tested owing to 4 deaths and 2
patients lost to follow-up. Patients in the ACSþ:HIVþ group
had significantly lower mean PC (P ¼ .0003) levels compared
to the ACSþ:HIV group. Of 19, 4 (21%) patients in the
ACSþ:HIVþ group (2 excluded due to warfarin usage) had
PC deficiency based on levels <70 IU/dL compared to 0
(0%) of 23 in the ACSþ:HIV group (1 patient excluded due
to warfarin usage, P ¼ .06). Factor VIII levels were also found
to be significantly higher in the ACSþ:HIVþ group (P ¼
.001). Of 21, 14 (67%) patients in the ACSþ:HIVþ group
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compared to 8 (33%) of 24 in the ACSþ:HIV group had levels
>150 IU/dL (P ¼ .07). The ACSþ:HIVþ group had higher
frequencies of aCL IgG (47% vs 10%, P ¼ .003) and aPT IgG
(87% vs 20%, P < .001) compared to the HIV-negative group.
There were no differences between groups with respect to the
other aPL frequencies.
Platelet studies. Light transmission aggregometry was per-
formed in 21 (70%) of 30 patients in the ACSþ:HIVþ group
and 24 (80%) of 30 patients in the ACSþ:HIV group. In the
ACSþ:HIVþ group, 16 (76%) of 21 patients were taking
aspirin (150 mg/d) and 2 (10%) of 21 clopidogrel (75 mg/d).
In the ACSþ:HIV group, 22 (92%) of 24 patients were taking
Table 3. Acute Coronary Syndrome Group: Thrombotic Profilea
ACSþ:HIVþ Group ACSþ:HIV Group P Value
Thrombotic screen at baseline, n (%) 30 (100) 30 (100)
Hemoglobin (g/dL) 13.6 + 2.8 14.5 + 1.8 NS
Platelet count (109/L) 301 + 113 302 + 72 NS
Antiphospholipid antibody frequencies, n (%)
Anticardiolipin (IgG) 14 (47) 3 (10) .003
Anticardiolipin (IgM) 3 (10) 1 (3) NS
Anticardiolipin (IgA) 0 (0) 3 (10) NS
Anti-ß-2 glycoprotein (IgG) 11 (37) 6 (20) NS
Anti-ß-2 glycoprotein (IgM) 3 (10) 0 (0) NS
Anti-ß-2 glycoprotein (IgA) 7 (23) 12 (40) NS
Antiprothrombin (IgG) 26 (87) 6 (20) .001
Antiprothrombin (IgM) 2 (7) 0 (0) NS
Antiprothrombin (IgA) 2 (7) 1 (3) NS
Thrombotic screen 6 weeks post event, n (%)b 21 (70) 24 (80)
Fibrinogen (g/L) 3.5 + 1.0 3.9 + 2.2 NS
D-Dimer quantitative (mg/L) 0.42 (0.2-2.49) 0.28 (0.2-3.08) NS
Antithrombin (IU/dL) 101+ 19 103 + 15 NS
Protein C (IU/dL)c 82+ 22 108 + 20 .0003
Protein S (IU/dL)c 91+ 29 107+ 25 NS
APCR 2.6 + 0.5 2.8 + 0.5 NS
Factor 8 (IU/dL) 201 + 87 136 + 45 .001
VWF antigen (%) 225 + 64 197 + 84 NS
VWF activity (%) 108 + 7 105 + 12 NS
Lupus anticoagulant, n (%) 0 (0) 0 (0) NS
NOTES: ACS ¼ acute coronary syndrome; Ig ¼ immunoglobulin; HDL ¼ high-density lipoprotein; HIV ¼ human immunodeficiency virus; LDL ¼ low-density
lipoprotein; NS ¼ not significant; VWF ¼ von Willebrand factor.
a Data are presented as mean + standard deviation, proportions, or median (min–max range).
b Nine patients in ACSþ:HIVþ group and 6 patients in ACSþ:HIV group were ineligible for testing at 6 weeks (see text).
c Patients receiving warfarin excluded from analysis (2 patients in ACSþ:HIVþ and 1 patient in ACSþ:HIV group).
Table 2. Acute Coronary Syndrome Group: Clinical Profilea
ACSþ:HIVþ (n ¼ 30) ACSþ:HIV (n ¼ 30) P Value
Demographic profile
Black African, n (%) 30 (100) 30 (100) 1
Mean age (years) 43+ 7 54 + 13 .0002
Men (%) 20 (67) 18 (60) NS
Coronary risk factors, n (%)
Smoking 22 (73) 10 (33) .004
Diabetes mellitus 1 (3) 7 (23) NS
Hypertension 7 (23) 23 (77) .0001
Total cholesterol (mmol/L) 3.6 + 1.0 4.6 + 1.4 .0031
LDL cholesterol (mmol/L) 2.2 + 0.9 3.0 + 1.2 .0032
HDL cholesterol (mmol/L) 0.8 + 0.3 1.1 + 0.4 .0006
Triglycerides (mmol/L) 1.4 + 0.8 1.1þ/-0.4 NS
BMI (kg/m2) 25+ 5 28 + 5 0.008
Other coronary risk factors 2 (7) 16 (53) 0.0001
NOTES: ACS ¼ acute coronary syndrome; BMI ¼ body mass index; HIV ¼ human immunodeficiency virus; NS ¼ not significant.
a Data are presented as mean + standard deviation or proportions.
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aspirin (150 mg/d) and 4 (17%) of 24 clopidogrel (75 mg/d).
Patients taking aspirin or clopidogrel were analyzed separately
from patients on no antiplatelet drugs. Of the patients taking
aspirin, 3 (17%) of 16 patients in the ACSþ:HIVþ and 2
(9%) of 22 in the ACSþ:HIV group showed evidence of
aspirin resistance with >20% aggregation to arachidonic acid
(P ¼ not significant [NS]). Of the patients taking clopidogrel,
1 (50%) of 2 patient in the ACSþ:HIVþ group and 2 (50%)
of 4 patients in the ACSþ:HIV had evidence of clopidogrel
resistance with normal aggregation to ADP (P ¼ NS). In the
patients not taking aspirin or clopidogrel, the response to ago-
nists was normal with no platelet hyperactivity in either group.
HIV Group (HIVþ)
Clinical profile. The clinical and thrombotic profiles of the
ACSþ:HIVþ and ACS:HIVþ groups are listed in Tables 4
and 5, respectively. The ACSþ:HIVþ and ACS:HIVþ
groups were well matched with respect to age, sex, and viral
load. The ACSþ:HIVþ group was less immunocompromised
as evidenced by higher CD4 counts (P ¼ .01) and less patients
with AIDS-defining criteria (P ¼ .01). Of 30, 18 (60%)
patients had early disease (stage A1/A2). In the ACS:HIVþ
group, 21 (70%) of 30 patients had AIDS-defining criteria.
In terms of coronary risk factors, there were more smokers
in the ACSþ:HIVþ group (P ¼ .0026), and the mean HDL
levels were lower compared to the ACS:HIVþ group
(P ¼ .011).
Thrombotic profile. Thrombotic screens were performed in 21
(70%) of 30 and 29 (97%) of 30 patients in the ACSþ:HIVþ
and ACS:HIVþ groups, respectively. Of 30, 1 (3%) patient
in the ACS:HIVþ group was not tested due to withdrawal
of consent. Mean PC levels were lower in the ACSþ:HIVþ
group (P ¼ .0163), but when analyzing the 2 groups with
respect to PC deficiency (PC <70 IU/dL), there was a nonsigni-
ficant trend toward a higher degree of PC deficiency in the
ACSþ:HIVþ group (4 [21%] of 19 vs 4 [14%] of 29, P ¼
.08). There were no significant differences between the groups
with respect to aPL frequencies but analysis of the actual aPL
titers revealed higher levels of anti-ß2-GP-1 IgM (3.0 [1.6-
10.2] vs 2.1 [1.3-15.3], P ¼ .007) in the ACS:HIVþ group
compared to the ACSþ:HIVþ as well as aPT IgG (20.2 [9.3-
165.1] vs 14.4 [7.5-40.2], P ¼ .0008), aPT IgM (4.8 [1.3-9.4]
vs 3.1 [1.4-30.9], P ¼ .012), and aPT IgA (5.8 [3.3-17.3] vs
4.6 [3.0-18.2], P ¼ .015).
Platelet studies. Light transmission aggregometry was per-
formed in 21 (70%) of 30 patients in the ACSþ:HIVþ group
and 28 (93%) of 30 patients in the ACS:HIVþ group. The
findings in the ACSþ:HIVþ group were described in the
ACS group results section. In the ACS:HIVþ group, 27
(95%) of 28 patients were not taking aspirin. Of these patients,
19 (70%) of 27 showed a normal aggregation response to ago-
nists and 8 (30%) of 27 showed a ‘‘flat’’ response to arachido-
nic acid in the absence of antiplatelet drugs. None of the
patients had evidence of platelet hyperactivity.
Discussion
Unlike other studies investigating the thrombotic profile of
HIV-positive patients receiving HAART, we took the almost
unique opportunity to study a HAART-naive population, thus
negating the potential effects of HAART on thrombotic risk.
First, when comparing the ACSþ:HIVþ group and the
Table 4. HIV Group: Clinical Profilea
ACSþ:HIVþ (n ¼ 30) ACS:HIVþ (n ¼ 30) P Value
Demographic profile
Black African, n (%) 30 (100) 30 (100) 1
Mean age (years) 43 + 7 41+ 8 NS
Men (%) 20 (67) 19 (63) NS
HIV-related factors
CD4 (cells/mm3) 230 (30-1356) 125 (6-1041) .0126
Viral load (RNA, copies/mL) 29 000 (25-7  105) 54 000 (25-11  105) NS
AIDS-defining criteria (CDC), n (%) 11 (37) 21 (70) .01
Coronary risk factors, n (%)
Smoking 22 (73) 11 (37) .0026
Diabetes mellitus 1 (3) 0 (0) NS
Hypertension 7 (23) 2 (7) NS
Total cholesterol (mmol/L) 3.6 + 1.0 3.7 + 0.8 NS
LDL cholesterol (mmol/L) 2.2 + 0.9 2.0 + 0.5 NS
HDL cholesterol (mmol/L) 0.8 + 0.3 1.0 + 0.5 .011
Triglycerides (mmol/L) 1.4 + 0.8 1.4þ/-0.8 NS
BMI (kg/m2) 25 + 5 21+ 4 .003
Other coronary risk factors 2 (7) 0 (0) NS
NOTES: AIDS ¼ acquired immunodeficiency syndrome; BMI ¼ body mass index; CDC ¼ Centers for Disease Control and Prevention; HDL ¼ high-density lipo-
protein; HIV ¼ human immunodeficiency virus; LDL ¼ low-density lipoprotein.
a Data are presented as mean + standard deviation, proportions, or median (min–max range).
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ACSþ:HIV group, consistent with previously published data,
the HIV group was younger in age, predominantly male, with a
higher percentage of cigarette smokers and lower HDL lev-
els.30 Active cigarette smoking is a consistent modifiable risk
factor identified in many trials on HIV and arterial thrombo-
sis,3,31 and the high rates seen in this study are consistent with
this. Besides smoking, there were less traditional risk factors
for MI in the ACSþ:HIVþ group, with a lower percentage
of patients with hypertension, LDL hyperlipidemia, and ‘‘other
coronary risk factors’’ compared to the HIV-negative group.
The low HDL levels found in our ACSþ:HIVþ group have fre-
quently been described in treatment-naive HIV-infected indi-
viduals32,33 and may contribute to thrombotic risk.34 The
ACSþ:HIVþ group had greater evidence of thrombophilia
compared to the ACSþ:HIV group. Mean PC levels were sig-
nificantly lower and there was a trend toward a greater degree
of PC deficiency, which would have met statistical significance
if the sample size had been bigger. Despite this, we feel that the
lower PC levels in the ACSþ:HIVþ group are significant find-
ings, given that ‘‘normal’’ values in the black South African
HIV population have not been clearly defined. Along the same
lines, factor VIII levels were also significantly elevated in the
ACSþ:HIVþ group compared to the ACSþ:HIV group,
with a trend toward statistical significance when defining a
cutoff value of >150 IU/dL. Antiphospholipid antibody fre-
quencies (aCL IgG and aPT IgG) were significantly higher in
the ACSþ:HIVþ group. What is the significance of these
findings?
Protein C deficiency is a well-known risk factor for VTE
and confers an increased risk of approximately 7-fold35 but has
also been described in the pathogenesis of MI in young patients
with otherwise normal coronary arteries.36,37 Protein C defi-
ciency results in an increased activity of factors Xa and IXa and
a hypercoagulable state.36 The mechanism of PC deficiency in
HIV-positive patients is probably multifactorial, including
altered synthesis and metabolism as well as low-grade dissemi-
nated intravascular coagulation (DIC) with consumptive coa-
gulopathy.8 Increased clotting factor VIII is known to elevate
the risk of VTE,38 but little is known about its relationship to
arterial thrombosis or HIV infection. Anticardiolipin antibo-
dies, particularly the b2-GP-dependent variety, were strongly
associated with the risk of MI in a prospective case–control
analysis from the Honolulu Heart Program.35 In a study among
survivors of MI, aCLs were detected in 14% of patients com-
pared with 3% of controls.39 The significance of the raised
aPLs in the ACSþ:HIVþ group remains unclear, however, as
the etiopathogenic link between aPL and thrombosis in HIV
is tenuous,14 and despite case reports, the aPLs that often
present in infectious diseases are not usually associated with
thrombotic complications.40 Patients with HIV have also been
shown to have higher degrees of endothelial activation, a risk
factor for thrombosis, compared to the HIV-negative
Table 5. HIV Group: Thrombotic Profilea
ACSþ:HIVþ Group ACS:HIVþ Group P Value
Thrombotic screen at baseline, n (%) 30 (100) 30 (100)
Hemoglobin (g/dL) 13.6 + 2.8 12.6 + 2.3 NS
Platelet count (109/L) 301+ 113 252 + 83 NS
Antiphospholipid antibody frequencies, n (%)
Anticardiolipin (IgG) 14/30 (47) 17/30 (57) NS
Anticardiolipin (IgM) 3/30 (10) 4/30 (13) NS
Anticardiolipin (IgA) 0/30 (0) 0/30 (0) NS
Anti-ß-2 glycoprotein (IgG) 11/30 (37) 10/30 (33) NS
Anti-ß-2 glycoprotein (IgM) 3/30 (10) 2/30 (7) NS
Anti-ß-2 glycoprotein (IgA) 7/30 (23) 8/30 (27) NS
Antiprothrombin (IgG) 26/30 (87) 29/30 (97) NS
Antiprothrombin (IgM) 2/30 (7) 0/30 (0) NS
Antiprothrombin (IgA) 2/30 (7) 3/30 (10) NS
Thrombotic screen 6 weeks post event n (%)b 21 (70) 29 (97)
Fibrinogen (g/L) 3.5 + 1.0 3.6 + 0.9 NS
D-Dimer quantitative (mg/L) 0.42 (0.2-2.49) 0.34 (0.2-5.47) NS
Antithrombin (IU/dL) 101+ 19 113 + 19 NS
Protein C (IU/dL)c 82+ 22 92 + 19 .0163
Protein S (IU/dL)c 91+ 29 85 + 23 NS
APCR 2.6 + 0.5 2.6 + 0.4 NS
Factor 8 (IU/dL) 201+ 87 228 + 130 NS
VWF antigen (%) 225+ 64 252 + 119 NS
VWF activity (%) 108+ 7 104 + 9 NS
Lupus anticoagulant 0 (0) 1 (3) NS
NOTES: ACS ¼ acute coronary syndrome; HIV ¼ human immunodeficiency virus; Ig ¼ immunoglobulin; NS ¼ not significant; VWF ¼ von Willebrand factor.
a Data are presented as mean + standard deviation, proportions, or median (min–max range).
b Nine patients in ACSþ:HIVþ group were ineligible for testing at 6 weeks (see text). All patients in ACS:HIVþ group were tested at baseline as this group was
event free.
c Patients receiving warfarin were excluded from analysis (2 patients in ACSþ:HIVþ group).
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population.8,11,41 In this study, VWF antigen and activity levels
were studied as a marker of endothelial activation, and
although levels of VWF antigen were higher in the HIV group,
this did not reach statistical significance. The incidence of
aspirin resistance was similar in the 2 ACS groups and compa-
rable with contemporary studies.42 There was no evidence of
platelet hyperactivity in either group.
Comparison of the HIV groups was performed to control for
the HIV status. The patients were well matched with respect to
age and sex, but the ACSþ:HIVþ group was less immunocom-
promised, with higher CD4 counts and no evidence of opportu-
nistic infection or AIDS-related malignancies, implying that
immune dysregulation did not seem to play a significant role
in the development of arterial thrombosis unlike its reported
role in VTE.43 The ACSþ:HIVþ group did, however, have
more classical risk factors for arterial thrombosis, with more
smokers and lower HDL levels. In terms of thrombotic profiles,
the ACSþ:HIVþ group had significantly lower PC levels com-
pared to the ACS:HIVþ group despite being less immuno-
compromised, making the finding even more relevant as PC
levels in HIV-positive patients tend to decrease with worsening
immunosuppresion.8 There were higher aPL titers (IgM anti-
ß2-GP-1 and aPT [all 3 isotypes]) in the ACS:HIVþ group
compared to the ACSþ:HIVþ group, possibly due to the
greater degree of immunosuppresion and immune dysregula-
tion,40 but no difference when comparing the aPL frequencies
between the groups. Several limitations of the study require
comment. Although the study constitutes one of the largest pro-
spective analyses on treatment-naive patients with ACS, the
sample size in each group was relatively small, resulting in a
lack of power to detect small differences between the groups,
which may have been significant. In addition, not all patients
underwent thrombotic screening, further weakening statistical
power. Imperfect matching of the 2 HIV groups with respect
to degree of immunosuppresion makes direct comparison of the
thrombotic profiles difficult but the fact that the ACS–:HIVþ
group had more advanced disease suggests that the degree of
immunosuppresion alone is unlikely to be a significant risk
factor for arterial thrombosis. Wherever possible, we have
adhered to the recently published Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE)
guidelines in our reporting of study data.44
In summary, we found that treatment-naive HIV-positive
patients presenting with ACS have different risk factor and
thrombotic profiles compared to the HIV-negative population.
Consistent with other studies, HIV-positive patients are
younger, more commonly smokers, and have less traditional
cardiovascular risk factors than HIV-negative patients.30
High-density lipoprotein levels are lower in HIV-positive
patients, but the significance of this with regard to arterial
thrombosis is unclear and needs further investigation.
Treatment-naive HIV-positive patients have lower PC levels,
higher levels of factor VIII, and higher titers of aPL compared
to the HIV-negative population. Furthermore, the PC levels
found in the ACSþ:HIVþ group were also significantly lower
than that in the ACS:HIVþ group, which constitutes an
important finding in this population and warrants further inves-
tigation. In addition, further studies are required to determine
the significance of the antiphospholipid antibody findings in
our HIV cohort with regard to thrombotic risk. It is possible
that the pathogenesis of thrombosis in these patients is
multifactorial, with the interaction of conventional risk factors
and HIV-specific coagulation abnormalities. To this extent,
smoking is the most important modifiable risk factor and
should be an important target for cardiovascular risk reduction.
Thrombophilic screening in HIV-positive patients with
minimal coronary risk factors presenting with ACS may be
justified to aid in decision making regarding anticoagulation
as a part of secondary prevention.
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CHAPTER SEVEN: ANTIPHOSPHOLIPID ANTIBODIES IN BLACK SOUTH 
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PREVALENCE AND CLINICAL CORRELATES 
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Summary: This manuscript, which has been submitted for publication, expands on 
Chapter 6 by exploring the role of antiphospholipid antibodies in the pathogenesis of 
coronary thrombosis in HIV patients, traditionally considered to be at low risk for acute 
coronary syndromes. 
 
Statement of originality document: Please see Appendix.
 1 
Abstract 
Background:  HIV infection is associated with a high prevalence of antiphospholipid 
antibodies (aPL) and increased thrombotic events but the aetiopathogenic link between 
the two is unclear. 
Methods and Results: Prospective single centre study from Soweto, South Africa, 
comparing the prevalence of aPL in highly active anti-retroviral therapy (HAART) naïve 
HIV positive and negative patients presenting with Acute Coronary Syndromes (ACS). 
Between March 2004 and February 2008, 30 consecutive black South African HIV 
patients with ACS were compared to 30 black HIV negative patients with ACS .The HIV 
patients were younger (43 ± 7 vs. 54 ± 13, p=0.004) and besides smoking (73% vs. 33%, 
p=0.002) and lower HDL levels (0.8 ± 0.3 vs. 1.1 ± 0.4, p=0.001) had fewer risk factors 
than the control group. HIV patients had a higher prevalence of anticardiolipin (aCL) IgG 
(47% vs. 10%, p=0.003) and anti-prothrombin (aPT) IgG antibodies (87% vs. 21%, 
p<0.001) but there was no difference in the prevalence of the antiphospholipid syndrome 
(44% vs. 24%, p=N/S) and aPL were not predictive of clinical or angiographic outcomes. 
Conclusion: Treatment naïve black South African HIV patients with ACS are younger 
with fewer traditional coronary risk factors than HIV negative patients but have a higher 
prevalence and different expression of aPL which is likely to be an epiphenomenon of the 
HIV infection rather than causally linked to thrombosis and the pathogenesis of ACS. 
  
KEYWORDS: Human Immunodeficiency Virus (HIV), Acute Coronary Syndrome 
(ACS), antiphospholipid antibody (aPL), antiphospholipid syndrome (APS)    
 2 
Background 
HIV infection is known to be associated with an increased prevalence of aPL but the link 
to the antiphospholipid syndrome (APS) with clinical thrombosis including myocardial 
infarction (MI) is tenous (1). Abuaf et al. (2) reported on the prevalence of aPL in HIV 
infection. Anticardiolipin antibodies (aCL) were reported to be present in 0-94%, anti-ß2-
glycoprotein-I (anti-ß2-GPI) in 4-47%, anti-prothrombin (aPT) in 2-12% of patients with 
lupus anticoagulant (LA) found in 0-53.5%. Very few data exist on the prevalence of aPL 
in black patients especially aPT and IgA aPL isotypes in the setting of infections 
including HIV (3). Loizou et al.(3) reported on the prevalence of aPL in 100 black South 
African HIV positive patients. There was a low prevalence of anti-ß2-GPI (6%), all 
exclusively belonging to the IgA isotype, as well as aCL (7%), which were mainly 
positive for IgG. A prevalence of 43% (mainly IgG) aPT was found showing that the 
pattern of aPL in black South Africans differs from that found in caucasians (3). Despite 
the unclear association between HIV, aPL and MI, there have been case reports in the 
non-HIV setting suggesting an association. A prospective case control analysis from the 
Honolulu Heart Program found that anticardiolipin antibodies, particularly the ß2-
glycoprotein-dependent variety were strongly associated with the risk of MI (4). In a 
study among survivors of MI, anticardiolipin antibodies were detected in 14% of patients 
compared with 3% of controls (5). The antiphospholipid syndrome is found more 
commonly in populations with MI who have a low burden of conventional cardiovascular 
risk factors with little or no evidence of atherosclerotic disease and the condition needs to 
be considered in patients with normal appearing infarct related arteries (4). We have 
shown that treatment-naïve HIV positive black South African patients presenting with 
acute coronary syndromes (ACS) are younger with fewer traditional risk factors 
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compared to HIV negative patients and have less atherosclerotic burden but higher 
thrombotic burden on angiography (6). In a subsequent study we showed that this group 
of HIV patients have evidence of thrombophilia as evidenced by lower protein C and 
higher factor VIII levels (7). In addition, preliminary results showed a higher prevalence 
of aPL the significance of which is uncertain. 
Study Aims 
It is within this context, that we investigated the role of aPL as a risk factor for ACS in 
treatment-naïve black South Africans with minimal traditional risk factors. We 
hypothesized that HIV patients with ACS, compared to HIV negative patients, would 
have a higher prevalence of aPL with a higher prevalence of the antiphospholipid 
syndrome (APS) and that aPL would be causally related to thrombosis and ACS. 
 
Methods 
Study design and patient enrollment 
We conducted a prospective single centre study in the Department of Cardiology at Chris 
Hani Baragwanth Hospital, Soweto, South Africa. The protocol was approved by the 
ethics committee of the University of the Witwatersrand and adheres to the Declaration 
of Helsinki. All patients gave informed consent before study entry. Between March 2004 
and February 2008, 30 consecutive black HIV patients presenting with ACS (ACS+ : 
HIV+ group) were enrolled. For each HIV patient with ACS we selected the first 
presenting non-HIV black patient with ACS as a case-control comparator (ACS+ : HIV- 
group). In addition a second control group consisting of 30 asymptomatic HIV patients 
matched for age, sex and ethnicity (ACS- : HIV+ group) were recruited from the HIV 
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clinic. ACS was defined as either ST-elevation myocardial infarction, non ST-elevation 
myocardial infarction or unstable angina. Patients were categorized as having diabetes, 
hypertension or dyslipidemia when being treated chronically for these conditions or when 
diagnosed with the condition on admission. Patients were classified as having “other” 
coronary risk factors if any of the following conditions were present: i) Family history of 
premature CAD (men <55 yrs, women <65 yrs), ii) chronic kidney disease , iii) post 
menopausal state and iv) abdominal obesity (abdominal circumference > 102cm in men 
and 88cm in women) . Demographic data was recorded for each patient and 
anthropometric measurements including weight, height, body mass index (BMI) , waist to 
hip ratio and abdominal circumference (AC) were measured on admission according to 
guidelines set out in the Interheart study (8). Infection with HIV was diagnosed with a 
standard enzyme linked immunosorbent assay and Western blot techniques after 
obtaining consent and offering pretest counseling. In the HIV group, Plasma HIV RNA 
level was determined by quantitative polymerase chain reaction. CD4 count was 
determined by flow cytometry and patients were staged according to the CDC staging 
system (9). Patients with ACS were managed according to accepted guidelines set out by 
the European Heart Association (10, 11) and followed up at the Chris Hani Baragwanath 
cardiac clinic.  
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Laboratory methods 
Blood was obtained by clean venipuncture with seated subjects and non-fasting venous 
blood was drawn into plastic tubes and allowed to clot at 37 degrees and then cetrifuged 
at 2500xg for 8 minutes for sera preparation. The serum was immediately stored at -80 
degrees until use. All sera were thawed only once in a water bath at 37 degrees Celcius 
for 15 minutes before testing. The analysis of aPL was performed at Lancet Laboratories, 
Johannesburg. Antiphospholipid antibodies including aCL, anti- ß2-GP-1, and aPT  (IgG, 
IgM, IgA) were measured at baseline in all patients and at least 12 weeks later in the ACS 
groups using  commercial enzyme linked immunosorbent assay (ELISA) kits (Orgentec 
Diagnostika, Mainz,Germany). The results were expressed in units, according to the 
manufacturer’s instructions. IgG, IgM and IgA aCL were expressed as U/mL. To 
establish normal values of aPL in our population we used the blood samples of 100 
asymptomatic HIV negative black South African blood donors matched for age and sex 
to the study population. Results for each of the aPL measured were considered positive 
when the optical density obtained for each patient exceeded that of the mean value plus 2 
standard deviations (SD) of the 100 sera from black South African normal healthy 
subjects. The antiphospholipid syndrome (APS) was diagnosed in patients with ACS who 
had the presence of aPL (aCL IgG/ IgM and/or anti- ß2-GP-1 IgG/ IgM) in titres greater 
than the mean plus 2SD from normal healthy subjects on two occasions at least 12 weeks 
apart (12). 
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Stastistical analysis 
Statistical analysis was performed using SAS 9.1 software (SAS, Cary, NC, USA). 
Normally distributed continuous data are presented as the mean (± standard deviation), 
and variables with non-Gaussian distribution as the median (min-max range). Categorical 
data are presented as frequencies and percentages. The initial analysis compared variables 
between the 3 groups using the one way anova test for continuous variables with normal 
distribution and the Kruskal Wallis test in case of non-normal distribution. For 
categorical variables the Chi square test was performed with a Fisher exact test when 
necessary. Significant differences between variables in the 3 groups was assumed at 
p<0.05. Subgroup analysis with multiple pairwise comparisons was then performed 
applying the Bonferroni correction with a p value< 0.0166 considered significant. 
Univariate logistic regression was performed to determine predictors of the variables: 
aCL IgG, aPT IgG and APS: data presented as odds ratios (OR) with 95% confidence 
intervals (CI). 
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Results 
Acute Coronary Syndrome (ACS+) group 
The clinical profile and prevalence of aPL in the ACS+ : HIV+ and ACS+ : HIV-groups 
are listed in Table 1. HIV positive patients were younger with a similar sex distribution. 
Besides smoking, (33% vs. 73%, p=0.004), coronary risk factors were higher in the 
ACS+ : HIV- group with more hypertension (p=0.0001), LDL hyperlipidaemia 
(p=0.003), diabetes mellitus (p=0.03) and “other coronary risk factors” (p=0.0001). The 
ACS+ : HIV+ group had lower HDL levels (p=0.0006) and a lower mean BMI (p=0.008). 
The ACS+: HIV+ group had higher frequencies of aCL IgG (47% vs. 10%, p=0.003) and 
aPT IgG (87% vs. 21%, p<0.001) compared to the ACS+: HIV- group. There were no 
differences between groups with respect to the other aPL frequencies. The ACS group 
(60 patients) was then analysed to determine the prevalence of APS. In the ACS+ : HIV+ 
group, 18/30(60%) patients had aPL results from two separate occasions, 12 weeks apart 
as per diagnostic guidelines (12). 12/30(40%) did not have repeat testing owing to 
9/30(30%) deaths and 3/30(10%) patients lost to follow up. In the ACS+: HIV- group, 
25/29(86%) patients had aPL results from two separate occasions, 12 weeks apart with 
4/29(14%) patients dying prior to repeat testing. The diagnostic criteria for APS were met 
in 8/18(44%) HIV patients vs. 6/25(24%) HIV negative patients, p=0.28. In the ACS+: 
HIV+ group, 7/8(88%) had aCL IgG antibodies, 1/8(13%) aCL IgM, 6/8(75%) anti- ß2-
GP-1 IgG and 1/8(13%) anti- ß2-GP-1IgM. 4/8(50%) patients had the presence of both 
aCL IgG and anti- ß2-GP-1IgG antibodies. In the ACS+ : HIV- group, 3/6(50%) had aCL 
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IgG antibodies, 1/6(17%) aCL IgM and 4/6(67%) anti- ß2-GP-1IgG. 2/6(33%) had the 
presence of both aCL IgG and anti- ß2-GP-1IgG antibodies. 
HIV (HIV+) group 
The clinical profile and prevalence of aPL in the ACS+ : HIV+ and ACS- : HIV+ groups 
are listed in Table 2. 
The ACS+ : HIV+ and ACS- : HIV+ groups were well matched with respect to age, sex 
and viral load. The ACS+ : HIV+ group were less immunocompromised as evidenced by 
higher CD4 counts (p=0.013) and less patients with AIDS defining criteria (p=0.01) 
which were all based on a CD4 count<200 cells/ml3. There were no opportunistic 
infections or HIV related malignancies in the ACS+ : HIV+ group and 18/30(60%) 
patients had early disease being classified as either stage A1 or A2 (9). In the ACS- : 
HIV+ group, 21/30(70%) patients had AIDS, 18/30(60%) due to a CD4 count <200 
cells/ml3 and 3/30(10%) patients with either oppurtunistic infections or AIDS related 
malignancies: 1/30(3%) patient having active pulmonary tuberculosis, 1/30(30%) with 
cutaneous Kaposi’s Sarcoma and 1/30(3%) with a non-Hodgkins lymphoma. 6/30(20%) 
had early disease (stage A1 or A2). In terms of coronary risk factors, there were more 
smokers in the ACS+ : HIV+ group (p=0.0026) and the mean HDL levels were lower 
(p=0.011) compared to the ACS- : HIV+ group. There were no significant differences 
between the groups with respect to aPL frequencies but analysis of the actual aPL titres 
revealed higher levels of ß2-GP-1 IgM [3.0(1.6-10.2) vs. 2.1(1.3-15.3), p=0.007] in the 
ACS- : HIV+ group compared to the ACS+ : HIV+ as well as aPT IgG [20.2(9.3-165.1) 
vs. 14.4(7.5-40.2), p=0.0008], aPT IgM [4.8(1.3-9.4) vs. 3.1(1.4-30.9), p=0.012] and aPT 
IgA [5.8(3.3-17.3) vs. 4.6(3.0-18.2), p=0.015]. On univariate logistic regression, HIV 
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infection was predictive of the presence of aCL IgG (OR 2.94, CI 1.60-5.40, p=0.0005) 
and aPT IgG antibodies (OR 16.07, CI 5.38-49.94, p<0.0001) but did not predict APS 
(OR 2.53, CI 0.69-9.36, p=0.16). The presence of aPL’s (aCL IgG , aPT IgG) and  APS 
did not predict any of the clinical or angiographic outcomes in the study including 
markers of atherosclerotic and thrombotic burden.  
 
Discussion 
HIV infection is known to be associated with increased frequencies of aPL (13) and the 
antiphospholipid syndrome is found more commonly in populations with ACS who have 
a low burden of conventional cardiovascular risk factors with little or no evidence of 
atherosclerotic disease (4) such as our HIV cohort. No data currently exists, however, on 
aPL frequencies and clinical correlates in HAART-naïve HIV patients. We took the 
almost unique opportunity to study a HAART-naïve population thus negating the effects 
of HAART on thrombotic risk.  Firstly, when comparing the ACS+: HIV+ group and the 
ACS+: HIV- group, consistent with previously published data,  the HIV group were 
younger in age, predominantly male, with a higher percentage of cigarette smokers and 
lower HDL levels (14). Besides smoking, there were less traditional risk factors for ACS 
in the ACS+: HIV+ group. With respect to aPL frequencies in the ACS group, significant 
differences were found with HIV patients having higher frequencies of aCL IgG and aPT 
IgG antibodies. The incidence of APS was, however, similar in both groups. What is the 
significance of these findings? The exact role of aPL in the aetiopathogenesis of 
thrombosis in HIV infected patients is controversial. Despite the findings of high aPL 
frequencies (2) and case reports of APS in HIV patients, antiphospholipid antibodies 
 10 
often present in infectious diseases are not usually associated with thrombotic 
complications (3). In order to address the question of significance of the aPL findings in 
our HIV patients with ACS, we looked at a similar HIV group matched for age, sex and 
degree of immunosuppression (ACS- : HIV+ group). The ACS+: HIV+ group, had a 
different pattern of aPL expression compared to recent studies investigating a 
predominantly caucasian population which reported aCL to be positive in 36-88%, anti- 
ß2-GP-1 in 4-27%, and aPT in 2-12% of patients (13, 15-17). In keeping with the study 
by Loizou et al (3) we found a high prevalence of aPT IgG antibodies in our black HIV 
cohort with 87% in the ACS+ : HIV+ group and 97% in the  ACS- : HIV+ group. The 
rates of aCL and anti- ß2-GP-1 antibodies seen in our black HIV population were similar 
to those described in the recent studies on Caucasian patients (13, 15-17). Comparing the 
aPL frequencies within the HIV group, there were no statistically significant differences 
between the ACS+ : HIV+ and ACS- : HIV+ groups but analysis of the actual aPL titres 
revealed higher levels of ß2-GP-1 IgM as well as aPT (IgG,IgM,IgA) in the ACS- : HIV+ 
group possibly due to a greater degree of immunosuppresion and immune dysregulation 
(3), suggesting that the higher frequencies of aPL seen in HIV patients are an 
epiphenomenon of HIV infection rather than causally linked to thrombotic events.The 
aPL seen in HIV patients could be induced by disturbances in regulation of cellular and 
humoral immunity, as a secondary consequence of HIV infection. Alternatively, their 
induction might result from the exposure of cell wall phospholipids as a consequence of 
damaged body cells resulting from the HIV-related inflammatory milieu (3).   Several 
limitations of the study require comment. Although the study constitutes one of the 
largest prospective analyses on treatment-naïve patients with ACS, the sample size in 
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each group was relatively small resulting in a lack of power to detect small differences 
between the groups which may have been significant. In addition, not all patients had 
repeat testing at 12 weeks which would have influenced the reported incidence of APS in 
the patients who had thrombotic events. Wherever possible, however, we have adhered to 
the recently published STROBE guidelines in our reporting of study data (18).  
In summary, we found that treatment-naïve HIV patients presenting with ACS have 
different risk factors and clinical features compared to the HIV negative population as 
well as a higher prevalence and different pattern of aPL expression. It is unlikely that aPL 
in this group of patients are causally linked to ACS and are more likely an 
epiphenomenon of HIV infection. It is possible that the pathogenesis of thrombosis in 
these patients is multifactorial with the interaction of conventional risk factors and other 
HIV-specific coagulation abnormalities which warrants further study. To this extent 
smoking is an important modifiable risk factor and should be an important target for 
cardiovascular risk reduction. Routine screening for antiphospholipid antibodies in HIV 
patients presenting with ACS and minimal risk factors cannot be justified based on these 
findings. 
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Table 1 ACS Group: Clinical profile and aPL prevalence 
  ACS+ : HIV+   ACS+ : HIV-   p value 
Demographic Profile:       
Black African n(%) 30(100) 30(100) 1.0 
Mean Age (years) 43 ± 7 54 ± 13 <0.001 
Men (%) 20(67) 18(60) N/S 
Coronary risk factors n(%):       
Smoking 22(73) 10(33) 0.004 
Diabetes Mellitus 1(3) 7(23) 0.05 
Hypertension 7(23) 23(77) <0.001 
Total cholesterol (mmol/l) 3.6 ± 1.0 4.6 ± 1.4 0.003 
LDL cholesterol (mmol/l) 2.2 ± 0.9 3.0 ± 1.2 0.003 
HDL cholesterol (mmol/l) 0.8 ± 0.3 1.1 ± 0.4 <0.001 
Triglycerides (mmol/l) 1.4 ± 0.8 1.1+/-0.4 N/S 
BMI (kg/m2) 25 ± 5 28 ± 5 0.008 
Other coronary risk factors 2(7) 16(53) <0.001 
Baseline aPL frequencies(%):        
Blood samples n(%) 30(100) 29(97)* N/S 
Anticardiolipin (IgG) 14(47) 3(10) 0.003 
Anticardiolipin (IgM) 3(10) 1(3) N/S 
Anticardiolipin (IgA) 0(0) 3(10) N/S 
Beta-2 Glycoprotein (IgG) 11(37) 6(21) N/S 
Beta-2 Glycoprotein (IgM) 3(10) 0(0) N/S 
Beta-2 Glycoprotein (IgA) 7(23) 12(41) N/S 
Anti-Prothrombin (IgG) 26(87) 6(21) <0.001 
Anti-Prothrombin (IgM) 2(7) 0(0) N/S 
Anti-Prothrombin (IgA) 2(7) 1(3) N/S 
Antiphospholipid syndrome (%): 8/18(44) 6/25(24) N/S 
Legend: Data are presented as the mean ± standard deviation or proportions 
Key:       BMI= body mass index 
               aPL= antiphospholipid antibody 
* 1 patient not analysed due to an inadequate blood sample 
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Table 2 HIV group: Clinical profile and aPL prevalence     
 
  ACS+ : HIV+ ACS- : HIV+ p value 
Demographic Profile:       
Black African n(%) 30(100) 30(100) 1.0 
Mean Age (years) 43 ± 7 41 ± 8 N/S 
Men (%) 20(67) 19(63) N/S 
HIV related factors:       
CD4(cells/mm3) median(range) 230 (30 -1356) 125 (6-1041) 0.013 
Viral load (RNA copies/ml) 
median(range) 29000 (25 - 7x105) 54000(25-11x105) N/S 
AIDS defining criteria  n(%) 11(37) 21(70) 0.01 
Current oppurtunistic infection 0 1(3) N/S 
HIV related malignancies 0 2(7) N/S 
Coronary risk factors n(%):       
Smoking 22(73) 11(37) 0.003 
Diabetes Mellitus 1(3) 0(0) N/S 
Hypertension 7(23) 2(7) N/S 
Total cholesterol (mmol/l) 3.6 ± 1.0 3.7+/-0.8 N/S 
LDL cholesterol (mmol/l) 2.2 ± 0.9 2.0 ± 0.5 N/S 
HDL cholesterol (mmol/l) 0.8 ± 0.3 1.0 ± 0.5 0.011 
Triglycerides (mmol/l) 1.4 ± 0.8 1.4+/-0.8 N/S 
BMI (kg/m2) 25 ± 5 21± 4 0.003 
Other coronary risk factors 2(7) 0(0) N/S 
Baseline aPL frequencies (%):        
Blood samples n(%) 30(100) 30(100) 1.0 
Anticardiolipin (IgG) 14/30(47) 17/30(57) N/S 
Anticardiolipin (IgM) 3/30(10) 4/30(13) N/S 
Anticardiolipin (IgA) 0/30(0) 0/30(0) N/S 
Beta-2 Glycoprotein (IgG) 11/30(37) 10/30(33) N/S 
Beta-2 Glycoprotein (IgM) 3/30(10) 2/30(7) N/S 
Beta-2 Glycoprotein (IgA) 7/30(23) 8/30(27) N/S 
Anti-Prothrombin (IgG) 26/30(87) 29/30(97) N/S 
Anti-Prothrombin (IgM) 2/30(7) 0/30(0) N/S 
Anti-Prothrombin (IgA) 2/30(7) 3/30(10) N/S 
Legend: Data are presented as the mean ± standard deviation or proportions 
Key:       BMI= body mass index 
               aPL= antiphospholipid antibody 
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HIV infection is associated with a pro-inflammatory and thrombophilic state but little is known about the 
link between inflammation and thrombosis in treatment-naïve patients with acute coronary syndromes 
(ACS). Prospective single centre study was conducted in Soweto, South Africa, comparing markers of 
inflammation and endothelial cell activation in highly active anti-retroviral therapy-naïve HIV positive 
and negative patients presenting with ACS. Between March 2004 and February 2008, 30 consecutive 
black South African HIV patients with ACS were compared to 30 black HIV negative patients with ACS. 
The HIV patients were younger (43 ± 7 vs. 54 ± 13, p = 0.004) and besides smoking (73% vs. 33%, p = 
0.002) and lower HDL levels (0.8 ± 0.3 vs. 1.1 ± 0.4, p = 0.001) had fewer risk factors than the control 
group. At baseline, HIV patients had higher levels of tumour necrosis factor- [5.8 (1.7 - 15.0) vs. 0.19 
(0.19 - 19.8) ng/ml, p = 0.0004] and vascular cell adhesion molecule-1 [263.3 (0.38 - 778.5) vs. 151.3 (80.6 
- 416.3) ng/ml, p = 0.007] compared to HIV negative patients as well as higher levels of macrophage 
chemoattractant protein-1 at six months [70 (30 -130) vs. 50 (30 - 90) ng/L, p = 0.004]. Treatment-naïve 
black South African patients with HIV and ACS have evidence of a pro-inflammatory state and greater 
degree of endothelial cell activation compared to HIV negative patients, both of which may play a direct 
role in the pathogenesis of ACS in this otherwise low risk population. MCP-1 may play an important role 
in HIV-associated coronary artery disease.  
 
Key words: Human immunodeficiency virus (HIV), acute coronary syndrome (ACS), inflammation, endothelial 
dysfunction, thrombosis.    
 
 
INTRODUCTION 
 
Inflammation and endothelial cell activation are key 
components in the initiation, progression and thrombotic 
complications of atherosclerotic coronary artery disease 
(CAD) (Koenig and Khuseyinova, 2007). C reactive 
protein (CRP) and Interleukin-6 (IL-6), both pro-inflam-
matory cytokines, as well as having pathogenic roles in 
atherosclerosis, also have strong and independent 
prognostic implications in patients with atherosclerotic 
vascular disease and acute  coronary  syndromes  (ACS) 
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(Koenig and Khuseyinova, 2007). Monocyte chemo-
attractant protein-1 (MCP-1) is a potent activator of 
macrophages and monocytes and is actively involved in 
the initiation and progression of atherosclerosis (de 
Lemos et al., 2003). A significant association between 
increasing concentrations of the endothelial activation 
markers [soluble E-selectin (sE-selectin), soluble 
intercellular adhesion molecule-1 (sICAM-1) and soluble 
vascular cellular adhesion molecule-1 (sVCAM-1)] and 
future cardiac events was shown in apparently healthy 
individuals in the ARIC (atherosclerosis risk in commu-
nities) study (Hwang et al., 1997). HIV infection is 
characterised by a profound inflammatory response with 
elevated   levels    of    a   number    of  pro-inflammatory 
  
 
 
 
cytokines including tumour necrosis factor- (TNF-), 
interleukin-1 (IL-1), IL-6 and CRP (Hsue et al., 2004; 
Hazenberg et al., 2000; Frostegard et al., 1999) which 
persist even after the introduction of highly active anti-
retroviral therapy (HAART) (Valdez et al., 2002) and 
contribute to endothelial dysfunction (Gupta et al., 2008), 
atherogenesis and a prothrombotic state. Among HIV 
patients with subclinical atherosclerosis by carotid and 
femoral ultrasound, MCP-1 plasma levels were higher 
compared to HIV patients without atherosclerosis 
(Alonso-Villaverde et al., 2004). Endothelial activation 
markers including sE-selectin, sICAM-1 and sVCAM-1 
have all been shown to be elevated in HIV positive 
patients (de Gaetano et al., 2004) but the link between in 
vitro findings and clinical events in HIV patients is still 
lacking. HIV-associated coronary artery disease 
described in the developed world is characterised by 
accelerated atherosclerosis and is thought to be due to a 
synergistic effect of viral mediated effects and the 
atherogenic effects of protease inhibitor (PI) containing 
HAART (Hsue and Waters, 2005). Little data exists on 
the nature of HIV-associated CAD in the developing 
world and specifically in South Africa where risk factors 
for CAD have traditionally been low (di Bisceglie et al., 
1982). Within the above context, we have shown that 
treatment-naïve HIV positive black South Africans 
presenting with ACS are younger with fewer traditional 
risk factors compared to HIV negative patients with less 
atherosclerotic burden but a higher thrombotic burden on 
angiography (Becker et al., 2010). In a subsequent study 
we showed that this group of HIV patients had evidence 
of thrombophilia as evidenced by lower protein C and 
higher Factor VIII levels (Becker et al., 2010). We sought 
to determine whether markers of inflammation and 
endothelial cell activation differ between treatment-naïve 
black HIV positive patients with ACS compared to the 
HIV negative population and in so doing try and 
determine their importance in the pathogenesis of HIV-
associated CAD and ACS. We hypothesized that HIV 
patients would have a higher inflammatory burden and 
higher levels of endothelial cell activation markers and 
that these would be contributory in the pathogenesis of 
ACS. 
 
 
METHODS 
 
Study design and patient enrollment 
 
We conducted a prospective single centre study in the Department 
of Cardiology at Chris Hani Baragwanth Hospital, Soweto, South 
Africa. The protocol was approved by the ethics committee of the 
University of the Witwatersrand and adheres to the Declaration of 
Helsinki. All patients gave informed consent before study entry. 
Between March 2004 and February 2008, 30 consecutive HIV 
patients presenting with ACS (ACS+/ HIV+ group) were enrolled. 
For each HIV patient with ACS, we selected the first presenting 
non-HIV patient with ACS as a case-control comparator (ACS+/ 
HIV- group). In addition, a second control group without ACS, 
consisting of 30 asymptomatic HIV patients  matched  for  age,  sex  
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and ethnicity (HIV+ alone group) were recruited from the HIV clinic. 
Consistent with current guidelines (Van der Werf, 2003; Bertrand et 
al., 2002), ACS was defined as either ST-elevation myocardial 
infarction, non ST-elevation myocardial infarction or unstable 
angina. Patients were categorized as having diabetes, hypertension 
or dyslipidemia when being treated chronically for these conditions 
or when diagnosed with the condition on admission. Patients were 
classified as having “other” coronary risk factors if any of the 
following conditions were present: (1) Family history of premature 
CAD (men < 55 years, women < 65 years); (2) chronic kidney 
disease; (3) post menopausal state and (4) abdominal obesity 
(abdominal circumference > 102 cm in men and 88 cm in women). 
Demographic data was recorded for each patient and 
anthropometric measurements including weight, height, body mass 
index (BMI) , waist to hip ratio and abdominal circumference (AC) 
were measured on admission according to guidelines set out in the 
INTERHEART study (Yusuf, 2004). Infection with HIV was 
diagnosed with a standard enzyme linked immunosorbent assay 
and Western blot techniques after obtaining consent and offering 
pretest counseling. In the HIV group, Plasma HIV RNA level was 
determined by quantitative polymerase chain reaction. CD4 count 
was determined by flow cytometry and patients were staged 
according to the CDC staging system (CDC, 1993).  
 
 
Laboratory methods 
 
Standardised venipuncture was used to collect blood samples (20 
ml in an EDTA tube) in all patients on enrollment and again at 6 
months in the two ACS groups only. Plasma was separated by 
centrifugation at 2500 rpm for 12 min within 15 min of collection. 
Aliquots were stored at -70°C. All plasma samples used in these 
studies were thawed only once for analysis. Markers selected for 
analysis included TNF-, IL-6, high sensitivity-CRP (hs-CRP) [pro-
inflammatory cytokines], MCP-1 [chemokine] and sE-selectin, 
sICAM-1 and sVCAM-1 [endothelial CAMS (cellular adhesion 
molecules)]. TNF-, IL-6, MCP-1, sICAM-1 and sVCAM-1 were 
measured using a Bio-Plex cytokine assay (Bio-Rad Laboratories, 
Hercules, CA).hs-CRP was measured by latex immunoassay (CRP 
Vario, Sentinal Diagnostics, Milano, Italy) and E-selectin with an 
enzyme-linked immunosorbent assay (Human sE-selectin 
immunoassay kit, Invitrogen Corporation, Carlsbad, CA). 
 
 
Stastistical analysis 
 
Statistical analysis was performed using SAS 9.1 software (SAS, 
Cary, NC, USA). Normally distributed continuous data are 
presented as the mean (± standard deviation), and variables with 
non-Gaussian distribution as the median (min - max range). 
Categorical data are presented as frequencies and percentages. 
The initial analysis compared variables between the 3 groups using 
the one way anova test for continuous variables with normal 
distribution and the Kruskal Wallis test in case of non-normal 
distribution. For categorical variables the Chi-square test was 
performed with a Fisher exact test when necessary. Significant 
differences between variables in the 3 groups was assumed at p < 
0.05. Subgroup analysis with multiple pair-wise comparisons was 
then performed applying the Bonferroni correction with a p value < 
0.0166 considered significant. 
 
 
RESULTS 
 
The clinical characteristics of the three study groups are 
presented in Table 1 and markers of inflammation and 
endothelial activation in Table 2. 
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Table 1 Clinical characteristics. 
  
  
ACS+ / HIV+ 
(n = 30) 
ACS+ /HIV- 
(n = 30) 
HIV+ alone 
(n = 30) p value 
Demographic Profile       
Black African n (%) 30 (100) 30 (100) 30 (100) - 
Mean age (years) 43 ± 7 54 ± 13* 41 ± 8 0.0002 
Men (%) 20(67) 18(60) 19(63) N/S 
     
Coronary risk factors n (%) 
      
Smoking 22(73) 10(33)* 11(37)* 0.004;0.003 
Diabetes Mellitus 1(3) 7(23)* 0(0) 0.05 
Hypertension 7(23) 23(77)* 2(7) < 0.001 
Total cholesterol (mmol/l) 3.6 ± 1.0 4.6 ± 1.4* 3.7+/-0.8 0.003 
LDL cholesterol (mmol/l) 2.2 ± 0.9 3.0 ± 1.2* 2.0 ± 0.5 0.003 
HDL cholesterol (mmol/l) 0.8 ± 0.3 1.1 ± 0.4* 1.0 ± 0.5* < 0.001; 0.011 
Triglycerides (mmol/l) 1.4 ± 0.8 1.1+/-0.4 1.4+/-0.8 N/S 
BMI (kg/m2) 25 ± 5 28 ± 5* 21± 4* 0.008;0.003 
Other coronary risk factors 
 
2 (7) 
 
16 (53)* 
 
0 (0) 
 
< 0.001 
 
HIV related factors 
      
CD4 (cells/mm3) median (range) 230 (30  - 1356) N/A 125 (6 - 1041) 0.013 
Viral load (RNA copies/ml) median (range) 29000 (25 – 7 x 105) N/A                                                                                  54000 (25 – 11 x 105) N/S
AIDS defining criteria n (%) 11 (37) N/A 21 (70) 0.01 
Current opportunistic infection 0 N/A 1 (3) N/S 
HIV related malignancies 0 N/A 2 (7) N/S 
 
Data are presented as mean ± standard deviation, percentages or median (range) 
Key: BMI = Body mass index; * p < 0.05 vs. ACS+/ HIV+ group.  
 
 
 
Patients presenting with an acute coronary syndrome 
 
Patients in the ACS+/ HIV+ group were younger with a 
similar sex distribution. Besides smoking, (33% vs. 73%, 
p = 0.004), coronary risk factors were higher in the ACS+/ 
HIV- group with more hypertension (p = 0.0001), LDL 
hyperlipidaemia (p = 0.003), diabetes mellitus (p = 0.03) 
and “other coronary risk factors” (p = 0.0001). Alter-
natively, this group had lower HDL levels (p = 0.0006) 
and a lower mean BMI (p = 0.008). The angiographic 
features of this group have been described previously 
(Becker et al., 2010).  
At baseline, the ACS+/ HIV+ group had higher levels of 
TNF- [5.8 (1.7 - 15.0) vs. 0.19 (0.19 - 19.8) ng/ml, p = 
0.0004] but there were no differences between the levels 
of IL-6, MCP-1 or hs-CRP. This group did however have 
higher levels of VCAM-1 [263.3 (0.38 - 778.5) vs. 151.3 
(80.6 - 416.3) ng/ml, p = 0.007] but there was no 
difference in levels of ICAM-1 or E-selectin. A 6 month 
comparison was made in this group to correct for the 
influence of acute thrombosis on inflammatory and 
endothelial markers. At 6 months, 12/30 (40%) patients in 
the ACS+/ HIV+ and 3/30 (10%) in the ACS+/ HIV- 
groups   had   died,  and  therefore  did  not  have  repeat 
testing. MCP-1 levels were higher in the ACS+/HIV+ 
group [70 (30 - 130) vs. 50 (30 - 90) ng/L, p = 0.004]. 
Alternatively, ICAM-1 levels were significantly higher in 
the ACS+/HIV- group [273.6 (64.8 - 1128.7) vs. 94.5 
(18.8 - 245.3) ng/ml, p < 0.0001] as were levels of E-
selectin [31.6 (2.4 - 80.4) vs. 8.8 (2.4 - 54.1) ng/ml, p = 
0.004].  
 
 
HIV+ alone patients 
 
The ACS+/ HIV+ and HIV+ alone groups were well 
matched with respect to age, sex and viral load. Patients 
with an ACS were less immune compromised as 
evidenced by higher CD4 counts (p = 0.013) and less 
patients with AIDS defining criteria (p = 0.01) which were 
all based on a CD4 count< 200 cells/ml3. There were no 
opportunistic infections or HIV related malignancies in the 
ACS+/ HIV+ group and 18/30 (60%) patients had early 
disease being classified as either stage A1 or A2 (CDC, 
1993). In the HIV+ alone group, 21/30 (70%) patients had 
AIDS, 18/30 (60%) due to a CD4 count < 200 cells/ml3 
and 3/30 (10%) patients with either opportunistic 
infections or AIDS related malignancies. 6/30  (20%)  had 
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Table 2. Markers of Inflammation and endothelial activation.  
 
  
ACS+/ HIV+ 
(n = 30) 
ACS+/ HIV- 
(n = 30) 
HIV+ alone 
(n = 30) 
p value 
 
Baseline Inflammatory markers 
      
TNF- (ng/ml) 5.8(1.7 - 15.0) 0.19 (0.19 - 19.8)* 3.5(0.38 - 94.1) 0.0004 
IL-6 (ng/ml) 26.2(3.3 - 479.0) 23.2(0.92 - 277.4) 6.2(1.5 - 21.7)* < 0.0001 
MCP-1(ng/L) 60(20 - 720) 50(30 - 90) 60(20 - 510) N/S 
hs-CRP (mg/L) 
 
36.1(0.5 - 173.8) 
 
59.9(2.3 - 255.1) 
 
6.1(0.34 - 51.7)* 
 
< 0.0001 
 
Baseline endothelial activation markers 
    
ICAM-1(ng/ml) 81.3(0.48 - 179.9) 112.3(41.2 - 248.4) 350.4(208.1 - 1659.5)* < 0.0001 
VCAM-1 (ng/ml) 263.3(0.38 - 778.5) 151.3(80.6 - 416.3)* 395.0(29.9 - 1141.9)* 0.007;0.0016 
E-selectin (ng/ml) 
 
18.5(2.4 - 65.9) 
 
21.3(2.4 - 58.2) 
 
44.1(2.4 - 148.2)* 
 
< 0.0001 
 
6 month Inflammatory markers 
    
TNF- (ng/ml) 3.1(0.19 - 8.2) 4.3(0.19 - 15.3) N/A N/S 
IL-6 (ng/ml) 5.6(0.92 - 54.1) 5.9(0.92 - 24.2) N/A N/S 
MCP-1(ng/L) 70(30 - 130) 50(30 - 90)* N/A 0.004 
hs-CRP (mg/L) 
 
4.5(1.4 - 109.8) 
 
4.3 (1.1 - 71.7) 
 
N/A 
 
N/S 
 
6 month endothelial activation markers 
    
ICAM-1(ng/ml) 94.5(18.8 - 245.3) 273.6(64.8 - 1128.7)* N/A < 0.0001 
VCAM-1(ng/ml) 296.1(153.0 - 555.5) 251.5(120.6 - 613.4) N/A N/S 
E-selectin (ng/ml) 8.8(2.4 - 54.1) 31.6(2.4 - 80.4)* N/A 0.004 
 
Data are presented as median (min - max range) 
Key: TNF-, Tumour necrosis factor- ; IL-6, Interleukin-6; MCP-1, Macrophage chemoattractant protein-1; hs-CRP, high sensitivity C reactive protein; 
ICAM-1, Intercellular adhesion molecule-1; VCAM-1, Vascular cellular adhesion molecule-1; sE-selectin, soluble Endothelial-selectin; * p < 0.05 vs. 
ACS+/ HIV+ group.  
 
 
 
early disease (stage A1 or A2). In terms of coronary risk 
factors, there were more smokers in the ACS+/HIV+ 
group (p = 0.0026) and the mean HDL levels were lower 
(p = 0.011) compared to the HIV+ alone group. At 
baseline, markers of inflammation were significantly 
higher in the HIV+/ACS+ group with higher levels of IL-6  
[26.2 (3.3 - 479) vs. 6.2 (1.5 - 21.7) ng/ml, p,0.0001] and 
hs-CRP [36.1 (0.5 - 173.8) vs. 6.1 (0.34 - 51.7) mg/L, p, 
0.0001]. Levels of endothelial activation markers were all 
higher in the HIV+ alone group: ICAM-1 [350.4 (208.1 - 
1659.5) vs. 81.3 (0.48 - 179.9) ng/ml, p, 0.0001], VCAM-1 
[395 (29.9 - 1141.9) vs. 263.3 (0.38 - 778.5) ng/ml, p = 
0.0016] and E-selectin [44.1 (2.4 - 148.2) vs. 18.5 (2.4 - 
65.9) ng/ml, p < 0.0001].  
 
 
DISCUSSION 
 
By studying a treatment naïve group of HIV patients with 
ACS we were able to look at markers of inflammation and 
endothelial cell activation without having the confounding 
effects of HAART. Considering the ACS+ group first, the 
pro-inflammatory cytokine TNF- was significantly higher, 
at baseline,   in  HIV  patients  (ACS+/HIV+  group)  com-
pared to their HIV negative counterparts (ACS+/HIV- 
group) despite being younger with less traditional risk 
factors for CAD. There was no evidence of infectious 
disease in either group at the time of blood collection 
making it unlikely that the difference in inflammatory 
markers could be explained by an underlying, 
confounding infectious process which has been shown 
previously to be a precipitant in the pathogenesis of ACS 
(Ross, 1999). Baseline markers of endothelial activation 
were also different between the two groups with higher 
levels of VCAM-1 in the HIV group. VCAM-1 is a member 
of the immunoglobulin super-family and is involved in the 
firm adhesion and transmigration of leucocytes through 
endothelial cells (de Gaetano et al., 2004). Increased 
levels of VCAM-1 have been shown to occur with 
stimulation of endothelial cells with pro-inflammatory 
cytokines (Figure 1) and have a strong predictive value of 
future cardiovascular events (Blankenberg et al., 2003). 
This pro-inflammatory state is likely related to the well 
described effects of the HIV virus on CD4 cell and 
macrophage activation with consequent elaboration of 
pro-inflammatory cytokines including TNF- and the 
interleukins (Frostegard et al., 1999) which in turn may 
lead to accelerated atherosclerosis  and  a  prothrombotic 
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Figure 1. A proposed link between HIV, inflammation and thrombosis.  
Key: TNF-, tumour necrosis factor-; IL-6, interleukin-6; hs-CRP, high sensitivity CRP; MCP-1, 
macrophage chemoattractant protein-1; ICAM-1, intercellular adhesion molecule-1; VCAM-1, 
vascular cell adhesion molecule-1; E-selectin, endothelial selectin; P-selectin, platelet-selectin; 
vWF, von Willebrand factor; sTM, soluble thrombomodulin. 
 
 
 
state with the elaboration of tissue factor which is acritical 
and potent factor in the initiation of coagulation in both 
physiologic and pathologic conditions  (Grignani and 
Maiolo, 2000) (Figure 1). The HIV+/ACS+ group were 
also found to have greater thrombus burden on 
angiography in a previous study (Becker et al., 2010) 
which may, in part, be related to this well documented 
relationship between inflammation and thrombosis 
(Frostegard et al., 1999) (Figure 1). Furthermore, we 
showed that this group of patients also had higher rates 
of in-stent restenosis (Becker et al., 2010) which is 
thought to be related to a heightened inflammatory state 
during percutaneous coronary intervention (PCI) (Hsue et 
al., 2004). There was no difference in the inflammatory 
markers at six months but levels of the pro-atherogenic 
chemokine MCP-1 was significantly higher in HIV+ 
patients. MCP-1 is a chemokine responsible for the 
recruitment of monocytes to sites of inflammation where 
they promote atherosclerotic lesions and plaque 
vulnerability (de Lemos et al., 2003). Levels of MCP-1 
have been shown to correlate with carotid intima-media 
thickness, a surrogate marker of atherosclerosis in HIV 
patients (Joven et al., 2006). Furthermore, MCP-1 is 
thought to play an important role in the pathogenesis of 
restenosis after PCI (Jianli and Kolattukudy, 2009). An 
unexpected   finding   was  that  ICAM-1  and  sE-selectin 
levels were significantly higher at six months in the 
ACS+/ HIV- group. This may have been due to selection 
bias as a greater number of HIV+  patients died prior to 
the six month follow up compared to those without HIV; 
thus selecting out the sicker patients who may have had 
a greater degree of endothelial activation. With respect to 
the HIV+ group comparison could only be made at 
baseline as the HIV+ alone group did not have markers 
performed at 6 months. At baseline, IL-6 and hs-CRP 
were significantly higher in the ACS+/ HIV+ group but 
when comparing the baseline levels of inflammatory 
cytokines of the  HIV+ alone group with the 6 month 
levels of the ACS+/ HIV+ group (that is both free of a 
thrombotic event), there was no difference. All markers of 
endothelial activation were significantly higher at baseline  
in the HIV+ alone group despite having a lower pro- 
inflammatory burden. This may be explained by the fact 
that endothelial cell activation in HIV has many triggers 
with pro-inflammatory cytokines being only one of them. 
Other known mechanisms include lipid disorders asso-
ciated with HIV infection (Grinspoon and Carr, 2005), 
viral protein-related endothelial activation (Ren et al., 
2002) and direct HIV infection of the endothelium and 
vascular smooth muscle cells (Conald et al., 1995). Of 
note, is that patients in the HIV+ alone group had lower 
CD4 cell counts with a higher percentage of patients  with  
  
 
 
 
AIDS; all factors which favour a greater degree of 
endothelial cell perturbation (Seigneur, 1997). A 
proposed link between HIV, inflammation and thrombosis 
is presented in Figure 1.  
Although the study constitutes one of the largest 
prospective analyses on treatment-naïve patients with 
ACS, certain limitations need to be acknowledged. Firstly, 
given the nature of clinical presentations and our planned 
analyses, we were unable to completely match case-
controls according to age, sex and risk parameters. The 
sample size in each group is relatively small resulting in a 
lack of power to detect small differences between the 
groups which may have been significant. In addition, not 
all patients had repeat testing at 6 months which would 
have influenced the validity of the 6 month markers of 
inflammation and endothelial cell activation in the patients 
who had thrombotic events. Wherever possible, however, 
we have adhered to the recently published STROBE 
guidelines in our reporting of study data (von Elm et al., 
2007).  
 
 
Conclusions 
 
Treatment-naïve black South African patients with HIV 
and ACS have evidence of a heightened pro-
inflammatory state and greater degree of endothelial cell 
activation compared to HIV negative patients, factors 
which may play a direct or indirect role in the path-
genesis of thrombosis and ACS in this otherwise low risk 
population. The role of MCP-1 as a potential risk factor 
and marker of HIV-associated CAD and restenosis needs 
to be further elucidated. 
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CHAPTER NINE: DISCUSSION AND CONCLUSIONS 
 
9.1  DISCUSSION  
 
The “Heart of Soweto” study (HOS) accumulated detailed clinical data over a one year 
period on the presentation, investigations and treatment of new and old patients with 
cardiovascular disease from the large urban area of Soweto (2006). Data from this study 
clearly supports the theory that this area, a microcosm of other urban areas in South 
Africa, is currently in a state of epidemiologic transition, with a high prevalence of 
modifiable cardiovascular risk factors for atherosclerosis and a combination of infectious 
and non-communicable forms of heart disease, often with late clinical presentations. The 
presence of a large component of non-communicable cardiovascular disease (e.g. 
hypertensive heart disease and CAD) and its common antecedent, type 2 diabetes 
mellitus, is consistent with a broadening spectrum of cardiovascular disease in this 
population.  
 
In view of its near historical absence in black South Africans, the number of documented 
cases of CAD in blacks (77 or 5% of all new cases of heart disease in the HOS study) is 
consistent with the finding of a high burden of modifiable risk factors in the population. 
Further evidence for an emerging epidemic of cardiovascular disease, in particular CAD, 
is presented in Chapter 4.This epidemiologic study demonstrates a substantial increase in 
the number of patients diagnosed with ACS at Baragwanath Hospital in recent years. 
Fifty years ago, three such patients were identified per year; about 25 years ago, five 
102 
 
patients were diagnosed per year; in 2004 there were 64 diagnoses; and in 2006, 77 black 
South Africans were diagnosed (“HOS” study). Consistent with a population in 
epidemiologic transition, there was a more than ten-fold increase in the rate of coronary 
events over two decades, paralleled by increased rates of modifiable risk factors.  
 
With the urban population of Soweto in epidemiologic transition and facing an HIV 
epidemic (Chapter 1 section 3), the future potential for an increase in cardiovascular 
morbidity and mortality is great. Furthermore, given that a greater proportion of HIV 
patients will be exposed to HAART in the future and that HAART has been associated 
with adverse metabolic complications and a greater risk of ACS (Chapter 1 section 5.3.3), 
the potential problem may be amplified. For these reasons a baseline understanding of the 
mechanisms relating to treatment-naïve HIV-related CAD is important if much needed 
guidelines regarding primary prevention and treatment are to be implemented. It is in this 
context that a focused study of this group of patients was undertaken.  
 
When looking at the demographic and clinical profiles of treatment-naïve black South 
Africans with HIV compared to their HIV negative counterparts, several differences were 
observed. Classical risk factors for ACS were more prevalent in the HIV-negative group, 
which comprised an older population with more hypertension, diabetes, hyperlipidaemia, 
abdominal obesity and other “non-traditional” risk factors. Cigarette smoking, however, 
was more prevalent in the HIV group and consistent with studies from developed 
countries. HIV patients also had significantly lower HDL cholesterol levels, an 
independent risk factor for CAD, thrombosis and ACS.  
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How do we interpret these results relative to previous documented reports on ACS in 
HIV patients? Consistent with other studies from the developed world (see Chapter 1 
section 5.2), HIV patients were younger and predominantly male, with a high proportion 
of cigarette smokers and low HDL levels (thought to be due to an impaired reverse 
cholesterol transport pathway mediated by the HIV regulatory protein nef) (see Chapter 1 
section 5.3.2). In contrast to findings in the developed world, none of the treatment-naïve 
HIV patients were intravenous drug abusers and none had opportunistic infections or 
HIV-related malignancies - factors known to confer a higher thrombotic risk (see Chapter 
1 section 5.5). The degree of immunosuppresion in HIV patients did not correlate with 
the risk of ACS. In terms of angiographic features, HIV patients had less atherosclerotic 
burden, with significantly more angiographically normal infarct related arteries (IRA), 
probably reflecting the younger age of the group with less classical risk factors.  
 
What was apparent in the HIV patients was a higher degree of thrombus burden in the 
IRA (see Pictures 1 and 2), suggesting a prothrombotic state. Percutaneous coronary 
intervention was the preferred method of revascularisation of the IRA in both groups, 
with good procedural success. However, this was complicated by a high incidence of 
diffuse proliferative in-stent restenosis (see Methods Appendix, Figure 1.5) at follow up 
in HIV patients receiving bare metal stents (see Pictures 3 and 4). This finding is 
consistent with reports on in-stent restenosis (ISR) in HIV patients from the developed 
world (see Chapter 1 section 5.2). The pathogenesis of ISR in HIV patients is thought to 
be due to the heightened inflammatory state at the time of PCI (see Chapter 1 section 
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5.2), including increased circulating levels of the pro-inflammatory chemokine, MCP-1 
(202).  
 
Drug eluting stents (DES) are currently the preferred treatment for in-stent restenosis, but 
no data exists on their efficacy or safety in the setting of HIV infection. In this study, four 
HIV patients with diffuse proliferative in-stent restenosis received DES, with good 
procedural success and no need for target lesion revascularisation during follow up.  
 
In terms of the overall clinical outcomes, MACE rates were higher in the HIV group, 
driven by increased rates of TLR but not death. Although the rates of death were not 
statistically significant, there was a higher death rate in the HIV group (30% vs. 17%) 
(Chapter 5) probably relating to direct complications of HIV infection as 67% of these 
deaths occurred after the index event and were not related to cardiovascular causes. 
 
In view of the following clinical and angiographic features in the HIV patients, a 
prothrombotic state was suggested: minimal traditional risk factors; low atherosclerotic 
burden; high thrombotic burden. A prothrombotic state has been well described in HIV 
patients in the developed world and is thought to be multifactoral in nature (Table 1.9). 
With respect to the findings of the thrombotic screens in this study, the ACS+: HIV+ 
group (Group 1) had greater evidence of thrombophilia compared to the ACS+: HIV- 
group (Group 2). Protein C (PC) levels were significantly lower and factor VIII levels 
significantly higher in the ACS+: HIV+ group. PC deficiency is a well-known risk factor 
for venous thromboembolism (VTE) (see Chapter 1 section 5.5) and confers an increased 
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risk of around seven-fold; but this has also been described in the pathogenesis of 
myocardial infarction in young patients with otherwise normal coronary arteries, such as 
this HIV group. PC deficiency results in increased factor IXa and Xa activity and a 
hypercoagulable state (see Methods Appendix,  Figure 1.6).The mechanism of PC 
deficiency in the setting of HIV infection is multifactoral in nature, including: decreased 
synthesis, increased  metabolism, as well as low grade disseminated intravascular 
coagulation (DIC) with consumptive coagulopathy (see Chapter 1 section 5.5).  
 
Increased factor VIII is known to elevate the risk of VTE, but little is known about its 
relationship to arterial thrombosis or HIV infection; its pathogenic role is thus 
questionable. There was no evidence of hyper-reactive platelets in any of the groups 
studied and the incidence of aspirin resistance was similar between the two groups.  
 
With respect to antiphospholipid antibodies (aPL), HIV infection is known to be 
associated with increased frequencies of aPL and the antiphospholipid syndrome (APS) is 
found more commonly in populations with ACS, which have a low burden of 
conventional risk factors with little or no evidence of atherosclerotic disease (see Chapter 
1 section 5.5). Significant differences were found in terms of aPL frequencies between 
the two groups, with HIV patients having higher frequencies of anticardiolipin (aCL) IgG 
and antiprothrombin (aPT) IgG antibodies. The incidence of APS was, however, similar 
in the groups and the the presence of APS did not predict any of the clinical or 
angiographic outcomes.  
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Comparison between the two HIV groups’ thrombotic profiles (ACS+: HIV+ (Group 1) 
and ACS-: HIV+ (Group 3)) was performed to control for HIV status. The patients were 
well matched with respect to age and sex, but the ACS+: HIV+ group were less 
immunocompromised, with higher CD4 counts and no evidence of opportunistic 
infections or AIDS related malignancies; this implied that immune dysregulation did not 
seem to play a significant role in the development of arterial thrombosis, unlike its 
reported role in VTE. The ACS+: HIV+ group had significantly lower PC levels 
compared to the ACS-: HIV+ group, despite being less immunocompromised; this made 
the finding even more relevant, as PC levels in HIV tend to decrease with worsening 
immunosuppresion (see Chapter 1 section 5.5).  
 
With respect to aPL frequencies, similar to a report by Loizou et al. (see Chapter 1 
section 5.5), who investigated HIV positive black South Africans, a different pattern of 
aPL expression was found in the HIV patients compared to recent studies investigating a 
predominantly Caucasian population (which reported aCL to be positive in 36-88%, anti-
ß2-GP-1 in 4-27%, and aPT in 2-12% of patients) (see Chapter 1 section 5.5). In keeping 
with the study by Loizou et al., a high prevalence of aPT IgG antibodies was found in the 
HIV group, with 87% in the ACS+ : HIV+ group and 97% in the ACS- : HIV+ group. 
The rates of aCL and anti-ß2-GP-1 antibodies seen in our black HIV population was 
similar to those described in the recent studies on Caucasian patients described above. 
There were no significant differences when comparing the aPL frequencies within the 
HIV group, but analysis of the actual titres revealed higher levels of anti-ß2-GP-1 IgM as 
well as aPT (IgG,IgM,IgA) in the ACS- : HIV+ group; this was  possibly due to a greater 
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degree of immunosuppresion and immune dysregulation, which suggests that the higher 
frequencies of aPL seen in HIV patients are an epiphenomenon of HIV infection, rather 
than causally linked to thrombotic events. Despite case reports of APS in HIV patients 
(see Chapter 1 section 5.5), the aPL often present in infectious diseases are not usually 
associated with thrombotic complications. These aPL could be induced by disturbances in 
regulation of cellular and humoral immunity, as a secondary consequence of HIV 
infection.  
 
Another mechanism considered important in the pathogenesis of thrombosis is the link 
between inflammatory cytokines and their activation of endothelial cells and monocytes 
(see Chapter 8, Figure 1.8). Inflammatory markers were found to be higher in the HIV+ : 
ACS+ group compared to the ACS+ : HIV- group, at baseline, with significantly higher 
levels of the pro-inflammatory cytokines TNF-α and IL-6. There was no evidence of 
acute infection at the time the assays were performed, making it unlikely that the 
difference in markers could be explained by an underlying, confounding infectious 
process, which has been shown to be a risk factor in the precipitant of ACS. This pro-
inflammatory state is likely related to the effects of the HIV virus on CD4 cell and 
macrophage activation, with consequent elaboration of pro-inflammatory cytokines; this 
may, in turn, lead to accelerated atherosclerosis and a prothrombotic state with the 
elaboration of tissue factor (Figure 1.8) and activation of the extrinsic coagulation 
cascade. This heightened inflammatory state, together with the factors mentioned earlier, 
may (to some extent) explain the finding of large thrombus burden in the IRA’s of HIV 
positive patients and the higher degree of in-stent restenosis.  
108 
 
 
There was no difference in the inflammatory markers at six months, but levels of the pro-
atherogenic chemokine MCP-1 were significantly higher in the HIV group. MCP-1 is a 
chemokine responsible for the recruitment of monocytes to sites of inflammation, where 
they promote atherosclerotic lesions and plaque vulnerability (see Chapter 1 section 5.3). 
MCP-1 levels have been shown to correlate with surrogate markers of atherosclerosis in 
HIV patients (see Chapter 8) and the molecule is considered a candidate marker for 
atherosclerosis. In addition, elevated MCP-1 levels in the HIV group in this study 
probably contributed to the high rates of in-stent restenosis seen in patients who received 
bare metal stents.  
 
Baseline endothelial markers between the ACS+ : HIV+ and ACS- : HIV+ group also 
showed a significant difference, with higher levels of VCAM-1 in the HIV group. 
Increased levels of this molecule have been shown to occur with stimulation of 
endothelial cells by pro-inflammatory cytokines (see Figure 1.8) and it has a strong 
predictive value of future cardiovascular death. With respect to the HIV group (ACS+ : 
HIV+ and ACS- : HIV+), comparison could only be made at baseline, as the ACS- : 
HIV+ group did not have markers performed at 6 months.  
 
Levels of IL-6 and hs-CRP were significantly higher in the ACS+ : HIV+ group, but 
when comparing the baseline levels of the ACS- : HIV+ group with the 6 month levels of 
the ACS- : HIV+ group (i.e. both free of a thrombotic event), there was no difference. All 
markers of endothelial activation were significantly higher in the ACS- : HIV+ group, 
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despite the group having a lower inflammatory burden. This may be explained by the fact 
that endothelial cell activation in HIV infection has many triggers, including HIV-
associated lipid disorders, viral protein related endothelial activation and direct infection 
of the endothelium with the virus (see Chapter 1 section 5.3.2, Figure 1.8). In addition, 
the ACS- : HIV+ group had a greater degree of immunosupression, with lower CD4 
counts and a greater number of patients with AIDS defining criteria, all of which favour a 
greater degree of endothelial cell activation.  
  
9.2  LIMITATIONS OF THE STUDY  
 
This study has a number of limitations that require comment. Although this represents a 
historically large cohort of treatment-naïve HIV positive patients presenting with an 
ACS, the overall study cohort was small and thus underpowered to detect small 
differences between the groups. Age specific MI rates in black patients from Soweto are 
not known and we were thus unable to determine whether the incidence of ACS is higher 
in treatment-naïve HIV patients compared to age-matched HIV negative patients.  
 
Incomplete data, particularly at the 6-month mark (due to a relatively high death rate, 
particularly in the HIV group), resulted in further weakening of statistical power. For 
example, not all patients receiving BMS underwent repeat angiography, which affected 
the reliability of the data regarding in-stent restenosis. In addition, not all patients 
underwent initial thrombotic screening and a significant number were not eligible for 
antiphospholipid assays and inflammatory markers at 6 months, which weakened the 
110 
 
statistical power and significance of these tests. Furthermore, imperfect matching of the 
two HIV groups, with respect to degree of immunosuppresion, made direct comparison of 
the thrombotic and inflammatory profiles difficult, but wherever possible we have 
adhered to the recently published STROBE guidelines (203) in our reporting of study 
data. 
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9.3  CONCLUSIONS 
 
Soweto, a large predominantly black urban area in South Africa, is in a state of 
epidemiologic transition with an increasing prevalence of modifiable cardiovascular risk 
factors and ischaemic heart disease. Treatment-naïve HIV positive black patients 
presenting with ACS in Soweto have different clinical and angiographic features 
compared to the HIV negative population. The patients were younger, more commonly 
male, with high rates of smoking, low HDL levels and less atherosclerotic burden, but a 
higher thrombotic burden, suggesting a prothrombotic state. This was confirmed by lower 
Protein C levels, higher factor VIII levels and a greater degree of inflammatory burden 
and endothelial cell activation. The exact pathogenic role of HIV, independent of 
associated modifiable and non-modifiable risk factors, is difficult to determine, but may 
be important as a contributory factor in an already “vulnerable” patient. A proposed link 
between HIV and atherothrombosis is depicted in Figure 9.1. Importantly, we identified 
modifiable risk factors in the HIV group. Smoking may play a crucial role in the 
pathogenesis of ACS in these otherwise seemingly low risk patients and remains an 
important target for cardiovascular risk reduction.  
 
The role of HDL in the pathogenesis and prevention of HIV-associated CAD needs to be 
further defined, as does the role of drug eluting coronary stents in the prevention of in-
stent restenosis. Thrombophilic screening in HIV positive patients with minimal coronary 
risk factors, presenting with ACS, may be justified to aid in decision making regarding 
anti-coagulation as part of secondary prevention. Cardiovascular risk assessment and 
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appropriate primary prevention should be an important component in the management of 
HIV patients, regardless of treatment status. 
 
Figure 9.1:  A proposed link between HIV, inflammation and thrombosis 
 
Becker et al. Journal of AIDS and HIV Research 2010; 2: 95-100  
Key: TNF-α - tumour necrosis factor-α; IL-6 -, interleukin-6; hs-CRP -, high sensitivity CRP; 
MCP-1 -, macrophage chemoattractant protein-1; ICAM-1 -, intercellular adhesion molecule-1; 
VCAM-1 -, vascular cell adhesion molecule-1; E-selectin -, endothelial selectin; P-selectin -, 
platelet-selectin; vWF -, von Willebrand factor; sTM -, soluble thrombomodulin 
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 Figure 9.2:  HIV and atherothrombosis 
HIV
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Key: DM - diabetes mellitus; HDL - high density lipoprotein; hs-CRP - high sensitivity C 
reactive protein; H/T - hypertension; IL-6 - interleukin-6; MCP-1 - macrophage chemoattractant 
protein-1; TNF-α - tumour necrosis factor-α 
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9.4  THE WAY FORWARD 
 
The studies in this thesis have shown that the cardiovascular risk facing treatment-naïve 
black South Africans with HIV is multifactoral, involving traditional risk factors and 
HIV-related risk factors (Figure 1.9). Furthermore, anti-retroviral drugs (ARV’s) are now 
relatively freely available at all major state hospitals in South Africa, which will result in 
an increased exposure of these patients to drugs which, while vitally important to the 
well-being of HIV patients, are potentially deleterious from a cardiovascular perspective 
and add a third arm to the potential risk facing these patients (Figure 9.1). According to 
the National Strategic Plan (Table 1.1), a significant increase in the utilisation of ARV’s 
is planned, with an ambitious target of 420 000 new adults initiated on ARV’s by 2011.  
 
Having the baseline data on modifiable and non-modifiable risk factors facing treatment-
naïve patients, several important areas for future research arising from this study have 
emerged and in order to manage the potential future epidemic of CAD in HIV positive 
patients decisively, three important data sets are required:  
1)   appropriate cardiovascular risk screening models;  
2)  effective primary prevention strategies;  
3)  appropriate treatment of ACS and optimisation of PCI. 
 
1) Screening of cardiovascular risk in HIV patients  
 
Prediction equations for CAD risk are useful tools that inform clinicians and patients 
about the absolute risk for developing CAD. A basic principle in CAD prevention is that 
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the intensity of risk-reducing interventions should be based on the individual patient’s 
absolute CAD risk. Given the increased life expectancy as a result of HAART, in the 
future more patients will experience complications not related to HIV per se and will 
reach an age at which they are at increased risk for developing CAD. There are currently 
no CAD risk calculations specifically designed for HIV positive patients; in fact, the most 
commonly used risk calculator, The Framingham risk score (see Appendix), was based 
on a North American Caucasian population. This has questionable validity in black South 
Africans as a whole, regardless of HIV status. Although traditional risk factors may 
operate in the same manner in HIV patients as in the general population, there is still a 
need to identify and evaluate HIV-specific CAD risk factors and develop new HIV-
specific CAD prediction equations for adults, adolescents and children in South Africa. 
 
Ideally, what is required is a large multi-center prospective study using a proportional-
hazards regression model that captures a core set of traditional and HIV-specific 
variables; these should all be collected at standard intervals in HAART-naïve and treated 
HIV-infected children, adolescents and adults to determine (with certainty) the optimal 
HIV-specific risk prediction algorithm and the relative contribution of HIV infection and 
HAART to CAD in this population. Ideally, such a study would obtain fundamental data 
on:  
1)   the relative contribution of HIV infection (replication, altered immunity and 
inflammation), HAART component(s), central adiposity, peripheral lipoatrophy 
and metabolic dysregulation to CAD risk in HIV 
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2)   the safety and efficacy of standard treatments (diet, weight loss, physical activity) 
and more intensive therapies (lipid, glucose and blood pressure lowering therapies, 
as well as optimal ARV regimens) for CAD in HIV.  
 
The starting point for the development of a CAD risk prediction equation in HIV patients 
would be a comprehensive medical history and clinical examination, with standardised 
collection of key predictor (independent) risk factors: age, sex, fasting lipids, systolic 
blood pressure, history of diabetes mellitus, fasting or post prandial glucose levels, and 
use of tobacco. Most existing equations predict CAD morbidity and mortality. Such end 
points need to be defined a priori and captured in data collection (dependent variables). In 
terms of HIV, the challenge is how to allow for HIV-specific factors, i.e. immunological 
state, levels of inflammation, duration of disease and types of ARV’s used.  
 
2) Primary prevention strategies 
 
A central tenet of preventing CAD is that the intensity of risk-reducing interventions 
should be based on the level of CAD risk. The first key step in offering primary 
prevention to HIV patients, therefore, is to: estimate the underlying CAD risk (discussed 
in the section on screening above); then to evaluate various therapies, which have been 
shown to be effective in the HIV-negative population, such as aspirin, statins, anti-
hypertensives and various less atherogenic ARV regimens. Important modifiable risk 
factors found in this study were cigarette smoking and low HDL levels. 
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2a)   Smoking 
 
Smoking is highly prevalent among patients with HIV and more prevalent than in the 
general population (see Chapter 1 section 5.3.2), as is the case with Black South Africans. 
Aside from having a history of CAD, current cigarette smoking is the most powerful 
predictor of CAD events among patients with HIV; therefore, preventing individuals with 
HIV from starting to smoke is critical, because stopping smoking remains a formidable 
challenge. Physicians of patients with HIV are less likely than non-HIV healthcare 
providers to ascertain smoking status and encourage quitting (204).  
 
Specific research aimed at encouraging smoking abstinence and encouraging quitting is 
required and appropriate research questions would be: 
• What is the general attitude of healthcare workers and patients regarding smoking 
and in particular to smoking cessation? 
• What are the factors that perpetuate the smoking habit in HIV patients, e.g. lack of 
healthcare provider awareness and/or encouragement to stop smoking, lack of 
social network support, lack of access to proven smoking cessation strategies or 
fatalism. 
•   Do simple, cost effective measures such as the “5A” approach make a difference 
in the rates of smoking cessation? [5A approach (204): Ask about tobacco use; 
Advise to quit; Assess willingness to make a quit attempt; Assist with quit attempt; 
Arrange for follow up]. 
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• Specific research regarding the safety and efficacy of smoking cessation 
pharmacotherapy in HIV patients and, in particular, pharmacokinetic and 
pharmacodynamic studies to evaluate the effects of smoking cessation on ART and 
drug interactions between ART and smoking cessation pharmacotherapy. 
 
2b)   HDL 
 
A strong inverse relationship between HDL cholesterol levels and risk for CAD is well 
established in the non-HIV population, but no data currently exists on its importance in 
HIV. There are no current HIV-specific guidelines in South Africa; current management 
is based on evidence from the non-HIV population and utilises guidelines from either 
South African Lipid Guidelines or those from the Third National Cholesterol Education 
Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol 
in Adults (NCEP ATP III) (205).  
 
Data from this thesis show significantly lower HDL levels in the HIV patients having an 
ACS and this may be an important target for primary prevention. Managing 
dyslipidaemia in HIV patients is potentially problematic, due to drug interactions, relative 
lack of efficacy and the problem of increasing pill burden in patients receiving multi-drug 
regimens. Ideally, as part of a larger prospective study on CAD risk (see section 1 above), 
the efficacy of various lipid lowering agents on raising HDL levels (and lowering LDL 
and triglycerides), in terms of cardiovascular outcomes, should be performed. However, 
costs and logistics may be prohibitive.  
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Prospective studies on progression of a surrogate marker, such as carotid intima media 
thickness would be useful. This would aid in formulating HIV-specific lipid guidelines 
appropriate to the South African context. 
 
3)    Optimising percutaneous coronary intervention 
 
Percutaneous coronary intervention (PCI) is the current standard of treatment for patients 
with ACS. Patients studied in this thesis, both HIV positive and negative had equally 
good acute results with low complication rates. What was of concern, however, was the 
high incidence of in-stent restenosis with bare metal stents (BMS) in the HIV group, 
which resulted in an unacceptably high incidence of target lesion revascularization. Drug 
eluting stents (DES) are the current standard of treatment for in-stent restenosis and were 
used effectively in four HIV patients with good success and no complications. Despite 
this, no formal data exists on their safety and long term efficacy in the setting of HIV.  
 
A prospective, randomised controlled trial assessing the long term success of DES vs. 
BMS in HIV patients is indicated, but due to cost constraints, an interim solution would 
be to study this as part of a National Cath Lab registry, from which appropriate data 
could be drawn. In addition, valuable data regarding the efficacy and safety of 
Clopidogrel, an anti-platelet agent used post-PCI, could be obtained. Currently, 
Clopidogrel is used for a period of at least 1 month post BMS implantation and 6 months 
post DES implantation. The appropriate duration of Clopidogrel use post-PCI in HIV 
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patients is unknown, but theoretically it may be required longer term due to the 
association with the prothrombotic state. In addition, Clopidogrel utilises the cytochrome 
P450 system and may interact with various important medications commonly prescribed 
in HIV patients, especially protease inhibitors, which raises questions about the safety of 
the drug.  
 
With the anticipated increase in CVD facing South Africa, owing to the many reasons 
detailed in this thesis, further research projects that are appropriate to the South African 
context will be vital in order to further quantify the need and explore cost-effective ways 
to provide primary and secondary prevention in order to effectively deal with the burden 
of epidemiological transition as well as the cardiovascular burden likely to be imposed by 
the HIV pandemic. 
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PICTURES 
 
 
Picture 1.  Angiographic image of thrombus in an otherwise angiographically normal 
left anterior descending coronary artery in a 43-yearold HIV positive male 
presenting with an ST-elevation MI. 
 
 
 
 
  
 
Picture 2.  Intravascular ultrasound (IVUS) image of thrombus in an otherwise 
angiographically normal left anterior descending coronary artery depicted in 
Picture 1. 
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Picture 3.  Diffuse proliferative In-stent restenosis (Type 3) in the right coronary 
artery of a 32-year-old HIV positive male 15 months post bare metal stent 
implantation. 
 
 
 
 
  
 
 
Picture 4.  Intravascular ultrasound (IVUS) image of diffuse proliferative In-stent 
restenosis (Type 3) in the patient depicted in Picture 3. 
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